



Synthesis of α-Cationic Phosphines and Their Applications as Ligands

Synthese von α-Kationischer Phosphine und deren Anwendung als Liganden

DISSERTATION

zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.)

Fakultät für Chemie und Chemische Biologie der TU Dortmund vorgelegt von Lianghu Gu

Eidesstattliche Erklärung:

Hiermit versichere ich, dass ich die eingereichte Dissertation nur unter Mitwirkung der an gegebner Stelle erwähnten Personen verfasst und keine anderen als die angegebenen Quellen und Hilfsmittel benutzt, sowie Zitate kenntlich gemacht habe.

Datum:_____

(Unterschrift)

- 1. Berichterstatter: Prof. Dr. Alois Fürstner
- 2. Berichterstatter: Prof. Dr. Klaus Jurkschat

Die vorliegende Arbeit entstand auf Anregung und unter Anleitung von Prof. Dr. Manuel Alcarazo am Max-Planck-Institut für Kohlenforschung in Mülheim an der Ruhr in der Zeit vom September 2012 bis November 2015. Teile dieser Arbeit wurden in den folgenden Artikeln veröffentlicht: L. Gu, G. Gopakumar, P. Gualco, W. Thiel, M. Alcarazo, *Chem Eur. J.* **2014**, *20*, 8575-8578; J. Carreras, G. Gopakumar, L. Gu, A. Gimeno, P. Linowski, J. Petuškova, W. Thiel Alcarazo, M. J. Am. Chem. Soc., **2014**, *136*, 3319-3319; E. Haldón, Á. Kozma, H. Tinnermann, L. Gu, R. Goddard, M. Alcarazo, *Dalton Trans.* **2016**, *45*, 1872-1876.

to my lovely family

Danksagung

Mein herzlichster Dank gilt Prof. Dr. Manuel Alcarazo für die Aufnahme in seinen Arbeitskreis und die Vergabe des interessanten Promotionsthemas.

Herrn Prof. Dr. Alois Fürstner, MPI für Kohlenforschung, und Herrn Prof. Dr. Klaus Jurkschat, TU Dortmund, danke ich für die freundliche Übernahme des Referats und Koreferats.

Weiterhin möchte ich der Max-Planck-Gesellschaft und im Besonderen dem Max-Planck-Institut für Kohlenforschung für die Bereitstellung meines Arbeitsplatzes und die finanzielle Unterstützung danken.

Ich möchte mich bei dem Stipendium CSC und bei der Georg-August-Universität Göttingen für die finanzielle Unterstützung bedanken.

Mein herzlichster Dank gilt Prof. Manuel Alcarazo für seine große Hilfe, die mich sowohl auf fachlicher und persönlicher Ebene stark zu entwickeln erlaubte. Ich bin ihm zutiefst dankbar für all die Motivation und kompetente Beratung, die er mir zur Verfügung gestellt hat.

Allen Mitgliedern der Arbeitsgruppen Fürstner und Alcarazo danke ich für die gute Zusammenarbeit, das angenehme Arbeitsklima und die schönen Stunden innerhalb und außerhalb des Laboralltags. Ich danke herzlich Sigrid Holle, Gerlinde Mehler, Pascal Ortsack, Christian Wille, Helga Krause, Günter Seidel, Karin Radkowski und Saskia Schulthoff für die ständige Hilfsbereitschaft im Labor. Für die große Hilfe bei organisatorischen Angelegenheiten danke ich recht herzlich Frau Lickfeld.

Mein Dank geht an die Mitarbeiter aller analytischen Abteilungen für die zuverlässige und schnelle Durchführung und Auswertung zahlreicher Analysen. Besonders bedanke ich mich bei Frau Phillips, Herrn Kochius, Herrn Dr. Farès und Frau Wirtz aus der NMR-Abteilung, bei Herrn Kampen, Frau Blumenthal und Herrn Klein aus der MS-Abteilung, bei Herrn Deege, Frau Kestermann und Frau Hinrichs aus der HPLC-Abteilung, und Herrn Dr. Goddard, Herrn Prof. Lehmann, Herrn Rust, Herrn Dr. Mondal, Frau Dreier und Frau Dreher aus der Kristallographie-Abteilung.

Mein Dank geht an die Mitarbeiter der theoretischen Abteilung für die gute Berechnung und hilfreichen Informationen zur Aufklärung der Mechanismen. Besonders bedanke ich mich bei Dr. Gopinadhanpillai Gopakumar, Dr. Larry Wolf, Dr. Yiying Zheng und Prof. Walter Thiel. Mein Dank geht an Dr. Eckhard Bill und Herrn Frank Reikowski, MPI für chemische Enerieconversion, für die EPR-Messungen und für die Simulation. Mein Dank geht an Herrn Christian Wille, Herrn Hendrik Tinnermann und Herrn Leo Nicholls, aus der Arbeitsgruppe Alcarazo für die Cyclovoltammetrie-Messungen.

Mein Dank geht an Dr. Pauline Gualco für die Synthese der Verbindungen 61, 66, 75, 78 und 81 und die Untersuchungen an N-gebundenen mehrkationigen Phosphinen. Mein Dank geht an Dr. Estela Haldón für die Hilfe bei der Synthese der Verbindungen 138a, 138b, 139a und 139b. Mein Dank geht an Dr. Jonathan Dube für die Hilfe bei der Synthese der Verbindungen 146.

Für das gründliche Korrekturlesen danke ich Prof. Manuel Alcarazo, Leo Nicholls, Dr. Jonathan Dube, Frau Lauren Dube und Dr. Yin Zhang herzlich.

Ich möchte an alle Freunde besonders danken für die gemeinsam verbrachte Zeit in Mülheim.

Mein ganz besonderer Dank geht meinen Ehefrau Fang Fang für ihre Unterstützung! Ich möchte ihr diese Arbeit widmen!

Abbreviations

| Å | Angstrom |
|--------------------------|---|
| Ac | Acetyl |
| acac | Acetylacetone |
| Ad | Adamantyl |
| Ar ^F | Pentafluorophenyl |
| atm | atmosphere |
| BIAN | 1,2-Bis(imino)acenaphthene |
| [BMIM][BF ₄] | 1-Butyl-3-methylimidazolium tetrafluoroborate |
| Bu | Butyl |
| cod | 1,5-Cyclooctadiene |
| Су | Cyclohexyl |
| DAB | 1,4-Diazabutadiene |
| dba | Dibenzylideneacetone |
| DBN | 1,5-Diazabicyclo(4.3.0)non-5-ene |
| DBU | 1,8-Diazabicycloundec-7-ene |
| dec. | Decomposation |
| DCE | 1,2-Dichloroethane |
| DIBAL | Diisobutylaluminium hydride |
| dipp | 2,6-Diisopropylphenyl |
| DMAP | 4-Dimethylaminopyridine |
| DMF | Dimethylformamide |
| DFT | Density functional theory |
| δ | Chemical shift (NMR) |
| Et | Ethyl |
| Equiv. | Equivalent |
| EtOAc | Ethyl acetate |
| eV | Electronvolt |
| GC-MS | Gas chromatography – mass spectrometry |
| h | Hour |
| Hal | Halogen |
| Hex | Hexyl |
| НОМО | Highest occupied molecular orbital |

| HPLC | High-performance liquid chromatography |
|--------|---|
| HRMS | High-resolution mass spectrometry |
| Hz | Hertz |
| IR | Infrared |
| J | Coupling constant |
| KHMDS | Potassium hexamethyldisilazane |
| L | Generalized ligand |
| L_nM | Generalized metal fragment with n ligands |
| LDA | Lithium diisopropylamide |
| LUMO | Lowest unoccupied molecular orbital |
| m | Meta |
| М | Generalized metal |
| Me | Methyl |
| MeO | Methoxy |
| Mes | Mesityl |
| min | Minutes |
| MS | Mass spectrometry |
| Ms | Methanesulfonate |
| MTBE | Methyl <i>tert</i> -butyl ether |
| n | Normal |
| NHC | N-Heterocyclic carbenes |
| NMM | <i>N</i> -Methylmorpholine |
| NMR | Nuclear magnetic resonance |
| Ũ | Frequency |
| 0 | Ortho |
| р | Para |
| Ph | Phenyl |
| PPTS | Pyridinium <i>p</i> -toluenesulfonate |
| Pr | Propyl |
| Ру | Pyridine |
| r.t. | Room temperature |
| t | Tertiary |
| Tf | Triflate |
| THF | Tetrahydrofurane |

| THT | Tetrahydrothiophene |
|-------|--------------------------------------|
| TLC | Thin layer chromatography |
| TMEDA | N,N,N',N'-Tetramethylethylenediamine |
| TMS | Trimethylsilyl |
| Ts | Tosyl |
| vs | Versus |
| Х | Generalized 1e anionic ligand |

SYNTHESIS OF α -CATIONIC PHOSPHINES AND THEIR APPLICATIONS AS LIGANDS . 1

| 1 | INT | roi | DUCTION | 17 |
|----------|-------------|---------|--|----|
| 1.1 | Pho | sphin | es in Organometallic Chemistry and Catalysis | 17 |
| 1.2 | Intro | oduct | ion of Charge (Cationic Phosphines) | 17 |
| 1.3 | α-Ca | ationi | c Phosphines | 19 |
| 1 | .3.1 | Def | nition and Scope | |
| 1 | .3.2 | Syn | thetic Approaches to Monocationic Phosphines | 20 |
| | 1.3.2 | 2.1 | Imidazolium-Substituted Cationic Phosphines | 20 |
| | 1.3.2 | 2.2 | Cyclopropenium-Substituted Cationic Phosphines. | 22 |
| | 1.3.2 | 2.3 | Pyridinium-Substituted Cationic Phosphines. | 23 |
| | 1.3.2 | 2.4 | Nitrogen-Substituted Cationic Phosphines | |
| 1 | .3.3 | Syn | thetic Approaches to Polycationic Phosphines | |
| 1 | .3.4 | Elec | tronic Properties of α -Cationic Phosphines | 27 |
| 1 | .3.5 | Арр | lications of Cationic Phosphine Ligands | |
| 1.4 | Sum | marv | 1 | 36 |
| Z CA' | ΓION | IS | | 37 |
| 2.1 | Intro | oduct | ion | 3/ |
| 2.2 | Resu | ults aı | nd Discussion | 38 |
| 2 | .2.1 | Syn | thesis of bis- and trispyrazolylborate-Stabilized P-centered Cations | 38 |
| 2.3 | Elec | tronic | Properties | 43 |
| 2.4 | Atte | empts | of Coordination | 44 |
| 2.5 | Sum | mary | И | 44 |
| 3 | DIC | саті | ONIC CHELATING PHOSPHINES: SYNTHESIS, STRUCTURE AND | |
| DE. | 210 Асті | VIT | | 45 |
| I L | | VII . | | ŦJ |
| 3.1 | Intro | oduct | ion | 45 |
| 3.2 | Synt | thesis | | 46 |
| 3 | .2.1 | Syn | thesis of Chelating Dicationic Ligands | |

| 3 | 8.2.2 | Synthesis of Monodentate Dications | 50 |
|---------|-------------|---|----------|
| 3.3 | Elec | tronic Properties of the phosphines | 51 |
| 3.4 | Coo | rdination Study | 55 |
| 3.5 | Red | uctive Elimination of Bis(pentafluorophenyl)palladium Complexes | 59 |
| 3 | 8.5.1 | Synthesis of the Biarylpalladium Complexes | 59 |
| 3 | 8.5.2 | Experimental Investigation of the Effect of Cationic Ligands in Reductive Elimination Processes | s 61 |
| 3 | .5.3 | Theoretical Investigation of Cationic Ligands in Reductive Elimination | 62 |
| Э | 8.5.4 | Reactivity of Dication 92 towards Pd(0) and Ni (0) | 65 |
| 3.6 | Арр | lication in Catalysis | 67 |
| 3 | 8.6.1 | Theoretical Investigation of Chelating Dicationic Ligands in Catalysis | 69 |
| 3.7 | Sum | ımary III | 70 |
| | | | |
| 4 DA | ISC DIC/ | DLATION AND COORDINATION CHEMISTRY OF CAACS SUBSTITUTED a | ζ- 71 |
| NА | DICF | AL F 1105F 111NE5 | / 1 |
| 4.1 | Intr | oduction | 71 |
| 4.2 | α-R | adical Phosphines based on CAACs | 73 |
| 4 | .2.1 | Synthesis of Cationic Phosphines | 73 |
| 4 | .2.2 | Electronic Properties of Cationic Phosphines | 76 |
| 4 | .2.3 | Coordination of the Cationic Ligands. | 78 |
| 4.3 | α-R | adical Phosphines | 80 |
| 4 | .3.1 | Synthesis of the Radical Phosphines | 80 |
| 4 | .3.2 | Coordination of α -Radical Phosphines towards Au(I) | 83 |
| 4 | .3.3 | Coordination of α -Radical Phosphines towards Other Metal Salts | 87 |
| 4.4 | Syn | thesis of Cationic Phosphine Oxide and the Radical thereof | 88 |
| 4.5 | The | oretical Analysis of Properties of α -Radical Phosphines | 91 |
| 4.6 | Sum | ımary IV | 95 |
| | | | |
| 5 | EX | PERIMENTAL PART | 96 |
| 5.1 | Gen | eral Experimental Conditions | 96 |
| 5 | 5.1.1 | Working Techniques | 96 |
| 5 | 5.1.2 | Analytical Methods | 97 |

| | 5.1.3 | Starting Materials as well as in Working Group-made Chemicals | 98 |
|-----|--------|---|-----|
| 5.2 | 2 Synt | hesis | 99 |
| | - | | |
| 6 | API | PENDIX | 140 |
| | | | |
| 6.1 | L NMF | R Spectra of Representative Compounds | 140 |
| 6.2 | 2 X-ra | y Strutures | 255 |
| | 6.2.1 | Crystal Data and Structure Refinement of Compound 63 | 255 |
| | 6.2.2 | Crystal Data and Structure Refinement of Compound 65 | 256 |
| | 6.2.3 | Crystal Data and Structure Refinement of Compound 67 | 257 |
| | 6.2.4 | Crystal Data and Structure Refinement of Compound 76 | 258 |
| | 6.2.5 | Crystal Data and Structure Refinement of Compound 79 | 259 |
| | 6.2.6 | Crystal Data and Structure Refinement of Compound 91 | 260 |
| | 6.2.7 | Crystal Data and Structure Refinement of Compound 92b | 261 |
| | 6.2.8 | Crystal Data and Structure Refinement of Compound 101a | 262 |
| | 6.2.9 | Crystal Data and Structure Refinement of Compound 103 | 263 |
| | 6.2.10 | Crystal Data and Structure Refinement of Compound 107a | 264 |
| | 6.2.11 | Crystal Data and Structure Refinement of Compound 108 | 265 |
| | 6.2.12 | Crystal Data and Structure Refinement of Compound 109a | 266 |
| | 6.2.13 | Crystal Data and Structure Refinement of Compound 109c | 267 |
| | 6.2.14 | Crystal Data and Structure Refinement of Compound 109d | 268 |
| | 6.2.15 | Crystal Data and Structure Refinement of Compound 109f | 269 |
| | 6.2.16 | Crystal Data and Structure Refinement of Compound 110 | 270 |
| | 6.2.17 | Crystal Data and Structure Refinement of Compound 112b | 271 |
| | 6.2.18 | Crystal Data and Structure Refinement of Compound 112f | 272 |
| | 6.2.19 | Crystal Data and Structure Refinement of Compound 112g | 273 |
| | 6.2.20 | Crystal Data and Structure Refinement of Compound 112h | 274 |
| | 6.2.21 | Crystal Data and Structure Refinement of Compound 113 | 275 |
| | 6.2.22 | Crystal Data and Structure Refinement of Compound 114 | 276 |
| | 6.2.23 | Crystal Data and Structure Refinement of Compound 138a | 277 |
| | 6.2.24 | Crystal Data and Structure Refinement of Compound 138b | 278 |
| | 6.2.25 | Crystal Data and Structure Refinement of Compound 138c | 279 |
| | 6.2.26 | Crystal Data and Structure Refinement of Compound 139a | 280 |
| | 6.2.27 | Crystal Data and Structure Refinement of Compound 139b | 281 |
| | 6.2.28 | Crystal Data and Structure Refinement of Compound 139c | 282 |
| | 6.2.29 | Crystal Data and Structure Refinement of Compound 140a | 283 |
| | 6.2.30 | Crystal Data and Structure Refinement of Compound 140c | 284 |
| | 6.2.31 | Crystal Data and Structure Refinement of Compound 141 | 285 |

| 7 | BIB | LIOGRAPHY | 292 |
|---|--------|---|-----|
| | | | |
| | 6.2.37 | Crystal Data and Structure Refinement of Compound 147 | 291 |
| | 6.2.36 | Crystal Data and Structure Refinement of Compound 146 | 290 |
| | 6.2.35 | Crystal Data and Structure Refinement of Compound 145 | 289 |
| | 6.2.34 | Crystal Data and Structure Refinement of Compound 144 | 288 |
| | 6.2.33 | Crystal Data and Structure Refinement of Compound 143 | 287 |
| | 6.2.32 | Crystal Data and Structure Refinement of Compound 142 | 286 |

1 Introduction

1.1 Phosphines in Organometallic Chemistry and Catalysis

Phosphines are the most widely used ligands in organometallic chemistry; hundreds of mono-, di-, or tridentate phosphines with various backbones and coordinating abilities have been devised and prepared for specific applications in homogeneous catalysis.^[1-2] Perhaps the most popular phosphine ligand used is triphenylphosphine, a shelf-stable solid that undergoes oxidation in air relatively slowly. Moreover, phosphines are able to coordinate metals in multiple oxidation states^[3] and, unlike most metal amine complexes, metal phosphine complexes tend to be lipophilic, displaying good solubility in organic solvents. These two features make metal phosphine complexes really useful in homogeneous catalysis. Prominent examples of metal phosphine complexes include Wilkinson's catalyst (Rh(PPh₃)₃Cl), Grubbs' catalyst, and tetrakis(triphenylphosphine)palladium(0) (Scheme 1).



Scheme 1. Examples of phosphine metal complexes with application in catalysis.

1.2 Introduction of Charge (Cationic Phosphines)

Homogeneous catalysts offer a number of important advantages over their heterogeneous counterparts. For example, all catalytic sites are accessible because the catalyst is usually a dissolved metal complex. Furthermore, it is often easier to tune the chemoselectivity, regioselectivity, and/or enantioselectivity by modification of the ancillary ligands.^[4] Despite of these advantages, heterogeneous catalytic systems are preferred in industry due to one major disadvantage of homogeneous ones: the difficulty to separate the reaction products from the catalysts and solvents. Distillation, which would be the most efficient process to conduct this separation, often requires elevated temperatures, at which most homogeneous catalysts decompose. Other conventional separation processes, for example, chromatography or extraction lead to catalyst loss and are typically time-consuming and expensive, since the use and recycling of big amounts of solvents are required.^[5-6]

In order to deal with this kind of problems, chemists have devoted efforts to modify the substituent on the ligands, thus providing catalysts with appropriate physical properties that allow their easy separation from the reaction mixture. One of these strategies consists of the attachment of polar groups or charges to the ligands, aiming to increase the solubility of the resulting catalyst in polar solvents.^[7-8] Several industrial processes already benefit from this strategy; an illustrative example is the Ruhrchemie/Rhône-Poulenc process for the Rh-catalyzed hydroformylation of propene by the use of the highly water-soluble trisulfonated phosphine **4**. After the reaction is completed, the effective separation and recovery of noble metal containing catalysts can be achieved by a simple phase separation. Subsequently, the recovered catalyst can be directly used for the next cycle.^[9]



Scheme 2. Examples of ionic phosphines with application in catalysis.

Another interesting application regarding charged phosphines is the *in situ* analysis of reaction intermediates and catalytic species by electrospray ionization mass spectrometry.^[10] ESI-MS was developed in the late 1980s by Fenn and co-workers^[11] and exploded in popularity in the 1990s due to its ability to analyze thermally fragile or highly polar (bio)molecules.^[12] The fundamental ability of this technique to transfer ions from solution to the gas phase with little or no fragmentation enables the direct study of complex mixtures. In combination with the standard advantages of mass spectrometry, the use of cationic ancillary ligands has led to the rise of the employment of ESI-MS in the investigation of catalytic mechanisms.^[13-19] For example, a cationic version of Grubbs' first-generation catalyst **6** has been imaginatively exploited by Chen and co-workers, who used it to explore the reactivity of a olefin metathesis catalyst in the gas phase using ESI-MS (Scheme 2).^[20-22] Finally, Ooi and his coworkers recently developed an achiral cationic ammonium–phosphine hybrid ligand which was paired with a chiral binaphtholate anion. This ion-paired chiral ligand **7** is able to impart a remarkable stereocontrolling ability and catalyzes a highly enantioselective allylic alkylation of α -nitrocarboxylates (Scheme 3).^[23]



Scheme 3. Ion-paired chiral ligands applied in asymmetric catalysis.

The above examples demonstrate that remote cationic (or ionic) functional groups have dramatic influences on the physical properties of phosphine ligands, which results in interesting applications. It is worth to remind that this kind of modification normally does not significantly alter the coordination properties of the phosphorus center provided that a long distance between the positive charge and the phosphorus atoms exist.

1.3 α -Cationic Phosphines

The well-established ligand toolbox, containing different types of phosphines ranging from electron-rich to electron-poor ones, provides a very powerful manifold to tune the primary reactivity of a metal catalyst. When a catalytic cycle demands very strong donation to the metal, trialkylphosphines are one of the most appropriate ancillary ligands; on the other hand, if moderate π -acceptor properties are necessary, phosphites are the ligands of choice.^[24] However, in some cases the catalytic process demands auxiliary ligands with even stronger π -acceptor properties than phosphites. Then, only few polyhalogenated phosphines, such PF₃, PCl₃ or P(CF₃)₃, are available. However, due to their difficult handling (flammable and toxic gases) and their moisture and oxygen sensitivity, their coordination chemistry is basically unexplored.^[25-26] It is in these situations that more stable and easy to use π -acceptor phosphines are required. The synthesis of ligands of this type by attachment of a positively charged group directly to the P-atom is one of the objectives of this thesis.^[27]

1.3.1 Definition and Scope

By definition, all α -cationic phosphines contain positive charged groups that are directly attached to the phosphorus atom. Due to their cationic nature and close position of the positive charge to phosphorus, ligands containing such moieties display not only different

solubility in organic solvents but also very different coordination properties. It can be anticipated that the presence of positive charges will simultaneously decrease the σ -donor and increase the π -acceptor abilities of the phosphines; therefore, dramatically influencing the electronic properties of the metal fragment to which they are attached.^[24, 27]

Most α -cationic phosphines known to date have been prepared by reaction of chlorophosphines with an appropriate amount of a Lewis base. This process is normally promoted by halide sequestering reagents and can be seen as a formal abstraction of the halide to generate a transient phosphenium cation, which is then immediately trapped by the base. A complementary synthetic pathway involves the nucleophilic attack of secondary phosphines or TMS-substituted ones to chloro-onium salts. Both strategies satisfactorily afford α -cationic phosphines by either use of carbon based nucleophiles (carbenes) or nitrogen based ones (amines) as shown in Scheme 4.^[24]



Scheme 4. Synthetic pathways to α -cationic phosphines with different substituents.

1.3.2 Synthetic Approaches to Monocationic Phosphines

1.3.2.1 Imidazolium-Substituted Cationic Phosphines

The majority of α -cationic phosphines known are imidazophosphines, which were first briefly mentioned by Zoller in 1988,^[28] and completely characterized by Kuhn *et al.* ten years later.^[29] He described the preparation of imidazophosphine **8a** in good yield by reaction of the corresponding carbene, imidazol-2-ylidene, with Ph₂PCl. Following this procedure, Chauvin *et al.* synthesized the imidazophosphines **8b** and **8c** bearing additional electron-withdrawing substituents, such as alkoxy groups (Scheme 5a).^[30] To avoid the use of free carbenes, which are sensitive to oxygen and moisture, Andrieu *et al.* described a new synthetic method consisting on the reaction of imidazolium-2-carboxylates with chlorophosphines. Under the reaction conditions applied, the free carbene, obtained by release of CO₂, reacted with R₂PCl to afford the desired compounds. Using this method, they could prepare a library of imidazolium phosphines **8d-8f** (Scheme 5b).^[31] In the case of **8e**, the molecular structure was

analyzed by X-ray diffraction analysis. This showed that the lone pair of electrons on the phosphorus atom is not delocalized along the imidazolium fragment and thus, remains available for metal coordination.^[31]



Scheme 5. Alternative routes to imidazolium-substituted cationic phosphines.

Weigand *et al.* recently reported an alternative synthesis of cationic phosphines using silyl protected carbenes [NHC-SiMe₃][TfO] instead of free ones (Scheme 6). Subsequent substitution of the Cl moieties on phosphorus provides access to cationic cyano- and azido-substituted derivatives **10a** and **10b**.^[32] Interestingly, if free NHCs instead of [NHC-SiMe₃][TfO] are used for the same reaction, either adducts of the type NHC-PCl₃ **11**^[33] or products coming from the reduction of the central phosphorus such as cation **12**^[34] were obtained.



Scheme 6. Alternative routes to imidazolium-substituted cationic phosphines.

Finally, a completely different method to prepare cationic imidazolium phosphines consists on the selective N-alkylation of neutral imidazophosphine precursors.^[35] This strategy was

recently applied for the preparation of phosphine-imidazophosphines **14** (Scheme 7a)^[36-37] and bis(imidazophosphine) **16**, through a double methylation strategy (Scheme 7b).^[38] With the correct selection of the methylating reagent, in this case MeOTf, this synthetic route could be used to alkylate the N-atom even if the phosphine moiety is already present on the ligand structure.^[39]



Scheme 7. Alternative routes to imidazolium-substituted cationic phosphines.

1.3.2.2 Cyclopropenium-Substituted Cationic Phosphines.

The preparation of cyclopropenylidene stabilized cationic phosphines **18a-g** was achieved in good to excellent yields by condensation of the readily available chlorocyclopropenium salt **17a** with a range of secondary phosphines and subsequent anion exchange, if necessary.^[40] This synthetic strategy allowed the preparation of the desired salts on a multigram scale as white, air-stable solids. It has been observed that these compounds exhibit attributes similar to classical phosphites (Scheme 8).^[41]



Scheme 8. Synthesis of cyclopropenium-substituted cationic phosphines 18a-f.

The π -acceptor properties of this type of cationic phosphines can be further increased by introduction of additional electron withdrawing groups in their structure. For example, ligand **20**, containing two very electron-withdrawing 3,5-bis-(trifluoromethyl)phenyl substituents was much stronger π -acceptor character (Scheme 9). However, none of the synthetic

procedures described above worked in this particular case due to the low nucleophilicity of bis(trifluoromethyl)phenyl phosphine. Hence, the secondary phosphine had to be first treated with ^{*n*}BuLi to form a phosphide, which was reacted with **17a** to afford the desired ligand **20** albeit in moderate yield.^[42]



Scheme 9. Alternative routes to cyclopropenylylidene-stabilized cation 20.

1.3.2.3 Pyridinium-Substituted Cationic Phosphines.

In addition, our group has also reported the preparation of N-alkyl/aryl pyridiniophosphines **21a-h** by condensation of 2-chloropyridinium salts with a range of secondary phosphines. Pyridinium substituted phosphines **21a-h** are envisioned as potentially very useful family of strong π -acceptor ligands owing to their much lower lying LUMO than those of cyclopropenium and imidazolium containing phosphines.^[24] Moreover, an increased solubility in organic solvents as well as very strong π -acceptor properties could be accessible by carefully selection of the two R groups at phosphorus or by introduction of substituents on the pyridinium ring (Scheme 10).^[43] Compared with polycationic phosphines, which show low tendency to form metal complexes, these monocationic ligands are able to coordinate a range of metals, due to the decreased Coulombic repulsive interaction.



Scheme 10. Synthesis of pyridinium-substituted phosphines.

1.3.2.4 Nitrogen-Substituted Cationic Phosphines.

Pyridines, guanidines and amines have also been used to effect halide displacement from halophosphines. An example is the synthesis of **23** from Ph₂PCl and DMAP complex **23** (Scheme 11a).^[44] Another representative one for this reactivity is the intramolecular halide displacement by a tertiary amine **24** with the aid of AlCl₃ to produce a series of cationic phosphines **25a-d** (Scheme 11b).^[45]



Scheme 11. Halide displacement from halophosphines by amines to form cationic phosphines.

1.3.3 Synthetic Approaches to Polycationic Phosphines.

Monocationic phosphines are relatively common and can be prepared via the reaction of strong N-, P-, or C-based Lewis bases with dialkyl- or diaryl-chlorophosphines.^[31, 46-49] Dicationic, and specifically tricationic phosphines of the general formula $[L_3P]^{3+}$ are much more scarce.^[48] In 1991, Weiss *et al.* reported the syntheses of di- and tri-cations **26**, **27** and **28** by reaction of PCl₃ with DMAP or DBN.^[50] Similar reactions for the synthesis of **29** were subsequently reported by Bertrand and coworkers in 1994 (Scheme 12a).^[51] It should be pointed out that only spectroscopic evidence has been reported for these compounds. Later in 2010, Lammertsma and coworkers reported a trication **30** by reaction of PCl₃ and 3,5-dimethyl-1-trimethylsilylpyrazole in the presence of TMSOTf (Scheme 12b). In this compound the positive charges are evenly distributed over two phosphorus centers. Although **30** was extremely moisture-sensitive, it appeared to be indefinitely stable at ambient temperature in a dry inert atmosphere and have also been characterized in the solid state.^[52]



Scheme 12. Halide displacement from chlorophosphines by amines to form cationic phosphines.

In 2011, our group described for the first time the isolation and structural characterization of the elusive $[(carbene)_{3}P]^{3+}$ species **31** (carbene = cyclopropenylydene) by use of an alternative synthetic approach, based on the use of an unprecedented "reverse electron demand" oniosubstituent transfer strategy. Instead of using silvlated bases and PCl₃ as starting materials, the alternative conceivable reaction partners, silyl-substituted phosphines and chlorocyclopropenium salts were used in this transformation. 1-Chlorocyclopropenium cations were the key precursors for this synthesis instead of the more common chloroimidazolium salts mainly due to the following beneficial factors: (a) an enhanced tendency to undergo nucleophilic attack at the chlorinated carbon;^[53] (b) the smaller steric hindrance derived from a carbene embedded in a three membered ring that facilitates the coordination of several of these ligands to the same central atom;^[54-57] (c) the stronger σ donor and weaker π -acceptor properties of cyclopropenylidenes as compared with NHCs. Note that the net donation from the carbene ligand must compensate for the continuous increase of formal positive charge on the phosphorus atom in order to allow the consecutive nucleophilic substitution process to take place.^[40, 58-59] Thus, by gentle heating of a mixture of 1-chloro-2,3-bis(dialkylamino)cyclopropenium salts with P(SiMe₃)₃, the desired P(III)centered trications 31 were isolated as white or light orange solids in moderate to good yields (Scheme 13a). Dication 32 could also be prepared by a two-step sequence. First, condensation of the readily available chlorocyclopropenium tetrafluoroborate 17a with PhPH₂ in refluxing THF afforded monocationic salt in 76% yield. Deprotonation of this salt with KHDMS at -30 °C and *in situ* trapping of the phosphalkene intermediate with a second equivalent of **17a**, finally yielded **32** as an air and water stable white solid. Consistent with the X-ray data, density functional calculations indicate that these compounds, despite their high positive charge, still feature a nonbonding electron pair on the P-atom (HOMO) and a very low-lying LUMO, depicting them as poor σ -donors and excellent π -acceptors.^[60] In 2015, Weigand *et al.* reported the synthesis of dication **33** and trication **34** by a similar strategy. In contrast to **31**, trication **34** is not able to coordinate metal fragments (Scheme 13b).^[61]



Scheme 13. Synthesis of $[L_3P]^{3+}$ cations.

Finally, it worth to mention that the preparation of bisimidazolium salts **37** has been reported by Chauvin group using a double methylation of **35** with MeOTf.^[62-63] Alternatively, the addition of two equivalents of MeOTf to 1,2-di(*N*-imidazolyl)benzene afforded the dicationic salt **38** in 88% yield. Subsequent addition of one equivalent of dichloro(ethyl)phosphite in the presence of Et₃N (2 equiv.) afforded diamidiniophosphinite **39** in 32% yield, which is expected to be a really electron poor ligand (Scheme 14).^[30]



Scheme 14. Alternative routes to imidazolium-substituted polycationic phosphines.

1.3.4 Electronic Properties of α-Cationic Phosphines

In phosphines the non-shared electron pair at phosphorus accounts for their σ -donor ability, while the $\sigma^*(P-C)$ orbitals are responsible for the π -acceptor properties. A formal increment of the electronegativity of one of the R groups on phosphorus is expected to lower the energy of all the molecular orbitals of the resulting phosphine. As a consequence, the resulting phosphine must behave as a poorer σ -donor, but also as a better π -acceptor ligand (Figure 1a). Regarding α -cationic ligands, the positive charges directly connected to the phosphorus atom can be considered as very strong electron withdrawing substituent and for this reason, decreased σ -donation and increased π -accepting properties on the resulting phosphines are expected (Figure 1b). Moreover, most positively charged substituents are aromatic rings containing empty low lying π^* orbitals, which are able to overlap with those of the phosphine that have adequate symmetry as is the case of the P electron pair. This also withdraws electron density from the phosphorus.^[24]



Figure 1. Molecular structure diagram for the explanation of electronic properties of α -cationic ligands.

The electronic properties of phosphine ligands were evaluated by Tolman by measuring the carbonyl stretching frequency $\tilde{v}(CO)$ of the nickel complexes [Ni(CO)₃L] (L= monodentate phosphine ligand).^[64-65] This frequency depends on the combination of σ -donating and π -accepting character of L with respect to the metal center. Electron density donated by L to the metal enhances back donation from the metal center into the LUMO orbital of the CO ligand, which is the antibonding $\pi^*(CO)$ orbital, leading to a decrease of $\tilde{v}(CO)$. Strong donation from the phosphine thus corresponds to a lower carbonyl stretching frequency. Compared with Ph₃P and (PhO)₃P, the complexes containing cationic ligands **8d-f** result in $\tilde{v}(CO)$ similar to those of phosphites (Table 1).^[31]

| Entry | | Ligand | R | ν (CO) ^[a] LNi(CO) ₃ |
|-------------|----------------|-----------------------------------|-----------------------------|---|
| 1 2 3 | 8d 8e 8f | Me N N Me | Ph ⁱ Pr Cy | 2082 2075 2078 |
| 4 | | Ph ₃ P | | 2069 |
| 5 | | P(O ⁱ Pr) ₃ | | 2076 |
| 6 | | P(OPh) ₃ | | 2085 |

Table 1: Carbonyl stretching frequencies in RhCl(CO)(L)₂ complexes in the solid state.

[a] Values in cm⁻¹

To avoid the use of highly toxic Ni(CO)₄, a range of other metal complexes, for example *trans*-[RhCl(CO)L₂], have also been investigated as model to evaluate donor properties of ancillary ligands (Table 2). In general, analogous trends are observed;^[66] however, we have detected some contradictions.

Firstly, the donor ability of the cyclopropenium substituted phosphines slightly surpasses that of Ph₃P (entries 2-6 and 16) when compared on this scale. Moreover, introduction of two -CF₃ group on the ligand structure should weaken its donor properties; however, **20** seems to be better donor than (MeO)₃P according to the recorded \tilde{v} (CO) data (entries 7 and 17).

Additional not matching results have also been found in the pyridinium family of ligands, when the donor properties were evaluated by analysis of the CO stretching frequencies in *trans*-[RhCl(CO)L₂] complexes (Table 2, entries 9-14). For example, ligand **21h** that bears five CF₃ groups should be weaker electron donor than **21e** that shares the same skeleton but carries only one -CF₃ substituent (Table 2, entries 11 and 14). According to the CO stretching frequencies (**21e**: 2004 cm⁻¹ vs **21h**: 2001 cm⁻¹), the trends seem to be the opposite.^[43]

An explanation for this incongruence may come from the structure of the Rh complexes. For $\tilde{v}(CO)$ analysis, the *cis*-located CO ligand may not be only sensitive to electronic effects, but also reflect geometrical distortions around the metal center owing to steric hindrance or through-space interactions between the CO and the other ligands. These distortions influence the overlap of the related CO orbitals and therefore, they decrease the wave number measured by IR spectroscopy. In fact, some structural distortions from the ideal square planar structure could be observed in the solid state of related rhodium carbonyl complexes.^[67-69]

An alternative experimental technique to rank the donor properties of phosphines is the determination of their oxidation potentials $E_{\rm P}({\rm ox})$ by cyclic voltammetry.^[70-72] Electron-rich phosphines are easier to oxidize than electron-deficient ones and, as a consequence, the former should exhibit lower oxidation potentials than the latter if the orbital containing the electron pair is of similar shape, which is normally the case. This classification, although used to a lesser extent than the Tolman scale, has several intrinsic advantages; namely, it does not require the preparation of any metal-carbonyl complex to carry out the measurements and therefore it is also formally independent of steric factors.^[24]

Hence, the oxidation potential E_p (ox) of all these compounds were determined by cyclic voltammetry.^[73-74] These data follow the expected tendency and suggest that ligands **18a**, **18f** and **18g** were donor abilities similar to that of (MeO)₃P, while **20**, **31** and **32** are even weaker donors than phosphites. This new ranking is in complete agreement with experiments on the catalytic activity of Au or Pt complexes bearing these ligands.

In addition, a quite complete Tolman stereoelectronic map has recently been reported by our group,^[24] combining experimental TEPs together with calculated ones employing Gusev's method for both cationic and neutral phosphines (Figure 2).^[75] It demonstrates that the overall donor ability of cationic phosphines **8a**, **18** and **32** are similar or slightly weaker than those depicted by typical phosphites. Therefore, they might be used as interesting phosphite surrogates in catalytic transformations. Even more interesting is the TEP estimated for **31** (2111 cm⁻¹). This value reveals that **31** can be ranked as weaker donors than any phosphite ligand; only the highly reactive PF₃ and P(CF₃)₃ were similar electronic properties. However, in sharp contrast to these polyfluorinated phosphines, **31** is easy to handle, air-stable solid. It is of note that the predicted donor endowment of bisimidazolium-substituted phosphines **39** is characterized by a calculated TEP of 2115 cm⁻¹ and, hence, it is expected to be the weakest donor along the complete series. Unfortunately, no metal complex bearing this ancillary ligand has been prepared to date.^[24, 30] The lack of electron density at the phosphorus atom probably inhibits its coordination chemistry.

| Entry | | Ligand | R | ν (CO) ^[a] RhCl(CO)L ₂ | E _p ox ^[b] |
|-------|-----|-----------------------------------|--|---|-------------------------------------|
| | | Me | | | |
| 1 | 8d | | Ph | 2003 | - |
| | | ⁻ N Me | | | |
| 2 | 18a | <i>_i</i> Pr | Ph | 1971 | 1.207 |
| 3 | 18b | <i>i</i> Pr—N | Су | 1968 | _[c] |
| 4 | 18d | €)—PR | p-(Me)C ₆ H ₄ | 1969 | [c] |
| 5 | 18e | iDr – N | <i>p-</i> (F)C ₆ H ₄ | 1976 | 1.246 |
| 6 | 18f | iPr | p-(MeO)C ₆ H₄ | 1969 | 1.040 |
| 7 | 20 | <i>/</i> 1 | 3,5-di(CF ₃)C ₆ H ₄ | 1991 | 1.548 |
| Q | 31 | Me Me | n = 3 | | 2 062 |
| 0 | 51 | P → P | 11 - 5 | - | 2.002 |
| 9 | 32 | Me-N | n = 2 | - | 1.541 |
| 10 | 21a | | $R = Me R^1 = H R^2 = Ph^2$ | 1996 | 1.398 |
| 11 | 21d | 4 | $R = Me, R^1 = F, R^2 = Ph;$ | 1994 | 1.355 |
| 12 | 21e | R | $R = Me, R^1 = CF_3, R^2 = Ph;$ | 2004 | 1.436 |
| 13 | 21f | | $R = Me, R^1 = F, R^2 = Cy;$ | 1982 | 1.297 |
| 14 | 21g | R FR2 | $R = Me, R^1 = OMe, R^2 = Cy$ | r; 1974 | 1.267 |
| 15 | 21h | | R = Et, R ₁ = CF ₃ , R ₂ = 3,5 ⁻ (CF ₃) ₂ (C ₆ H ₃) | 2001 | 1.578 |
| 16 | | Ph ₃ P | | 1979 | 0.687 |
| 17 | | (MeO) ₃ P | | 2011 | 1.287 |
| 18 | | Cy ₃ P | | 1943 | 0.542 |
| 19 | | ^t Bu ₃ P | | - | 0.534 |
| 20 | | [p-(MeO)Ph] ₃ P | | - | 0.520 |
| 21 | | [<i>p</i> -(F)Ph] ₃ P | | 1943 | 0.502 |

Table 2: Carbonyl stretching frequencies in $RhCl(CO)L_2$ complexes in the solid state and electrochemical redox potential of the ligands. The values of commonly used phosphorus ligands are also included for comparison.

[a] Values in cm⁻¹. [b] Oxidation peak potentials reported in V. Calibrated versus $Cp_{2}^{*}Fe/Cp_{2}^{*}Fe^{+}$ ($E_{1/2} = 0.24$ V), $Bu_{4}NPF_{6}$ (0.1 M) in CH₂Cl₂. [c] Not determined.



Figure 2. Tolman stereolectronic map for neutral and cationic phosphines.

1.3.5 Applications of Cationic Phosphine Ligands.

Pioneering research in the area of α -cationic phosphines was focused on the synthesis of phosphite mimics with high solubility in ionic liquids. The derived catalysts could benefit from the recycling opportunities provided by these ligands. For example, Knochel *et al.* reported that in the presence of the cationic phosphine **8g**, the use of an ionic liquid/toluene biphasic solvent system allows for fast palladium catalyzed cross coupling reaction between organozinc reagents and aryliodides (Scheme 15). The work-up of these reactions is remarkably simple, since the ionic liquid phase containing the palladium catalyst is separated by decantation from the toluene phase. Attempts to reuse the palladium catalytic system show that after the third cycle, a significant decrease in yield is observed (20% lower yield and triple reaction time).^[76]



Scheme 15. The application of cationic ligands in Negishi coupling.

Andrew and coworkers have investigated the catalytic activity of a related ligand **8h**, which also exhibited very strong π -accepting character, in two transformation, both in an ionic liquid phase (Scheme 16a and 16b). In the first of these two reactions, it was observed that the increase of the π -acceptor character in ligand **8h** was beneficial for the alkynylation reaction of aryl bromides with phenylacetylene. The catalytic activity decreased after catalyst recycling due to the sensitivity of ligands to protonation in the ionic phase. Moreover, the accumulation of a large excess of acidic pyrrolidinium bromide might promote the C-P bond cleavage through the protonation of the carbenic 1,3-dimethylimidazol-2-ylidene moiety of the ligand at the relatively high temperatures employed. Multiple recycling of the catalyst in non-acidic media could be achieved for the platinum-catalyzed hydrogenation reaction of *m*-chloronitrobenzene to the corresponding aniline. The selectivity of the reaction is also improved by decreasing the undesirable formation of dehalogenation products. The system was recycled six times without noticeable metal leaching in the organic phase, and no loss of activity.^[77]



Scheme 16. The application of cationic ligands in alkynylation and hydrogenation.

Another transformation where imidazolium phosphines have found application is the hydroformylation of alkenes (Scheme 17). Stelzer and coworkers have reported the synthesis of two cationic ligands **8i** and **51**, both of which have been tested in the hydroformylation of 1-octene in the ionic liquid [BMIM][PF₆]. In these experiments, the active catalyst was

prepared *in situ* by mixing Rh(CO)₂(acac) with two equivalents of the ligand in the ionic liquid [BMIM][PF₆]. The reaction was carried out at 100 °C and 30 bar synthesis gas pressure (CO: H₂ = 1:1) for 1 h. The biphasic hydroformylation of 1-octene under these conditions showed significantly higher turnover frequency (TOF) values with ligand **8i** (TOF 552, linear/branched ratio = 1.1), in which the positive charge is near to the P-atom. Thus, these data demonstrated that the increased π -acceptor character of α -cationic phosphines make the catalyst superior in this transformation^[78] In addition, it should be noted that in both cases no significant leaching of the Rh catalyst into the almost colorless organic layer was observed.^[79]



Scheme 17. The application of cationic ligands in hydroformylation.

As already shown in Table 2, most cationic ligands are more electron-poor than neutral phosphines and many even surpass phosphites in this regard. Even more intriguing than just preparing phosphite surrogates is to utilize their strong π -accepting properites as ancillary ligands in transition-metal catalysis. These phosphines withdraw electron density from the metals they coordinate to and, consequently, they are expected to improve catalytic processes whenever high π -acidity at the metal center is required, such as in π -acid catalysis promoted by Pt(II) and Au(I) complexes.

As mentioned before, N-alkyl/aryl pyridiniophosphines are also quite weak σ -donor and quite strong π -acceptor ligands due to the very low lying π^* orbitals in the pyridinium cation. These attributes confer a substantially enhanced π -acidity to the derived Pt(II) and Au(I) complexes which, as a result, also show improved ability to activate alkynes towards nucleophilic attack, when compared to other monocationic ligands. This superior performance has been demonstrated for several mechanistically diverse Pt(II) and Au(I) catalyzed transformations such as the hydroarylation of propargyl aryl ether to chromene and the cycloisomerization of enynes to cyclobutenes (Scheme 18). In particular, the study of this reaction allows a direct comparison between pyridiniophosphines and commercially available π -acceptor ligands. As can be seen in Scheme 18, CO (1 atm), which is the paradigmatic π -acceptor ligands, performed better in terms of reactivity than any the other ligands tested: $(PhO)_3P$ and $(C_6F_5)_3P$. However, catalysts **54a** and **54b** were much more efficient and cyclobutene **53** could be obtained in excellent yields after only few minutes.^[43]



Scheme 18. Ligand effect on the Pt-catalyzed cycloisomerization of enyne to cyclobutene

Apart from the reaction above, the cyclization of **55**, which is known to be extremely dependent on the global electron density at the gold atom,^[80-81] provides an additional measurement for donor properties of the ligands. π -Acidic ligands **L** can enhance the carbocationic nature of intermediate **55A**, thus promoting ring contraction by a 1,2-alkyl shift to afford **56**. In contrast, the formation of **57** through the 1,2-hydride migration process is favored by strongly σ -donating ligands at the gold center that increase the carbone character of **55A**. As illustrated in Scheme 19 the selectivity obtained using cationic ligands with cyclopropenium group is comparable to that of phosphines.^[41]



Scheme 19. Comparison of the selectivity of different ligands in the gold-catalyzed cyclization of allene diene.

Polycationic phosphines have also proven to be excellent π -acceptor ligands in catalysis. A catalyst intensively studied in our group is complex [**31**][PtCl₃]. The three positive charges of this ligand dramatically enhance the ability of Pt to activate π -systems toward nucleophilic attack. As a consequence, a remarkable acceleration of hydroarylation reaction was observed when compared with other classical π -acceptor ligands such as P(OPh)₃ or P(C₆F₅)₃ (Scheme 20).^[82] Although the Pt-catalyst derived from the trication **31** is more reactive than those derived from phosphites or fluorophenylphosphines, this catalyst still has some limitations: (a) only Pt(II) has been successfully coordinated to ligand **31**, which severely limits its range of application; (b) stereochemical properties of **31** are difficult to modulate and (c) the low solubility of **31** in organic solvents demands the use of non-coordinating apolar anion.



Scheme 20. Cyclization of 2-Ethynyl-1,1'-binaphthalene into pentahelicene as model reaction.

1.4Summary I

 α -Cationic ligands originally received attention because of their intrinsic advantages regarding catalyst recycling. However, our group has demonstrated that the strong π -acceptor character induced at the P-atom by the positive charge can also be beneficial in catalytic cycles where the rate determining step is accelerated by increasing the Lewis acidity at the metal center. Further development for this type of ligands are expected in two directions. First, the synthesis of even more electron-poor cationic ligands is interesting because it may help to develop new reactions that do not proceed with traditional catalysts. In addition, the coordination chemistry of polycationic ligands should be further studied, since ligands with two or three positively charged substituents at α -position only coordinate Au(I) and Pt(II) so far. Once the coordination was expanded to a diverse metal scope, an entire inventory of new reactions might be developed.
2 Bis- and Trispyrazoylborate/methane-Stabilized P(III)-Centered Cations

2.1 Introduction

As mentioned before, our group have prepared a series of α -cationic phosphines that have Cbased substituents at P-atom. These ligands are stable towards oxygen and moisture. Moreover, they show superior performance in π -acid catalysis due to their excellent π acceptor character induced by the positive charges.^[24, 27, 36, 41, 82-83]

To further improve the π -acceptor character of these phosphines, α -cationic phosphines containing N-based substituents might be appropriate options because N is more electron negative than C. Specifically, regarding P-based trications stabilized by N-bases, the precedents reported in the literature are **26-29**, which were obtained by reaction of PCl₃ with DMAP, DBN or guanidine; however, their connectivity was only evidenced by spectroscopy.^[50-51] Only recently, a solid structure of trication **30**, in which the three positive charges are equally distributed on two phosphorus centers, has been reported by Lammertsma and coworkers. Unfortunately, this compound is highly sensitive towards moisture and air, and therefore its coordination chemistry remains unexplored.^[52]



Scheme 21. Representative polycationic phosphines.

In this regard, we envisioned that the replacement of monodentate ligands by chelating ones or even scorpionates should be beneficial to mitigate their inherent instability and obtaining more amenable P-centered polycations. Moreover, the introduction of a remote negative charge on the ligand architecture might additionally increase the stability of the resulting complexes through attractive Coulombic interaction between the anionic ligand and the positively charged phosphorus atom.^[84] This rationale makes bis-/trispyrazoylmethane and

bis-/trispyrazoylborate ligands ideal candidates to attempt the synthesis of more robust Pcentered polycations and study their coordination properties.

2.2 Results and Discussion

2.2.1 Synthesis of bis- and trispyrazolylborate-Stabilized P-centered Cations

To test this hypothesis, we embarked on the preparation of the desired cationic phosphanes using pyrazolyl borate ligands.^[50-51] Our starting material, potassium bispyrazoyl borate **61** was prepared from the condensation of pyrazol (4 equiv.) and NaBH₄ (1 equiv.) in toluene.^[85] Suspensions of potassium bispyrazoyl borate **61** in CH₂Cl₂ were then treated with three different chlorinated phosphines (PCl₃, PhPCl₂, and CyPCl₂) in the presence of TMSOTf (2 equiv.) to afford white to yellow precipitates that could be easily separated from the reaction mixtures in all cases. Their ³¹P-NMR spectra showed signals at $\delta = 86.2$, 87.1, and 102.8 ppm, respectively, which are consistent with the desired coordination of **61** to the P center and formation of **62-64** (Scheme 22). Subsequently, the expected connectivity could be unambiguously confirmed by X-ray diffraction of a single crystal of **62** (Figure 3).

Remarkable features of **62** are the P1-N1 and P1-N2 bond distances [1.7474(11) Å and 1.7500(11) Å, respectively] that are only slightly longer than those found in trispyrazoylphosphine [1.714(4) Å], despite their dative nature.^[86] Likewise the degree of pyramidalization at phosphorus (71.7%) is notable which clearly indicates retention of a nonbonding electron pair on this atom.^[87] Also interesting is the P1-O1 distance (3.139 Å), which is shorter than the sum of the van der Waals radii, as well as the nearly linear arrangement observed for O1, P1, and N4 (171.8°). These two structural parameters indicate donation of electron density from the triflate anion to a σ^* (P1-N4) orbital of the cation which is indicative of some Lewis acid character at the phosphorus atom.



Figure 3. Molecular structure of 63 in the solid state (hydrogen atoms and solvent molecules removed for clarity; ellipsoids set at 50% probability)

Once the preparation of compounds **62-64** was achieved, we evaluated the synthesis of dicationic species by employing the neutral bispyrazoylmethane ligand **66**, which was prepared from pyrazole and CH₂Cl₂ in the presence of ^{*n*}Bu₄NHSO₄ and K₂CO₃.^[88] Treatment of a CH₂Cl₂ solution of PhPCl₂, CyPCl₂, or (Et₂N)PCl₂ with an equimolar amount of **66** and two equivalents of TMSOTf induced the slow precipitation of white solids **67-68**, which were found to be analytically pure. Their ³¹P NMR spectra displayed resonances at δ = 85.8, 110.1, and 107.8 ppm, respectively, which support the coordination of **66** to the P-center (Scheme 23 and Figure 4).

Quite intriguing are the structural features observed in the molecular structure of **69** (Figure 5). In this compound both P1-N1 and P1-N2 bond lengths [1.8376(12) and 1.8328(13) Å] are clearly elongated compared with those in **67** [1.7581(13) and 1.7692(13) Å]. On the other hand, the P1-N5 distance [1.6264(13) Å] is shorter than expected for a typical covalent

P-N bond. Moreover, the nitrogen atom shows a planar trigonal environment (sum of angles = 360°) and the C1-N5-C1 plane bisects the N1-P1-N3 angle.



Scheme 23. Synthesis of 67-69.



Figure 4. Molecular structure of **67** in the solid state (hydrogen atoms, solvent molecules and one triflate anion removed for clarity; ellipsoids set at 50% probability).



Figure 5. Molecular structure of **69** in the solid state (hydrogen atoms, solvent molecules and one triflate anion removed for clarity; ellipsoids set at 50% probability).

The isolation of **67-69** suggests that similar compounds may be prepared in a related manner employing other neutral bidentate ligands instead of pyrazoylmethanes. Particularly interesting is the possible use of bisoxazolidines^[89] (BOX ligands) since they might offer a fast and highly modular route for the preparation of chiral enantiopure P-centered dications.

We were pleased to see that bisoxazolidine **72** indeed reacted with PhPCl₂, under the conditions already developed for bispyrazoyl methane ligands, affording the desired complex **73** as a crystalline material in moderate yield. Although the limited data quality impeded satisfactory structure refinement, X-ray diffraction of a crystal **73** was good enough to confirm the structure of **73** (Scheme 24).



Scheme 24. Synthesis of 73.

Finally, we also attempted the isolation of formal P^{3+} cations stabilized by scorpionate ligands. To this end, we chose tris(3,5-dimethylpyrazoyl)borate 75^[90], tetra(pyrazoyl)borate $\mathbf{78}^{[91]}$, and tris(3,5-dimethylpyrazoyl)methane $\mathbf{81}^{[92]}$ as ancillary ligands, and treated them with PCl₃ and three equivalents of TMSOTf. The white solids that precipitated from the reaction mixture were crystallized from CH₃CN/Et₂O, affording compounds 76, 79 and 82 in an analytically pure form. The ¹H NMR spectra of **76** and **82** showed only two singlets in the aliphatic region, indicative of C_3 symmetry of the newly formed complexes. Moreover, ³¹P NMR resonances at 7.3 (76), -2.4 (79), and -9.9 (82) ppm also support a tridentate coordination of the pyrazoyl ligands to the central phosphorus atom in these compounds (Scheme 25). Single crystals suitable for X-ray diffraction analysis could be obtained for 76 and 79 confirming the proposed connectivities (Figure 6 and 7). It was observed that the P-N distances in 76 and 79 are practically identical to those observed for 63 and 67. However, the geometry of the trispyrazoyl ligand produces a higher degree of pyramidalization at the phosphorus center that reaches 85.7% in 76 and 92.4% in 79.^[87] In addition, each P atom is closely surrounded by three triflate anions in the unit cell. The P1-O1 distance in 79 is, as expected, the shortest among the complete series of compounds under study (2.734 Å), while the much longer P1-O1 contact in **76** (3.192 Å) must be attributed to the steric hindrance derived from the additional methyl groups on the pyrazol rings. The positive charges at Patom efficiently stabilize the three $\sigma^*(P-N)$ orbitals and thus, confer Lewis acid character to the phosphorus atom. This explains the observed short distances between the central P-atom and the triflate anion in these compounds.



Scheme 25. Synthesis of 76, 79 and 82.



Figure 6. Molecular structure of **76** in the solid state (hydrogen atoms, solvent molecules and one triflate anion removed for clarity; ellipsoids set at 50% probability).



Figure 7. Molecular structure of **79** in the solid state (hydrogen atoms, solvent molecules and one triflate anion removed for clarity; ellipsoids set at 50% probability).

2.3 Electronic Properties

To better understand the electronic structure and bonding of these compounds, DFT calculations were performed at the BP86/6-311++G** level. The Wiberg bond index (*Wi*) on cation **63** was found to be 0.94 for the P1-C1 bond, but only 0.73 for both P1-N1 and P1-N3 bonds, which is in line with their dative nature. The computed charge at phosphorus was +1.23e (natural population analysis), which explained the low energy of the lone pair at phosphorus (HOMO-6; E = -11.46 eV) and of the antibonding σ^* (P-N) orbital (LUMO+1; E = -5.99 eV) that confers Lewis acidity at the phosphorus center (Figure 8).



Figure 8. Lone pair (HOMO-6, left) and low lying $\sigma^*(P-N)$ orbital (LUMO+1, right) of 63.

DFT calculations were again very useful to explain the structural features found in **69**. Figure 9 shows the shape of the HOMO in this cation. The P1-N5 bond exhibits significant π -bonding character due to the overlap between the σ^* (P-N) orbital (LUMO+1) and the electron lone pair on N5 (Figure 9). As a result, electron density is transferred from nitrogen to phosphorus and a partial double bond is established between these two atoms. Consequently, the P1-N5 *Wi* value increases to 1.13. On the other hand, the partial population of the antibonding orbital of 2e symmetry weakens the P-N bonds between phosphorus and pyrazol (*Wi* value of only 0.57) and lengthens them considerably (Figure 9).



Figure 9. Fragment analysis of the HOMO of 69.

2.4 Attempts of Coordination

The polycationic species were shown to display Lewis acid properties. Presumably for this reason, all attempts to use them as ligands resulted in either no reaction or decomposition. Moreover, despite their stability in argon for days at room temperature, once exposed to air, they decomposed immediately, demonstrating strongly hydroscopic properties.

2.5 Summary II

In summary, making use of an –onium substituent transfer strategy, we have been able to isolate and structurally characterize several P-centered polycations stabilized by bis- and tris-(pyrazoyl)borate or methane ligands. In all of these compounds, the phosphorus center adopts a pyramidal environment, which is indicative of the presence of a lone pair mainly located on this atom. However, the high positive charge at phosphorus lowers the energy of this orbital to a level that makes it unavailable for donation. The same positive charge also stabilizes quite efficiently the σ *(P-N) orbitals, thus conferring Lewis acid character to the phosphorus atom. This Lewis acidity is evident from the short contacts observed between the triflate anions and the phosphorus centers.

3 Dicationic Chelating Phosphines: Synthesis, Structure and Reactivity

3.1 Introduction

 α -Cationic phosphines have attracted increased attention during the past years due to the superior performance of the catalysts containing these ligands.^[24, 27, 93-94] However, the strongest cationic π -acceptor phosphines that can be prepared following this strategy, namely di- and tricationic ones, show little affinity to form coordination complexes and, until now, they have only been able to bind metal fragments that efficiently engage in back donation such as Au(I) and Pt(II). Our attempts, and that of others, to expand the coordination to other metal sources unfortunately failed.^[30, 60, 83]



Scheme 26. Coordination chemistry of polycationic ligands.

In an attempt to circumvent the intrinsic shortage of polycationic ligands and gain access to a broader repertoire of potential metal catalysts bearing these ligands, the introduction of an additional donating group was envisioned as an anchor to bring the cationic moiety into the vicinity of the metal and thus, induce its coordination. This strategy has been used previously to coordinate Lewis acidic centers such as boranes to metals (Scheme 27a).^[95-96] Another example of the use of this strategy is the coordination of N-heterocyclic nitrenium ions **85**^[97] after the introduction of chelating phosphorus atoms on their architecture (Scheme 27a), even though it is known that boranes or nitrenium cations by itself are not able to coordinate these metals. More intriguingly, some of these complexes display superior performance in catalysis due to the strong π -acceptor properties of the ligands they bear. In this regard, we reasoned that it might be possible to use a similar strategy to facilitate the coordination of the dicationic ligands to metals. Hence, we decide to prepare dicationic chelating phosphines bearing a latent -PPh₂ moiety, such as the ones described in Scheme 27b.



Scheme 27. Representative examples for induced coordination and the simplified structure of chelating polycationic ligands.

3.2 Synthesis

3.2.1 Synthesis of Chelating Dicationic Ligands

To put our idea into practice, we first prepared phosphine **90** from dibromobenzene in three steps according to a modified literature procedure (Scheme 28).^[98-99] First, monolithiation of dibromobenzene with ^{*n*}BuLi in dry THF at -110 °C followed by addition of Ph₂PCl afforded the corresponding monophosphinated product **88**. A subsequent second lithiation with ^{*n*}BuLi in dry THF at -78 °C followed by reaction with ClPO(OEt)₂ gave phosphonate **89** which was finally reduced with LiAlH₄ to diphosphine **90** in 64% yield.





Unfortunately, reaction of primary phosphine **90** with **17a** in the presence of Et_3N (2 equiv.) at 60 °C afforded an unexpected cyclic compound **91**, whose structure was confirmed by single X-ray diffraction analysis (Figure 10). Once the connectivity of **91** was elucidated, we concluded that probably the desired salt **91A** was formed as an intermediate, but an attack of the electron lone pair from the -PPh₂ moiety to C-1 of one cyclopropenium center, led to the formation of spirocyclic compound **91B**, which ring opens to afford intermediate **91C**.



Subsequent 1,5-hydride migration afforded intermediate **91D**, which cycloisomerized to **91** (Scheme 29).

Scheme 29. Proposed mechanism for the formation of 91.



Figure 10. Molecular structure of compound **91** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms, tetrafluoroborate counter anions and solvent molecules have been omitted for clarity.

Because the formation of the undesired compound **91** requires the attack of the electron pair from the P(neutral) atom to the 3-membered cyclopropenium ring, other cationic groups less prone to suffer from this attack were also tested. Thus, dimethyldihydroimidazolium groups

were selected as more appropriate substituents due to the less strained nature of these cycles. In fact, treatment of 2-chloro-3,5-dihydroimidazolium with primary diphosphine **90** in the presence of base easily provided the desired dications **92a**. Anion exchange gave access to dications **92b-c**, containing SbF_{6}^{-} and $B(\text{Ar}^{F})_{4}^{-}$ counter anions. The structure of dication **92b** was unambiguous confirmed by single X-ray diffraction analysis (Scheme 30 and Figure 11).



Scheme 30. The synthesis of dihydroimidazolium substituted dication 92.



Figure 11. Molecular structure of compound **92b** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms, hexafluoroantimonate counter anions and solvent molecules have been omitted for clarity.

As a structure modification of the basic architecture of dication **92**, our first goal was to replace the phenyl backbone by a biphenyl one that functions as a linker between the two phosphorus atoms. This was desirable for two reasons: (a) the increased distance and flexibility between the two phosphorus atoms may result in completely different reactivity, and (b) the species derived from a rotationally hindered biphenyl system could later be prepared in enantiopure form once the synthesis is optimized.

The route depicted in Scheme 31 was designed for the synthesis of dication **101**. Dianiline **96** was prepared in three steps according to a known literature procedure, consisting Sandmeyer reaction, Ullmann coupling, and the reduction of both nitro groups.^[100] Then **96** was subjected to Sandmeyer reaction conditions to afford the biaryl diiodide **97**, which was lithiated with ^{*n*}BuLi in dry THF at -78 °C followed by reaction with Ph₂PCl to afford the corresponding monophosphinated product **98**. Subsequent lithiation with ^{*n*}BuLi in dry THF at -78 °C,

followed by reaction with ClPO(OEt)₂ afforded phosphonate **99**, which was finally reduced by LiAlH₄ to deliver the desired diphosphine **100** in 85% yield. Treatment of this compound with 2-chloro-3,5-dihydroimidazolium **17c** in the presence of base easily provided the desired dication **101a**. Anion exchange allowed the access to dication **101b**, containing SbF_6^- counter anion.

The ³¹P NMR spectra of both dications, **92** and **101**, consists of two doublets ($\delta_P = -8.5$, -43.8 ppm; $J_{P-P} = 212$ Hz for **92**, and $\delta_P = -14.7$, -44.1 ppm; $J_{P-P} = 86.7$ Hz for **101**), which can be attributed to the –PPh₂ and [-P(H₂Im)₂]²⁺ moieties, respectively. Single crystals suitable for X-ray structure determination were obtained (depicted in Figures 11 and 12). All C-P bond lengths from **92** and **101** are in accord with typical single bonds,^[101] but interestingly, the P1-P2 distance in **92** (3.076 Å) is shorter than in its neutral analogue 1,2-bis(diphenylphosphino)benzene (3.165 Å).^[102] This shortening might indicate a reduction of the repulsive interaction between the electron lone pairs on the two phosphorus atoms.



Scheme 31. The synthesis of dication 101a-b.



Figure 12. Molecular structure of compound **101a** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms, tetrafluorborate counter anions and solvent molecules have been omitted for clarity.

3.2.2 Synthesis of Monodentate Dications

In order to compare the coordination properties of chelating and monodentate dications, compounds **102-104** were also prepared following a similar sequence. Initially, PhPH₂ and CyPH₂ were reacted with chlorodihydroimidazolium salts; however, after many trials, these reactions failed to produce the desired dications in a clean manner. Once the chloroimidazolium **17c** was replaced by chloroamidinium **17d**, the desired dications **103** and **104** were obtained in moderate yield. Thus, it was estimated that the failed condensation between chlorodihydroimidazolium and either PhPH₂ or CyPH₂ might be caused by the insolubility of the monocationic intermediate that is necessarily formed after the first condensation. Hence, 2-biphenylylphosphine, which contains a more lipophilic substituent and thus, depicts increased solubility in organic solvents, was chosen as the starting material. To our delight, after this modification dication **102** could be isolated as a white solid, albeit in low yield (Scheme 32a). In addition, chelating diphosphine **105** and **106**, prepared for comparison reasons, were synthesized by lithiation of **88** followed by reaction of $(C_6F_5)_2PCI^{[103]}$ and $(1-pyrrole)_2PCI^{[104]}$ respectively (Scheme 32b).



Scheme 32. The synthetic route of monodentate dication and bidentate phosphines.



Figure 13. Molecular structure of compound **103** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms and hexafluoroantimonate counter anions have been omitted for clarity.

3.3 Electronic Properties of the phosphines

At this point the donor abilities of the newly prepared ligands were estimated by comparative analysis of their cyclic voltammograms.^[69, 73-74] Ligand **92** and **101** showed oxidation peaks at 1.050 and 0.974 V respectively, which can be assigned to the oxidation of the –PPh₂ groups. Comparison with reference compounds reveals that the –PPh₂ lone pair in **92** and **101** is less available than that in PPh₃ (Table 3, Entry 3), probably as result of the strong electron

withdrawing effect that the dicationic group exerts on the neutral phosphine moiety. This influence is markedly stronger in **92** due to the closer proximity of the two phosphorus atoms imposed by the *o*-phenylene linker. Accordingly, the reduction potentials of **92** and **101** (-1.528 V and -1.504 V respectively), that can be ascribed to the electrophilic character of the $[-P(H_2Im)_2]^{2+}$ fragments, are slightly lower than that of **102** (Table 3, Entry 5) denoting, as expected, a marginal loss of their strong acceptor properties when compared with their monodentate analogue.

| based ligands and reference of | compounds | are included for | comparison. | |
|--------------------------------|-----------|------------------|-----------------------|------------------------|
| | Entry | Ligand | Ep(ox) ^[a] | Ep(red) ^[a] |
| | | | 4.050 | 4 500 |

Table 3: Electrochemical redox potentials of ligands 92 and 101. The values for commonly used phosphorus-

| - | - | , | |
|---|---------------------|-------|--------|
| 1 | 92 | 1.050 | -1.528 |
| 2 | 101 | 0.974 | -1.504 |
| 3 | PPh ₃ | 0.687 | _[b] |
| 4 | P(OMe) ₃ | 1.297 | _[b] |
| 5 | 102 | [c] | -1.457 |
| 6 | 103 | 1.812 | -1.350 |
| 7 | 104 | 1.855 | -1.319 |
| 8 | 105 | 0.870 | _[b] |

[a] Oxidation/reduction peaks potential reported in V and calibrated versus $Cp_2^*Fe/Cp_2^*Fe^+$, Bu_4NPF_6 (0.1 M) in CH_2Cl_2 ; [b] No reduction signal observed from 0 to -2.5 V; [c] no signal detected from 0 to 2V;

To further investigate the electronic properties of these ligands, a series of Mo-derivatives **107a-d**^[105] were synthesized by reaction with Mo(CO)₆ in THF (Scheme 33). The donor endowment of **92** was compared with that of other chelating phosphines of similar structure by analysis of the CO stretching frequencies in the corresponding [LMo(CO)₄]ⁿ⁺ (n = 0 or 2) derivatives. These data suggest that the dihydroimidazolium substituents impart stronger acceptor properties to the phosphorus atom than 1-pyrrole or $-C_6F_5$ units. Thus, **92** and **101** can be defined as bidentate ligands which possess a neutral σ -donating group together with an exceptionally good π -acceptor functionality. The structure of the dicationic complex **107a** was confirmed by single X-ray diffraction analysis, as shown in Figure 14.



Scheme 33. Evaluation of the donor ability of 92 by IR spectroscopy



Figure 14. Molecular structure of compound **107a** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms, hexafluoroantimonate counter anions and solvent molecules have been omitted for clarity.

Finally, an additional probe of the Lewis acidity of the $[-P(H_2Im)_2]^{+2}$ moiety could be obtained from the X-ray structure of compound **108**, which was itself prepared by selective oxidation of the $-PPh_2$ group in **92** with elemental sulfur (Scheme 34 and Figure 15). This compound features a S1-P1 distance of only 3.200 Å, which is significantly shorter than that of a neutral analogue.^[106] This value also reveals an attractive P1-S1 interaction in **108** that is attributed to donation from sulfur to one of the low lying $\sigma^*(P1-C1)$ orbital.



Scheme 34. Selective oxidation of the phosphorus atom on dication 92b.



Figure 15. Molecular structure of compound **108** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms and hexafluoroantimonate counter anions have been omitted for clarity.

To better understand the electronic properties of dication **92**, its electronic structure was evaluated theoretically at the M06-L/TZVP level. The optimized structure compares well with that obtained from X-ray analysis (Figure 16). The inspection of the frontier orbitals sheds light on the multifaceted properties of **92**. The HOMO is localized largely on the neutral phosphorus atom, while the significant localization of the LUMO and LUMO+1 orbitals on the positively charged fragment suggests suitable symmetry for π -acidic character upon metal coordination. Also noteworthy is the observation that the HOMO-LUMO gap for ligand **92** is 1.0 eV lower than that of the analogous neutral ligand of 1,2-bis(diphenylphosphino)benzene. This suggests the possibility of a P-P bonding interaction.



Figure 16. Molecular orbitals of 92 and their orbital energies computed at the M06-L/TZVP level.

An AIM and bond order analysis in fact supports the presence of a bonding interaction. The electron density and its corresponding Laplacian reveal a closed shell, dative interaction between the P-P atoms. To assess whether the interaction is attributed purely to the proximity induced by the bridging ligand backbone, the phenyl backbone was replaced by two hydrogen atoms to determine the approximate bond strength (Figure 17). A constraint free optimization of the fragments resulted in **92-frag** where the P-P distance increased only slightly to 3.13 Å from 2.99 Å in **92**. The M06-L/TZVP bonding energy is determined to be -31.3 kcal/mol. The physical nature of the interaction was evaluated through energy decomposition at the BP86/TZ2P//M06-L/TZVP level. While dispersion interactions (ΔE_{disp}) are expected to make

up a large percentage of the total favorable interaction due to a π -stacking component in this case, the most prominent favorable interaction component is attributed to orbital interactions (ΔE_{orb} ; 40%). Moreover, this bonding interaction may effectively account for the slightly reduced oxidation and reduction potentials for **92** in comparison to its monodentate analogue (Table 3, entries 1 and 5) through mixing of the lone pair orbital on the neutral phosphorus with the antibonding orbitals on the dicationic phosphorus.



| | 92 | 92-frag | | 92-frag |
|---------------------------------------|-------|---------|----------------------------|---------|
| $ ho_{ m b}$ (P1-P2) | 0.033 | 0.024 | ΔE_{Pauli} | 34.2 |
| $ abla^2 ho_{ m b}({ m P1-P2})$ | 0.036 | 0.030 | ΔE_{elstat} | -26.4 |
| BO | 0.124 | 0.155 | $\Delta E_{\rm orb}$ | -29.6 |
| $n_{P1} \rightarrow \sigma^*_{P1-C1}$ | 6.7 | 8.6 | $\Delta E_{\rm disp}$ | -18.0 |
| | | | $\Delta E_{\rm int}$ | -39.8 |
| | | | $\Delta E_{\rm dist}$ | 3.5 |
| | | | ΔE | -36.3 |

Figure 17. Theoretical investigation of the interaction of the two phosphorus atom on **92**. Geometries, AIM parameters ρ_b and $\nabla^2 \rho_b$, Wiberg bond index, NBO perturbation energies (kcal/mol), and ETS energy decomposition analysis for **92** and the **92-frag** computed at the BP86-D3/TZ2P//M06-L/TZVP level.

3.4 Coordination Study

Encouraged by this analysis we decided to evaluate the ability of **92** to function as a chelating ligand for different metals. To our delight, when **92b** was allowed to react with $PtI_2(PhCN)_2$, a yellow solid **109a** was obtained. The ³¹P-NMR spectrum of this product showed downfield shifts ($\delta_P = 39.2$, 5.4 ppm, $J_{P-P} = 4.6$ Hz) compared to the original chemical shift of the free ligand **92b** ($\delta_P = -12.3$, -47.6 ppm, $J_{P-P} = 212.4$ Hz), as well as the appearance of characteristic ¹⁹⁵Pt satellites ($J_{P(neutral)-Pt} = 2856.1$ Hz, $J_{P(cationic)-Pt} = 3457.9$ Hz) which indicated the coordination of both phosphorus centers to platinum. Subsequently, this connectivity was unambiguously confirmed by X-ray diffraction analysis (Figure 18). In **109a** the geometry about the Pt center is slightly distorted square planar and the P1(cationic)-Pt1 bond distance [2.2058(10) Å] is shorter than the P2(neutral)-Pt1 bond [(2.2559(10) Å], a clear

consequence of the strong π -acceptor character of the $[-P(Im)_2]^{2+}$ group. Reactions with PtCl₂(CH₃CN)₂ and PdCl₂(CH₃CN)₂ were equally successful, affording isostructural complexes 109b and 109e respectively. The reactivity of 92b towards Rh(I) centers was also analyzed. Salt 92b readily displaced cyclooctadiene in [RhCl(cod)]₂ to generate a binuclear tetracation **109c** in which both $[-P(H_2Im)_2]^{2+}$ groups adopted a distal orientation (Figure 19). Again in this structure the shorter P1(cationic)-Rh1 bond length [2.1319(13) Å], compared to the P2(neutral)-Rh1 one [2.1924(13) Å], indicates strong π -acceptor properties at the cationic phosphine. In compound 109c, the columbic repulsion between the fragments facilitates its dissociation and thus, after the addition of a few drops of acetonitrile to solutions of **109c**, an equilibrium was established and the monomeric 109d was the predominant species, as depicted in Scheme 35. As expected from a coordinately saturated metal fragment, in complex 109f the Au atom coordinates with 92b only through the R-PPh₂ moiety. However, it is worth mentioning that the P1(cationic)-Au1 distance in this compound (3.365 Å), which is just below the sum of the Van der Waals radii of both elements, suggests a weak Au \rightarrow P(cationic) interaction. In addition, an aurophilic interaction was also observed in the solid state of 109f (3.147 Å) (Figure 21).



Scheme 35. The coordination study of dication 92b.



Figure 18. Molecular structure of compound **109a** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms, hexafluoroantimonate counter anions and solvent molecules have been omitted for clarity.



Figure 19. Molecular structure of compound **109c** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms, hexafluoroantimonate counter anions and solvent molecules have been omitted for clarity.



Figure 20. Molecular structure of compound **109d** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms, hexafluoroantimonate counter anions and solvent molecules have been omitted for clarity.



Figure 21. Molecular structure of compound **109f** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms and hexafluoroantimonate counter anions have been omitted for clarity.

Dicationic bisphosphine **101a** was also allowed to react with [RhCl(cod)]₂ affording an orange solid **110** (Scheme 36). The ³¹P-NMR spectrum showed downfield shifts ($\delta_P = 38.1$, 9.9 ppm, $J_{P\cdot P} = 50.4$ Hz) compared to the original resonances of **101** ($\delta_P = -15.0$, -44.4 ppm, $J_{P\cdot P} = 87.0$ Hz), along with the appearance of characteristic P-Rh coupling constants ($J_{P(neutral)-Rh} = 154$ Hz, $J_{P(cationic)-Rh} = 216$ Hz) that indicate the coordination of both P centers to Rh. Subsequently, this connectivity was unambiguously confirmed by X-ray diffraction analysis (Figure 22). In product **110** the geometry about the Rh center is slightly distorted square planar and the cationic P1(cationic)-Rh1 bond distance [2.1608(8) Å] is shorter than the P2(neutral)-Rh1 one [2.2358(8) Å], again as consequence of the strong π -acceptor character of the [-P(Im)₂]²⁺ group. The bigger coupling constant and the shorter bond length for the cationic P-atom demonstrate its strong interaction with the Rh center.



Scheme 36. The coordination study of dication 101a.



Figure 22. Molecular structure of compound **110** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms and hexafluoroantimonate counter anions have been omitted for clarity.

Interestingly, mixing monodentate dication **102** with different metal precursor in CD_2Cl_2 did not produce any metal complex as could be demonstrated by analysis of ³¹P NMR of the reaction mixtures. Compared with the free ligands, no modification was observed. This result strongly confirms that the coordination of **102** to various metal salts is only possible due to the incorporation of a chelating phosphorus atom (Figure 23).



Figure 23. ³¹P NMR Spectra of the reaction of compound **102** with different metal salts. Ligand **102** (5.0 mg, 0.006 mmol) in CD_2Cl_2 (0.6 ml) and the corresponding metal salts were added to an NMR tube and the sample stirred for 5 h. After that, the magnetic stirrer was removed and ³¹P NMR spectra were recorded.

3.5 Reductive Elimination of Bis(pentafluorophenyl)palladium Complexes

3.5.1 Synthesis of the Biarylpalladium Complexes

Reductive elimination is an elementary reaction step present in many catalytic cycles. During this process, the oxidation state from the metal is reduced by two units, making the metal more electron-rich. For this reason, strong π -acceptor ligands usually facilitate this step, since the additional charge on the metal can be easily delocalized along the ligand. This makes our ligands potentially quite interesting in transformations where the rate-determining step is reductive elimination.^[107-108]

In order to test this working hypothesis, relevant biarylpalladium complexes **112a-h** were prepared, all of them bearing $-C_6F_5$ substituents.^[109] Polyfluorinated aryls were chosen, because the reductive elimination of these very electron-poor moieties is known to be especially difficult. In fact, the reaction is known to proceed only under extremely harsh conditions (concentrated HNO₃).^[109]



Scheme 37. Synthesis of biarylpalladium complexes.



Figure 24. Molecular structure of compound 112b in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 25. Molecular structure of compound **112f** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 26. Molecular structure of compound **112g** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms, tetrafluoroborate counter anions and solvent molecules have been omitted for clarity.



Figure 27. Molecular structure of compound **112h** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms, tetrafluoroborate counter anions and solvent molecules have been omitted for clarity.

3.5.2 Experimental Investigation of the Effect of Cationic Ligands in Reductive Elimination Processes

Compounds **112a-e** were completely ineffective for this process, and no trace of the desired perfluorobiphenyl was detected under our working conditions (CD₃CN at 70 °C). Gratifyingly, the reductive elimination of C_6F_5 - C_6F_5 from **112g** proceeded smoothly and a remarkable conversion of 72% was achieved in 15 hours (Figure 28).

This preliminary evidence on the beneficial effect of dicationic ligand **92a** encouraged us to test the complex **112h** in this same transformation (Figure 28). It is well known in palladium catalysis that the employment of ancillary ligands with large bite angles also facilitates reductive elimination steps, because they better stabilize the linear zero valent complex resulting from the elimination and efficiently delocalize the excess electron density on the metal after this step.^[110-111] The kinetic profile for **112h** was illustrated in Figure 28. Acetone was used as solvent due to the instability of **112h** in acetonitrile. The reactivity clearly surpasses that of **112g**, and gave rise to the quantitative formation of perfluorobiphenyl in only six hours, thus confirming our predictions. It should be mentioned that complex **112f**

also provided reasonable conversion under the same conditions and the rate of the reaction is even superior to the one of **112g**. This reductive elimination surely takes place through a tricoordinated palladium species. Therefore, a new question arosed. Do **112h** and **112g** eliminate directly through four coordinated palladium species, or is a coordination site liberated (by decoordination of the $[-P(Im)_2]^{2+}$ moiety) before the actual reductive elimination takes place? Calculations were performed to answer this question.



Figure 28: The reductive elimination of the related biarylpalladium complexes. [a] Ligand effect on the reductive elimination of C_6F_5 - C_6F_5 from Pd(II) complexes **112a-h**. Reactions were carried out in acetonitrile at 70 °C. Due to its instability in acetonitrile, acetone was used as the solvent in the case of **112h** and DCE was used as the solvent in the case of **112f**. Conversions were determined by ¹⁹F NMR.

3.5.3 Theoretical Investigation of Cationic Ligands in Reductive Elimination

The energy profiles for the reductive elimination of **112g**, **112h**, and **112b** were explored at the M06-L(SMD-CH₃CN)/def2-TZVP//BP86-D3/def2-TZVP level of DFT (Figure 29). The direct reductive elimination from **112g** is predicted to occur with a relatively facile barrier of 22.9 kcal mol⁻¹ and is overall exergonic by 8.8 kcal mol⁻¹. The possibility for hemilability in ligand **92** during or before the reductive elimination of **112g** is dismissed on account of monodentate structure **112g-1** being 3.4 kcal mol⁻¹ higher in energy than the transition state

for the bidentate coordination mode in **112g-TS**. In contrast, the analogous neutral complex **112b** experiences a reductive elimination barrier that is 9.3 kcal mol⁻¹ higher in energy than that for **112g**. In addition, the reaction is endergonic by 11.3 kcal mol⁻¹. The difference in reaction free energies suggests that ligand **92** binds more strongly to Pd(0) than Pd(II) while 1,2-bis(diphenylphosphino)benzene forms a much stronger complex **112b** with Pd(II) than Pd(0). Lastly, the reaction barrier for ligand **101** is predicted to be 1.3 kcal/mol lower than that for **112g**. Hence, the increase in activity observed with **112h** can be readily rationalized based on the increased bite angle which diminishes the C-Pd-C angle and consequently, less distortion is required to reach the product resulting in a lower overall barrier.



Figure 29. Gibbs Free Energy profile for the reductive elimination of complexes **112g** (black), **112h** (blue) and **112b** (red) determined at the M06-L(SMD_{CH3CN})/def2-TZVP//BP86-D3/def2-TZVP level of DFT.

The details of the **L**-Pd binding energy were deconstructed with the aid of energy decomposition from the Pd(II) complex to the reductive elimination product. While the change in the repulsion terms ($\Delta\Delta E_{\text{Pauli}}$ and $\Delta\Delta E_{\text{dist}}$) is greater in **112g-TS**, it exhibits far greater compensation interaction terms than **112b-TS**. The orbital term is the strongest of the interaction terms favoring **112g-TS** and indicates that the decreasing orbital interactions for reaching the TS is significantly less than that for **112b-TS**. Moreover the change in charge transfer ($\Delta\Delta q$) from the ligand to the Pd(C₆F₅)₂ fragment on going from the reactant complex

to the transition state of reductive elimination is less for **112g** than for **112b** which may contribute to the reduced energy barrier for **112g**.

| | $\Delta \Delta E_{\text{Pauli}}$ | $\Delta \Delta E_{\rm elec}$ | $\Delta \Delta E_{\rm orb}$ | $\Delta \Delta E_{\rm disp}$ | $\Delta \Delta E_{\rm int}$ | $\Delta\Delta E_{\rm dist}$ | $E_{\rm a}$ | $\Delta\Delta q$ |
|----------|----------------------------------|------------------------------|-----------------------------|------------------------------|-----------------------------|-----------------------------|-------------|------------------|
| 112g | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 112g-TS | -22.95 | 4.30 | 22.88 | 4.94 | 9.17 | 10.84 | 20.01 | -0.35 |
| 112g-PRT | 30.20 | -63.48 | 17.00 | 25.13 | 8.85 | -13.98 | -5.13 | -0.76 |
| 112b | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 112b-TS | -38.19 | 16.98 | 41.73 | 8.86 | 29.38 | 0.96 | 30.34 | -0.41 |
| 112b-PRT | 24.46 | -41.57 | 29.50 | 23.26 | 35.65 | -18.27 | 17.38 | -0.83 |

Table 4. Energy decomposition analysis and NBO charge transfer (Pd(C₆F₅)₂ \rightarrow L). $E_a = \Delta\Delta E_{int} + \Delta\Delta E_{dist}$

Charge transfer from the ligand inhibits $Pd(II) \rightarrow Pd(0)$ reduction. The principle orbital interaction governing this conversion is that between the ligand HOMO and the Pd complex LUMO and thus, the preference can be probed through this interaction. The orbital energies and corresponding orbital overlaps between the ligand and $Pd(C_6F_5)_2$ fragments for the reactant complexes **112b** and **112g** as well as their transition states of reductive elimination 112b-TS and 112g-TS are shown in Table 4. The large fragment orbital energy difference for 112g ($\Delta E = 4.94 \text{ eV}$) as compared with 112b ($\Delta E = -0.89 \text{ eV}$) implies a much stronger interaction in the latter. Moreover the HOMO in ligand 112g is more localized on the neutral phosphorus atom whereas in 112b the HOMO is equally distributed on both phosphorus atoms. This distribution difference is reflected in a more enhanced orbital overlap for the equally distributed neutral ligand in 112b. Upon conversion to the transition state a much greater distortion in the $Pd(C_6F_5)_2$ fragment for **112b** than that for **112g** is required. This demand is expressed in diminished Ar-Ar bond distance resulting in an increased energy for the corresponding LUMO. Furthermore the overlap is diminished by 26% upon conversion to the TS for 112b whereas the overlap is only diminished by 10% in 112g. The greater decrease in the overlap combined with the increased orbital energy difference in $112b \rightarrow 112b$ -TS signifies the greater need for reduced charge transfer from the ligand as the change in oxidation state favors charge removal from the $Pd(C_6F_5)_2$ as the Ar-Ar bond forms (Figure 30).



Figure 30. Frontier fragment orbitals for 112g, 112g-TS, 112b, and 112b-TS with their orbital energies and orbital overlaps, s, computed at the BP86/TZ2P//BP86/def2-TZVP level.

By virtue of the positive charge in ligand **92**, a bimodal adjustment to the ligand is imparted as compared to the neutral analogue for the ligand in complex **112b**. The energy of the HOMO relating to the lone pair orbitals on the phosphorus atoms is significantly lowered by ~-5.6 eV as compared with the neutral analogue, resulting in a significantly weaker bonding interaction. The second effect is the localization of the HOMO on the neutral phosphorus atom. This asymmetry in a chelating ligand results in diminishing overlap with transition metal d orbitals translating to a weaker bond as compared with a chelating ligand with a suitably symmetric HOMO distribution as in **112b**.

3.5.4 Reactivity of Dication 92 towards Pd(0) and Ni (0)

Encouraged by these results, we decided to study the coordination of **92** towards Pd(0) and Ni(0) complexes, since metal complexes are formed after reductive elimination of the biaryl moiety from compound **112g-h**. Hence, treatment of **92b** with an equivalent amount of Pd₂(dba)₃ in CH₂Cl₂ resulted in the precipitation of a yellow solid **113**, depicting two singlets in its ³¹P NMR spectrum, one at $\delta_P = 49.4$ ppm, which surely corresponds to the R-PPh₂ fragment, and a quite indicative signal at $\delta_P = 15.9$ ppm, which could not be directly attributed to the original [-P(H₂Im)₂]²⁺ group (Scheme 38). Moreover, in contrast to the complex formed before, the ¹H NMR spectrum of **113** indicated unequivalency of its four methyl groups.

Fortunately, after several attempts, crystallization from acetonitrile afforded single crystals of this product and its connectivity could be determined (Figure 31). In product **113** an oxidative addition of Pd(0) into one of the C-P(H₂Im) bonds has taken place, providing a phosphinidene complex where the Pd(II) atom additionally coordinates an acetonitrile molecule. Identical reactivity was observed on reaction of **92b** with Ni(cod)₂, although in this case the exchange of acetonitrile by 2,6-(dimethyl)phenylisonitrile was necessary to obtain a crystalline material **114** (Figure 32). It is worth mentioning that the cationic P(H₂Im)-fragments in **113** and **114** still bear a non-shared electron pair at phosphorus that might still be used for coordination of a second metal center.



Scheme 38. The coordination study of dication 92b with Pd(0) and Ni(0).



Figure 31. Molecular structure of compound **113** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms and hexafluoroantimonate counter anions have been omitted for clarity.



Figure 32. Molecular structure of compound **114** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms and hexafluoroantimonate counter anions have been omitted for clarity.

The catalytic hydroalkylation of alkenes is a valuable, atom-economical methodology for the formation of C–C bonds from readily available starting materials.^[112] Pioneering studies have led to the development of intermolecular processes that employ styrenes,^[113] inactivated alkenes,^[114-115] allenes,^[116-117] and alkynes^[118-119] as effective substrates that can react with appropriate C-based nucleophiles.^[120] The hydroalkylation of diene substrates is synthetically useful; such reactions convert readily available unsaturated hydrocarbons into versatile allyl-containing building blocks, in which the double bond can be functionalized in a later reaction. Normally, the process of hydroarylation requires the activation of the alkenes by π -acidic metal centers. This renders them electrophilic and therefore, susceptible to addition by arene nucleophiles.^[121]

In the coordination study of 92 with Rh, it was observed that an equilibrium was established between 109c and its monomeric 109d, which has a vacant coordinate site available for further coordination. Considering the strong π -acceptor properties of 92, we reasoned that 109d might be suitable catalyst for the type of processes mentioned above. Hence, the intermolecular hydroarylation of 1,3-dienes with electron-rich aromatics was chosen as model to test the reactivity of our catalyst. We began our investigations by treatment of phenylbutadiene with **92b** (5 mol %), [RhCl(CO)₂]₂ (2.5 mol %) in the presence of indole as nucleophiles. KB(Ar^F)₄ (Potassium tetrakis(pentafluorophenyl)borate, 10 mol %) was added as anion exchange reagent to increase the solubility of **109d** in DCE. Under these conditions, 94% conversion of 116 into 118 was observed. The regioselectivity was also very good (96:4 $\gamma:\alpha$), probably due to the hindrance originated by the -Ph group that precluded the nucleophilic attack at the γ position of phenylbutadiene (Table 5). Further control experiments proved that neither $KB(Ar^{F})_{4}$ nor $[RhCl(CO)_{2}]_{2}$ could catalyze this reaction. In order to determine if KB(Ar^F)₄ was responsible for the increased catalyst reactivity, the cationic ligand 92c was synthesized. Hydroarylation of 116 in the presence of [RhCl(CO)₂]₂ and 92c (5 mol %) also afforded the desired compound in 91% conversion and a 92:8 γ/α ratio. This reaction demonstrated that the K^+ from KB(Ar^F)₄ did not influence the catalytic activity. When ligands 101b, 105, 106 or 115 were used instead of 92b under identical conditions, the desired product was formed in less than 5% conversion. These initial observations demonstrated the ability of ligand 92 as a π -acceptor ligand to increase the acidity of the Rh atom, thus facilitating the catalytic transformation. Of note, the use of 4-methyl-2,6-di-^tBu-pyridine (5 mol%) as a Brønsted acid scavenger did not inhibit the reaction as depicted in entry 13, while a strong Brønsted acid like TfOH led to decomposition of the diene, resulting in a complicated mixture (entry 7).

Table 5: Optimization of Rh(I)-catalyzed hydroarylation of phenyldiene with indole.



[a] Conversion to the products and the ratio of **118a** and **118b**; values determined by analysis of ¹H NMR spectra of unpurified mixtures with CH_2Br_2 as an internal standard; [b] Isolated yield; [c] The diene decomposed; [d] 4-methyl-2,6-di-^{*t*}Bu-pyridine (5 mol%) was added to the reaction.

Next, a range of electron-rich arenes was investigated. As shown in Table 6, phenylsubstituted 1,3-diene underwent site-selective hydroarylation with a series of indoles at 70 °C to afford **118-124** in moderate to excellent yields with good to excellent selectivity. More intriguingly, 1,3-dimethoxybenzene also participates in the reaction, delivering **124** in 63% yield (91:9 γ : α).

In addition, we could expand the scope of the Rh(I)-catalyzed protocol to more challenging site-selective additions using internal dienes as substrates, but at expense of the yield. Thus, 1-aryl-4-alkyl-substituted dienes underwent catalytic hydro-heteroarylation with *N*-methyl-2-phenylindole and 1,3-dimethoxybenzene to deliver functionalized products **125** and **126** in 33% and 43% yields respectively, with a significant increase in regioselectivity (99:1 γ : α) in the case of the more hindered *N*-methyl-2-phenylindole. Electron-deficient dienes could be also used for this transformation,^[122] although the yields were low in all cases. The selectivity of the addition was 96:4 γ : α and 97:3 γ : α for **128** and **129** respectively.



Table 6: Substrate scope of Rh(I)-catalyzed hydroarylation of diene with electron-rich aromatic compounds.

[a] Diene (0.2 mmol), aromatics (0.2 mmol), **92b** (5 mol%), $[RhCl(CO)_2]_2$ (2.5 mol%), $KB(Ar^F)_4$ (10 mol%) in DCE (1.0 ml) was heated for 18 h at 70 °C; [b] Isolated yield; [c] the ratio of products were determined by analysis of ¹H NMR spectra of unpurified mixtures or GCMS.

3.6.1 Theoretical Investigation of Chelating Dicationic Ligands in Catalysis

The origin of activation for ligand **92** was theoretically evaluated by comparing the reactant complex **INT2** to the complex with the analogous neutral ligand (Figure 33). Presumably, the lowest unoccupied orbital on the diene would be the relevant orbital to interact with the nucleophile in the addition step. In the neutral complex, this orbital is the LUMO and in **INT2**, the orbital is the LUMO+3 (the LUMO, LUMO+1, and LUMO+2 orbitals are localized elsewhere but are all similar in energy). The LUMO+3 on **INT2** is significantly lower than

the LUMO on the neutral complex by ~ 5 eV. Furthermore, the computed NBO charge transfer upon complexation reveals a net transfer of 0.02 e from the metal to the diene while complexation in **INT2** results in a net transfer of 0.21 e from the diene to the Rh complex. The significantly lower LUMO of the diene and resulting positive charge accumulation readily accounts for the enhanced reactivity using ligand **92** relative to neutral chelating ligands.



Figure 33. The relevant unoccupied orbitals are shown for INT1 and a neutral analogue. The NBO charge transfer is also shown.

3.7 Summary III

In summary, we outlined herein the preparation of new bidentate dicationic phosphines and their coordination chemistry towards different metals. Moreover, we showcased for the first time the utility of cationic ligands to promote difficult reductive elimination processes under mild condition, such as the formation of polyfluorinated biaryls from Pd(II) centers. Finally, the unique properties of these ligands in catalysis has been proven in the hydorarylation of phenyl diene with indoles and electron rich arenes.

4 Isolation and Coordination Chemistry of CAACs substituted α-Radical Phosphines

4.1 Introduction

Carbenes are compounds that feature a divalent carbon atom with only six electrons in its valence shell. In the singlet state, they possess a lone pair of electrons and a vacant orbital and therefore exhibit Lewis acidic and Lewis basic properties, which explains their high reactivity.^[123] Following the preparation by Bertrand group in 1988 of the first representative [bis-(diisopropylamino)phosphino](trimethylsilyl)carbene **130**,^[124] a variety of stable carbenes were prepared and are now available, the most popular being the cyclic diaminocarbenes **131** also known as NHCs.^[125-126] Following the pioneering work by Herrmann, NHCs have been recognized as excellent ancillary ligands for transition metal-based catalysts and also as organic catalysts in their own right.^[127-129] In the last decade, Bertrand *et al.* have developed a new type of carbene **132**, namely the cyclic (alkyl)(amino)carbenes (CAACs) , which have attracted more and more attention due to their unusual reactivity in main group chemistry derived from special electronic and steric properties.^[123, 130]



N atoms: π -donating and σ -withdrawing

Scheme 39. Representative carbenes that have been developed recently.

In CAACs one of the electronegative and π -donor amino substituents of diaminocarbenes is formally replaced by a σ -donating but not π -donating alkyl group. As a consequence, CAACs are more nucleophilic (σ -donating) but also more electrophilic (π -accepting) than diaminocarbenes. Additionally, the presence of a quaternary carbon in the position α to the carbene center provides steric environments that differentiate CAACs dramatically from all other carbenes (Scheme 39b). Theses peculiar stereoelectronic properties of CAACs allow for the stabilization of unusual diamagnetic and paramagnetic main group based species.^[123, 130] For examples, Bertrand and coworkers described the preparation of room temperature stable diphosphorus^[131] and diantimony^[132] derivatives in which the central heteroatom is in the zero oxidation state (Scheme 40a). Nucleophilic boron compounds have also been synthesized using CAACs (Scheme 40b).^[133-134]

a) CAACs for the stabilization of main elements in the zero oxidation state



b) CAACs for the stabilization of nucleophilic boron derivatives



Scheme 40. Structurally characterized CAACs stabilized main group compounds.

CAACs are also excellent ligands for transition metal complexes. Their most recent application consists in their use for the stabilization of paramagnetic complexes, in which the metal is in a formal zero or even lower oxidation state. Indeed, bis(CAAC)M complexes have been isolated in which the central metal is $gold^{[135-136]}$, platinum^[137], palladium^[138], copper^[139], cobalt^[140-141], iron^[140], nickel^[142], manganese^[141, 143], and zinc^[144]. These results demonstrate that CAACs are excellent π -acceptor ligands, a necessary property for the stabilization of zero-valent mononuclear metal complexes (Scheme 41).



M: Au, Pt, Pd, Cu, Co, Fe, Ni, Mn, Zn

Scheme 41. Structurally characterized CAACs stabilized metal complexes with zero oxidation state.

Because CAACs possess a singlet spin ground state and a smaller energy gap between the HOMO and the lowest unoccupied molecular orbital (LUMO) than NHCs.^[145] The isolation of CAACs stabilized radicals is also possible. The better π -accepting properties of CAACs are able to enhance the delocalization of the single electron to their π system, resulting in the decreased energetic state of the SOMO. Moreover, the presence of a quaternary center
adjacent to the carbene makes CAACs sterically demanding. This avoids radical dimerization As a consequence, CAACs have proved to be excellent ligands for the stabilization of phosphorus-,^[146-147] boron-,^[133, 148] silicon-^[149-152] and even carbon-centered neutral or cationic radicals^[153-155] (Scheme 42).



Scheme 42. Structurally characterized CAACs stabilized radicals.

4.2 a-Radical Phosphines based on CAACs

The major task of my research was to synthesize α -cationic ligands with stronger π -accepting character via reaction of diverse carbenes with chlorophosphine and to explore the isolation of the derived radicals.^[123].

4.2.1 Synthesis of Cationic Phosphines

CAAC **137** was obtained via the same method reported by the Bertrand group.^[130] Imine **135**, formed by condensation of isobutylaldehyde with 2,6-diisopropylaniline, was lithiated with LDA followed by reaction with isobutyl epoxide and addition of Tf_2O to afford imine **136** in one pot. This compound was deprotonated by LDA to afford carbene **137** (Scheme 43).



Scheme 43. Synthesis of 137.

Then, CAAC **137** in THF was treated with Ph_2PCl , Cy_2PCl and $[p-(F)Ph]_2PCl$ to generate yellow precipitates, which were separated from the reaction mixture by simple filtration. After anion exchange and recrystallization, CAAC-stabilized phosphines **138a**, **138b** and **138c** were obtained in moderate to good yields (58-66%), proving the generality of our strategy (Scheme 44).^[156]



Scheme 44. Synthesis of CAAC stabilized cationic ligand 138a-c.

The formation of cations **138a-c** was first indicated by the appearance of a signal in the ³¹P NMR resonance ($\delta = 0.0, 21.6, -4.3$ ppm). These values were comparable to the ones reported

for imidazolium or cyclopropenium substituted compounds. Moreover, the molecular structures of 138a-c were unambiguously characterized by X-ray crystallography (Figure 34-36). Two structural parameters are crucial for the understanding of the electron environment around the phosphorus atom in **138a-c**. The P1-C1(carbene) bond lengths [**138a**: 1.864(3) Å, 138b: 1.8846(11) Å, 138c: 1.8529(15) Å] are similar to those observed in neutral aromatic phosphines, but are significantly longer than typical P=C double bonds.^[157] On the other hand. the N1-C1(carbene) bond lengths [138a: 1.305(3) Å, 138b: 1.3057(14) Å, 138c: 1.3067(19) Å] are comparable to the C=N bond observed from imines (1.279 Å in DBN). In addition, the degrees of pyramidalization at phosphorus (138a: 56.5%, 138b: 55.3%, 138c: 53.3%) are comparable to those observed for neutral aromatic phosphines (56.7% for PPh₃).^[87] These two parameters reveal marginal back-donation from the phosphorus to the CAAC rings and suggest retention of a nonbonding electron pair on this atom. The pyramidalization in **138c** is smaller than in **138a** and **138b**, probably because the -CF₃ group on the phenyl ring lowers the energy of the π -system of the phenyl group, increasing delocalization of the P electron pair into this ring. This also suggests indirectly that the P1-C1(carbene) bond in 138c contains more single bond character than 138a and 138b.



Figure 34. Molecular structure of compound **138a** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms and solvent molecules have been omitted for clarity.



Figure 35. Molecular structure of compound **138b** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 36. Molecular structure of compound **138c** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.

4.2.2 Electronic Properties of Cationic Phosphines

The donor abilities of phosphines **138a-c** were evaluated by cyclic voltammetry. Phosphines **138a-c** display higher oxidation potential than phosphites and even most monocationic phosphines, which suggests their stronger π -acceptor properties. Among them, **138c** containing -CF₃ groups on the phenyl ring shows the highest oxidation potential and therefore, should represent the strongest π -acceptor properties. In addition, it was observed that the one electron reduction is quasi-reversible at $E_{1/2}$ (**138a**: -1.347 V, **138b**: -1.436 V, **138c**: -1.187 V) against the Cp^{*}₂Fe/Cp^{*}₂Fe⁺, as shown in Table 7 and Figures 37-39, which indicates the formation of stable radical that might be isolated and characterized.

Table 7: Electrochemical redox potentials of ligands 138a-c. The values for commonly used phosphorus-based ligands and reference compounds are included for comparison.

| Entry | Ligand | Ep(ox) ^[a] | Ep(red) ^[a] |
|-------|---------------------|-----------------------|------------------------|
| 1 | 138a | 1.536 | -1.347 |
| 2 | 138b | 1.494 | -1.436 |
| 3 | 138c | 1.791 | -1.187 |
| 4 | PPh_3 | 0.687 | _[b] |
| 5 | P(OMe) ₃ | 1.297 | [b] |

[a] Oxidation/reduction peaks potential reported in V and calibrated versus $Cp_2^*Fe/Cp_2^*Fe^+$, Bu_4NPF_6 (0.1 M) in CH_2Cl_2 ; [b] No reduction signal observed from 0 to -2.5 V; [c] no signal detected from 0 to 2V.



Figure 37. Cyclic voltammograms of **138a** reported in V and calibrated versus $Cp_2^*Fe/Cp_2^*Fe^+$, Bu_4NPF_6 (0.1 M) in CH_2Cl_2 .



Figure 38. Cyclic voltammograms of **138b** reported in V and calibrated versus $Cp_{2}^{*}Fe/Cp_{2}^{*}Fe^{+}$, $Bu_{4}NPF_{6}$ (0.1 M) in $CH_{2}Cl_{2}$.



Figure 39. Cyclic voltammograms of **138c** reported in V and calibrated versus $Cp_2^*Fe/Cp_2^*Fe^+$, nBu_4NPF_6 (0.1 M) in CH_2Cl_2 .

4.2.3 Coordination of the Cationic Ligands.

Based on the analysis of the donor ability of **138a-c**, it is expected that the electron lone pairs on the phosphorus atoms are still available for coordination to metal salts. Thus ligands **138a-c** were reacted with (Me₂S)AuCl to afford **139a-c** as shown in Scheme 45. Importantly, the coordination of phosphorus to the gold center in each complex was confirmed by the displacement of the original ³¹P NMR signal, and ultimately by X-ray diffraction (Figure 40-42).



Scheme 45. Synthesis of 139a-c.



Figure 40. Molecular structure of compound 139a in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 41. Molecular structure of compound 139b in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 42. Molecular structure of compound 139c in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.

4.3 α-Radical Phosphines

4.3.1 Synthesis of the Radical Phosphines

Encouraged by the distinctive cyclic voltammetry observed for these compounds, we decided to ascertain whether stoichiometric one electron reduction of these cations to the corresponding radicals could be carried out. To this end, **138a** was treated with Mg(0) powder^[155] or Li(0) sand in THF at room temperature; however, no significant change was observed by the ³¹P NMR analysis and only starting material was recovered. This suggested that the reductants used were not strong enough to transfer electrons to the cationic phosphorus ligands.



Scheme 46. Synthesis of radical 140a-c.

When one of the strongest reductants KC_8 (potassium graphite) was used for the same purpose, the reaction mixture turned deep red, indicating the possibility of radical formation, since the majority of radicals are quite colorful (Scheme 46). To further prove this hypothesis, a small amount of the deep red solution was taken out from the Schleck and exposed to air, losing its color within a few seconds. To confirm the existence of radicals, the solid obtained after evaporation of the solvent from the reaction mixture was dissolved in toluene and analyzed by EPR. The X-band EPR spectrum of **140a** in toluene displays a multiplet (g = 2.0056) due to a large hyperfine coupling constant with the phosphorus nucleus [a(31P) = 18.00 G] and a small hyperfine coupling constant with the nitrogen nucleus [a(¹⁴N) = 6.00 G] (Figure 43). This spectrum was well-simulated with that of a carbon-centered radical that shows coupling with phosphorus and nitrogen atoms. Thus, this experiment unambiguously supported the radical nature of **140a**. In a similar manner, radicals **140b** and **140c** were also synthesized from **138b** and **138c** in excellent yields respectively. Their EPR spectra are shown in Figure 44 and 45.



Figure 43. X-band EPR spectrum of **140a** in toluene [observed spectrum in blue, simulated spectrum in red; g = 2.0056, $a(^{31}P) = 18.00$ G, $a(^{14}N) = 6.00$ G].



Figure 44. X-band EPR spectrum of **140b** in toluene [observed spectrum in blue, simulated spectrum in red; g = 2.0055, $a(^{31}P) = 1.04$ G, $a(^{14}N) = 5.17$ G].



Figure 45. X-band EPR spectrum of **140c** in toluene [observed spectrum in blue, simulated spectrum in red; g = 2.0056, $a(^{31}P) = 14.69$ G, $a(^{14}N) = 6.12$ G].

Finally, the connectivity of **140a** and **140c** was unambiguously confirmed by single X-ray diffraction analysis after obtaining crystals by cooling solutions of **161a** and **161c** in pentane (Figure 46 and 47). The first evidence for the formation of the radicals from cationic phosphines was the absence of SbF₆⁻ counter anions that was present in the starting material. Due to the single electron reduction, the N1=C1(carbene) double bonds [**133a**: 1.305(3) Å, **138c**: 1.3067(19) Å] on cationic phosphines reduce their bond order as reflected in the elongation of the bond lengths [**140a**: 1.3979(17) Å, **140c**: 1.394(3) Å]. On the other hand, the P1-C1(carbene) bonds on radicals [**140a**: 1.7881(14) Å, **140c**: 1.785(2) Å] were shorter than those in their cationic precursors [**133a**: 1.864(3) Å, **138c**: 1.8529(15) Å], showing partial delocalization of the single electron into the σ^* orbitals of P-C(Ph).^[158] In addition, the degree of pyramidalization at phosphorus (**140a**: 53.6%, **140c**: 53.8%) was slightly smaller than that observed for neutral aromatic phosphines (56.76 for PPh₃). This parameter revealed that backdonation from the phosphorus to the CAAC rings must be marginal and suggest retention of a nonbonding electron pair on this atom.



Figure 46. Molecular structure of radical 140a in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 47. Molecular structure of radical **140c** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.

4.3.2 Coordination of α-Radical Phosphines towards Au(I)

The electron lone pairs on the phosphorus atoms of **140a-c** were still available for the coordination to metal salts. To the best of our knowledge, there is no successful example of α -radical phosphines ever investigated in coordination chemistry, probably due to its highly reactive properties. Hence, our next goal was to study radicals **140a-c** in coordination chemistry.

Initially, **140a** smoothly reacted with $(Me_2S)AuCl$ in THF affording the radical complex **141**, which was insoluble in pentane, giving the first indication of the successful coordination. In a similar manner, **142** and **143** were synthesized from **140a** and **140b** respectively in excellent yields. However, mixing **140c** and $(Me_2S)AuCl$ in THF led to a complicated mixture, in which black precipitates, probably Au(0) were formed in the reaction mixture. During this process, the radical phosphine was probably oxidized to the cationic phosphine (Scheme 47).



Scheme 47. Synthesis of 141-143.

Subsequently, to additionally confirm the existence of radicals, each of the solids **141-143** was dissolved in toluene and evaluated by EPR analysis. The X-band EPR spectrum of product **141** in toluene (Figure 48) displays a multiplet (g = 2.0053) due to a small hyperfine coupling constant with the phosphorus nucleus [a(31P) = 7.70 G] and a large hyperfine coupling constant with the nitrogen nucleus ($a(^{14}N) = 13.83$ G]. The resulting spectrum could be well-simulated and matched that of a carbon-centered radical involving phosphorus and nitrogen atoms. In a similar manner, radicals **142** and **143** in toluene were also analyzed by EPR spectra as shown in Figures 49-50 and their spectra were well-simulated with that of a carbon-centered radical that shows coupling with phosphorus and nitrogen atoms.



Figure 48. X-band EPR spectrum of **141** in toluene [observed spectrum in blue, simulated spectrum in red; g = 2.0053, a(31P) = 7.70 G, a(14N) = 13.83 G].



Figure 49. X-band EPR spectrum of **142** in toluene [observed spectrum in blue, simulated spectrum in red; g = 2.0046, $a(^{31}P) = 2.05$ G, $a(^{14}N) = 6.16$ G].



Figure 50. X-band EPR spectrum of **143** in toluene [observed spectrum in blue, simulated spectrum in red; g = 2.0056, $a(^{31}P) = 7.75$ G, $a(^{14}N) = 5.90$ G].

Finally, radicals **141-143** derived from **140a** and **140b** were unambiguously confirmed by single X-ray diffraction analysis (Figure 51-53). The absence of counter anions proved the presence of neutral radical Au complexes. Like in the free ligands, the P1-C1(carbene) bond lengths [**141**: 1.7825(13) Å, **142**: 1.7985(9) Å, **143**: 1.7715(13) Å] were shorter in comparison to their cationic species [**139a**: 1.873(2) Å, **139b**: 1.883(4) Å], showing the delocalization of the single electron into σ^* orbitals of the P-C(Ph) bonds. Conversely, the N1-C1(carbene) bond lengths [**141**: 1.3955(16) Å, **142**: 1.4018(12) Å, **143**: 1.3904(16) Å] were elongated in comparison to their cationic species [**139a**: 1.300(3) Å, **139b**: 1.301(5) Å], since the N1=C1(carbene) double bond reduce the bond order after the single electron reduction. The Au1-P1 bond lengths [**141**: 2.2377(4) Å, **142**: 2.2473(4) Å, **143**: 2.2840(5) Å] were similar to those of their cationic species [**139a**: 2.2221(6) Å, **139b**: 2.2269(10) Å].



Figure 51. Molecular structure of compound 141 in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 52. Molecular structure of compound 142 in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 53. Molecular structure of compound 143 in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms and solvent molecules have been omitted for clarity.

4.3.3 Coordination of α-Radical Phosphines towards Other Metal Salts

In order to further explore the coordination chemistry of the radical ligands, **140a** was chosen as model ligand. Initially, $AgSbF_6$ and $(Me_2S)CuBr$ were reacted with **140a**, affording cationic phosphines **138a** and **144**, in which the metal salts were reduced by single electron transfer. Similarly, mixing of **140a** with CoCl₂ afforded the cationic compound **145**, with $[CoCl_4]^{2-}$ as the counter anion (Scheme 48).



Scheme 48. Attempts to coordinate 140a to other metal salts.



Figure 54. Molecular structure of the decomposed product **144** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 55. Molecular structure of the decomposed product **145** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms and solvent molecules have been omitted for clarity.

4.4 Synthesis of Cationic Phosphine Oxide and the Radical thereof

Phosphine oxides feature tetrahedral phosphorus centers, in which the P-O bond is short and polar. Phosphine oxides are useful ligands in various reactions, such as Kumada–Corriu cross-couplings^[159] and Suzuki–Miyaura Reactions^[160]. In addition, it is quite popular to use phosphine oxides as hemilabile pre-ligands in catalysis.^[161-162] Therefore, it would be interesting to know whether we could obtain the cationic phosphine oxides by the oxidation of cationic phosphine **138a**. Thus, we subjected compound **138a** to oxidation using *m*-CPBA in CH₂Cl₂ at room temperature. The oxidation proceeded in quantitative yield affording a white solid **146**, which was unambiguously confirmed by X-ray diffraction analysis to be the desired oxide (Scheme 49 and Figure 56). Subsequently, compound **146** was investigated by cyclovoltammetry, depicting a quasi-reversible redox potential, which indicated the possibility of isolating the corresponding radical (Figure 57).



Scheme 49. Synthesis of cationic phosphine oxide 146.



Figure 56. Molecular structure of **146** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity



Figure 57. Cyclic voltammograms of **146** reported in V and calibrated versus $Cp_{2}^{*}Fe/Cp_{2}^{*}Fe^{+}$, ${}^{n}Bu_{4}NPF_{6}$ (0.1 M) in $CH_{2}Cl_{2}$.

The oxide **146** was subjected to the same reaction conditions as before, using KC₈. This produced a new red solid **147** (Scheme 50). The confirmation about the radical nature of **147** came from EPR and X-ray analysis (Figures 58 and 59). The X-band EPR spectrum of **147** in toluene displayed a multiplet (g = 2.0057) due to a small hyperfine coupling constant with the phosphorus nucleus [a(31P) = 6.14 G] and a large hyperfine coupling constant with the nitrogen nucleus (a(¹⁴N) = 16.96 G] (Figure 59). The resultant spectrum was well-simulated

with that of a carbon-centered radical involving phosphorus and nitrogen atoms. Thus, the EPR data unambiguously supported the presence of a radical **147**. Finally, red crystals of **147** suitable for X-ray crystallography studies were obtained from pentane in the freezer and its structure in the solid state was confirmed by X-ray diffraction. The most obvious evidence for the radical is the absence of counter anions that are present in the starting material. Like in the ligands, the P1-C1(carbene) bond length [**147**: 1.7878(7) Å] was shorter in comparison to their cationic species [**146**: 1.8819(16) Å], showing the delocalization of the single electron into σ^* orbital of P-C(Ph) bond. Conversely, the N1-C1(carbene) bond length [**147**: 1.299(2) Å], since the N1=C1(carbene) double bonds on cationic phosphine oxide again reduces its bond order.



Scheme 50. Synthesis of radical 147.



Figure 58. Molecular structure of the decomposed product **147** in the solid state. Thermal ellipsoids at 50% probability; hydrogen atoms have been omitted for clarity.



Figure 59. X-band EPR spectrum of **147** in toluene [observed spectrum in blue, simulated spectrum in red; g = 2.0057, $a(^{31}P) = 6.14$ G, $a(^{14}N) = 16.96$ G].

4.5 Theoretical Analysis of Properties of a-Radical Phosphines

The coordination between AuCl and radical phosphine 140a was evaluated as an example using charge decomposition analysis (CDA) and extended charge decomposition analysis (ECDA). The result displayed in Figure 60 reveals that the HOMO/SOMO of complex 140a-AuCl is mainly contributed by the HOFO of 140a. The LUFO of AuCl with d_{z2} of Au and the HOFO-1 of 140a with lone pair on P atom contribute to the HOMO-5 of 140a-AuCl, which invloves the Au-P bond formation. Hence, the closer energy difference for LUFO of MCl (M = Au, Cu, Ag) and HOFO-1 of ligands is more favorable for M-P bond formation of the complex.



Figure 60. Orbital correlation diagram for **140a-AuCl** of the interaction between framents **AuCl** and **140a**. A plot of important molecular orbitals of **140a-AuCl** and its related fragments are also presented. LUMO: lowest unoccupied molecular orbital; HOMO: highest occupied molecular orbital; LUFO: lowest unoccupied fragment orbital; SOMO: single occupied molecular orbital.

The important frontier orbital energies (in eV) for all radical phosphines **140a-c** and metal salts **MCl** (**M** = Au, Cu, Ag) were computed at the UB3LYP-D3/def2-TZVP level as shown in Table 8. The LUMO energies of CuCl ($E_{LUMO} = -3.30 \text{ eV}$) and AgCl ($E_{LUMO} = -3.63 \text{ eV}$) are much higher than that of AuCl ($E_{LUMO} = -4.21 \text{ eV}$). Thus, the reaction of metal salt CuCl and AgCl with radical phosphine ligands may be less stable than the ones of AuCl. This is also consistent with the complex forming energies (E_{L-MCl}) shown in Table 8 that the E_{L-MCl} values for CuCl and AgCl related complexes are more than 10 kcal/mol less than the ones for **140a**-AuCl. The energy of HOMO-1 for **140b** ($E_{HOMO-1} = -5.06 \text{ eV}$) and **140c** ($E_{HOMO-1} = -5.48 \text{ eV}$). Comparatively, complex **140b**-AuCl might be more stable than **140a**-AuCl, while the complex **140c**-AuCl might be less stable.

| Entry | Species | Е_{SOMO-1}1 | Ε_{SOMO}² | E _{LUMO+1} | EL-MCI |
|-------|-------------------|----------------------------|-------------------------------------|---------------------|--------|
| 1 | 140a | -3.83 | -1 19 | -0.80 | |
| 2 | 140b | -3.81 | -1.09 | -0.27 | |
| 3 | 140c | -4.24 | -1.68 | -1.62 | |
| 4 | 140a -AuCl | -4.52 | -1.84 | -1.32 | -73.2 |
| 5 | 140b-AuCl | -4.49 | -0.18 | -0.38 | -77.9 |
| 6 | 140c-AuCl | -4.89 | -2.24 | -2.06 | -70.6 |
| 7 | 140a-CuCl | -4.40 | -1.76 | -1.25 | -58.8 |
| 8 | 140b-CuCl | -4.38 | -1.68 | -0.47 | -63.2 |
| 9 | 140c-CuCl | -4.75 | -2.22 | -2.00 | -56.4 |
| 10 | 140a-AqCI | -4 49 | -1 85 | -1.33 | -52 7 |
| 11 | 140h-AgCl | -4.47 | -1.77 | -0.44 | -57.3 |
| 12 | 140c-AgCl | -4.86 | -2.26 | -2.09 | -50.1 |
| | | F | F | F | |
| | | ⊏номо-1 | -номо | L UMO | |
| 13 | AuCl | -7.81 | -7.81 | -4.21 | |
| 14 | CuCl | -7.20 | -7.20 | -3.30 | |
| 15 | AgCl | -7.33 | -7.33 | -3.63 | |

 Table 8. The SOMO/HOMO and LUMO energies (in eV) for all the species at the UB3LYP-D3/def2-TZVP

 level. SOMO-1 and SOMO represent occupied and unoccupied SOMO respectively.



¹The HOMO-1 and HOMO orbitals for MCl (M = Au, Cu, and Ag) are degenerated. ²The HOMO orbital for the ligands and coordinated species is a SOMO orbital due to the stable radical.

In the case of the free ligands, the Mulliken spin density is mostly concentrated at the C1 (ca. 65%) and N (ca. 25%) atoms, and also some small distribution on the P atom. Similar results could be perceived by visualizing the SOMO. There is also some small distribution of spin density on C13 (Scheme 47) for **140a** and **140c**. This is consistent with the DFT calculated larger hyperfine coupling constant of C13 for both ligands in comparison with **140b**. Consequently, the spin densities on P for both ligands are slightly higher. The ³¹P atom still exhibit detectable hyperfine coupling in the EPR spectrum despite rather small spin densities

on it (<5%). The computed hyperfine coupling constants for ¹⁴N and ³¹P agree well with the ones from the simulated EPR, while the overestimation of ³¹P on **140b** might be caused by the negative spin density (Table 10). Computationally, the α -spin density is positive, and the β -spin density if negative. When the computed absolute β -spin density value is bigger than the α -spin density, the total spin density is negative. In this case the discrepancy may be related to the use of an unrestricted approach, which is known to generally overestimate the difference between α -spin and β -spin populations.^[163-164] After the ligand binds to AuCl, the spin density distributed on Au is very small. This is also consistant with the experimental EPR simulation results that indicate no coupling for Au. Hence, both spin density and hyperfine coupling constant results are similar with the ones observed for ligands.

 Table 9. The Mulliken spin densities and SOMO-1 plot of all the ligands and AuCl coordinated species at the

 UB3LYP-D3/def2-TZVP level.



140a N: 23.2%, C1: 66.3%, P: 0.6%, C13: 5.1%

141

N: 25.9%, C1: 62.4%, P: 1.5%

Au: 0.5%, C13: 4.8%



140b N: 20.9%, C1: 70.5%, P: -2.7%



142 N: 26.8%, C1: 65.2%, P: 1.9%, Au: 0.1%,C13: 5.1%



140c N: 24.5%, C1: 64.3%, P: 0.6%, C13: 4.9%



143 N: 23.8%, C1: 67.1%, P: 1.3%, Au: 0.2%

| Atom | 140a | 140b | 140c | 141 | 142 | 143 |
|------------------|-------|-------|-------|-------|-------|-------|
| Р | 13.06 | 5.14 | 10.95 | 2.67 | 2.29 | 6.38 |
| P(exp) | 18.00 | 1.04 | 14.69 | 7.70 | 2.05 | 7.75 |
| Ν | 4.34 | 3.58 | 4.50 | 4.51 | 10.71 | 4.62 |
| N(exp) | 6.00 | 5.17 | 6.12 | 13.83 | 6.16 | 5.90 |
| C ₁ | 18.24 | 20.68 | 17.27 | 17.38 | 44.68 | 19.78 |
| C_2 | -6.27 | -6.23 | -6.06 | -5.83 | -8.58 | -6.14 |
| | 2.24 | 2.62 | 2.19 | 2.65 | 2.61 | / |
| C₄ | -2.81 | -2.62 | -2.86 | 1 | -4.27 | -2.78 |
| C_5 | 4.69 | 12.05 | 2.37 | 3.68 | 4.35 | 9.80 |
| $\tilde{C_6}$ | 12.90 | 10.23 | 4.36 | 11.86 | 13.61 | 10.62 |
| C ₇ | 5.12 | 3.02 | 3.19 | 4.53 | 5.42 | 3.51 |
| C ₈ | 3.09 | / | 5.11 | 3.72 | 4.16 | / |
| C ₉ | / | / | / | -2.91 | -4.16 | / |
| $\tilde{C_{10}}$ | 3.12 | 4.79 | 5.60 | 3.25 | 6.59 | 4.87 |
| C ₁₁ | 5.59 | 2.90 | 3.19 | 6.46 | 4.29 | 2.33 |
| C ₁₂ | 2.11 | 6.32 | 2.53 | 2.10 | 3.91 | 4.52 |
| C ₁₃ | 15.05 | 6.10 | 15.52 | 11.11 | 18.83 | 4.24 |

Table 10. Calculated hyperfine coupling constants (A in 10^{-4} cm⁻¹) of all species at the UB3LYP-D3/def2-TZVP level of theory. A_{iso} values greater than 2.0 are only reported. Experimental data was reported in red color.

4.6 Summary IV

We have successfully isolated and characterized a series of CAAC derived cationic phophines. Their cyclovoltammetry showed a quasi-reversible redox potential, which indicated that stable radicals were formed after one electron reduction. As a result, a series of α -radical phosphines have been synthesized and fully characterized. More intriguingly, these radical phosphines could coordinate to Au(I) and form a range of stable gold complexes that are unprecedented. In addition, we were also able to synthesize the radical phosphorus oxide. All of the synthesized radicals have been characterized by EPR and most have been crystallized. These novel compounds could be named as α -radical phosphine ligands, which might be useful in catalysis.

5 Experimental Part

5.1 General Experimental Conditions

5.1.1 Working Techniques

All moisture- and oxidation-sensitive reactions were performed in carefully dried glassware under argon atmosphere. The saturated aqueous solutions of sodium chloride, sodium bicarbonate, sodium carbonate and ammonium chloride, were saturated over sediment, unless indicated otherwise.

Solvents and reagents

All solvents were purified by distillation before use by following standard procedures. Dry solvents were obtained by distillation over the appropriate drying agent (*vide infra*) and then kept under argon atmosphere: diethyl ether, tetrahydrofuran, toluene, benzene, pentane and ^{*n*}hexane (sodium, benzophenone as indicator); *N*,*N*'-dimethylformamide (Desmodur[®], dibutyltin dilaurate); CH₂Cl₂, acetone, acetonitrile, Et₃N (calcium hydride); fluorobenzene (phosphorus pentoxide), methanol and ethanol (magnesium). 1,2-Dichloro-ethane was purchased from Sigma-Aldrich and used as received. Other commercial reagents were obtained from various sources and used without further purification.

Inert gas atmosphere

Air and moisture-sensitive reactions were conducted under argon atmosphere. Argon was obtained from *Air Liquide* with higher than 99.5% purity.

Chromatographic methods

Reactions were mostly monitored by **thin layer chromatography** (**TLC**) using silica gel pre-coated polyester sheets (40×80 mm, Polygram[®] SIL G/UV254 from Macherey-Nagel). The spots were visualized with UV-light ($\lambda = 254$ nm) and/or by staining with phosphomolybdic acid or potassium permanganate stains.

Flash column chromatography was performed using silica gel 60 (Merck, 60 Å, 230-400 mesh 0.040-0.063 mm) and separations were conducted at slightly elevated pressure in a glass column.

5.1.2 Analytical Methods

Nuclear magnetic resonance spectroscopy (NMR)

Spectra were recorded on Bruker DPX 300 (¹H: 300 MHz, ¹³C: 75 MHz, ³¹P: 121 MHz), Bruker AV 400 (¹H : 400 MHz, ¹³C: 100 MHz, ³¹P: 161 MHz), and Bruker AV 500 (¹H: 500 MHz, ¹³C: 125 MHz, ³¹P: 202 MHz) spectrometers at room temperature (298 K). Chemical shifts (δ) are given in parts per million (ppm) relative to tetramethylsilane (¹H and ¹³C, internal standard) and H₃PO₄ (³¹P, external standard) and coupling constants (*J*) in Hertz (Hz). The corresponding solvent signals were used as a references: CDCl₃: δ C 77.0 ppm, δ H 7.26 ppm; CD₂Cl₂: δ C 54.0 ppm, δ H 5.32 ppm; CD₃CN: δ C 1.32 ppm, δ C 118.26 ppm δ H 1.94 ppm; [D8]-toluene δ C 20.4 ppm, δ H 7.01 ppm and δ H 7.09 ppm. The ¹H NMR multiplicities are assigned as follows: singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin), sextet (sext), septet (sept), multiplet (m), broad (br.). The signals have been assigned using 1D and 2D experiments.

Infrared spectroscopy

IR spectra were recorded using ATR (attenuated total reflection) on a Spectrum One (Perkin-Elmer) spectrometer at room temperature. The characteristic absorption bands are given in wavenumbers [cm⁻¹].

Analytical gas chromatography

GC-MS couplings were performed on an *Agilent Technology* GC 6890 Series and MSD 5973 (carrier gas: helium) with HP6890 Series Injector, employing an MN Optima[®]5 column (30 m \times 0.25 mm \times 0.25 mm). The mass spectra were recorded with an *Agilent Technology* 5973 Network MSD spectrometer. Quantitative evaluation of the integration was based on the substance peaks without considering response factors, unless stated otherwise.

Mass spectrometry (MS)

Mass spectra were measured on a Finnigan MAT 8200 (70 eV) or MAT 8400 (70 eV) spectrometer by electron ionization, chemical ionization, or fast atom/ion bombardment techniques. High resolution masses were determined on a Bruker APEX III FT-MS spectrometer (7 T magnet). All masses are given in atomic units per elementary charge (m/z) and reported in percentage relative to the basic peak. The mechanistic studies (cf. Chapter 4.5.2) were performed by ESI-MS with a Finnigan Ultra Mass TSQ 7000.

X-ray crystal structure analysis

The crystal structures were measured in the X-ray department of the Max Planck Institute for Coal Research in Mülheim an der Ruhr, led by Dr. C. W. Lehmann. The measurements were made using a Bruker-AXS Kappa CCD diffractometer.

Electron paramagnetic resonance (EPR)

X-band EPR spectra were recorded on a Bruker ELEXSYS E500 spectrometer equipped with a Bruker dual-mode cavity (ER4116DM) and a Bruker high-sensitivity microwave bridge Super-X (ER-049X) with integrated microwave frequency counter. The magnetic field controller was externally calibrated with a Bruker NMR field probe (ER035M). The liquid samples were measured in 2mm quartz tubes and the spectra were simulated with the program ESIM/ISO (available from E. Bill by mail to <u>ebill@gwdg.de</u>).

5.1.3 Starting Materials as well as in Working Group-made Chemicals

Commercially available chemicals were used without further purification unless otherwise stated. Working group's internal chemicals: 2-phenylylphosphine.

Compound 62



PCl₃ (0.16 ml, 1.8 mmol) and TMSOTf (0.65 ml, 3.6 mmol) were added at – 78°C to a solution of K[BH₂(Pz)₂] (0.334 g, 1.8 mmol) in CH₂Cl₂ (5 ml). The mixture was allowed to warm up to r.t. overnight. Then the solvent was filtered off and the yellow solid washed with CH₂Cl₂ (2 x 5 ml). The crude product thus obtained was extracted with CH₃CN (2 x 5 ml) at 0 °C and the combined solvents removed *in vacuo* to afford **62** as a white solid (157.1 mg, 24 %). m.p.: 95 °C (dec.). ¹H NMR (CD₃CN, 300 MHz): δ = 8.60 (d, *J* = 2.1 Hz, 2H), 8.42 (s, 2H), 6.86 (m, 2H), 4.08 – 3.53 ppm (br s, 2H). ¹³C NMR (CD₃CN, 100 MHz): δ = 146.9, 143.2 (d, *J*_{*C*-*P*} = 30.8 Hz), 122.2 (q, *J*_{*C*-*F*} = 320.2 Hz), 111.1 ppm (d, *J*_{*C*-*P*} = 6.0 Hz). ³¹P NMR (CD₃CN, 121 MHz): δ = 85.7 ppm. ¹¹B NMR (CD₃CN, 128 MHz,): δ = 8.1 ppm. ¹⁹F NMR (CD₃CN, 282 MHz): δ = – 79.3 ppm. IR \tilde{v} = 442, 516, 575, 633, 779, 913, 1024, 1060, 1084, 1162, 1225, 1419, 2456, 3112, 3139 cm⁻¹. Elemental analysis for C₇H₈BClF₃N₄O₃PS (362.46): *calcd*. for C 23.20%, H 2.22%, N 15.46%, *found*: C 23.14%, H 2.56%, N 16.12%.

Compound 63



PhPCl₂ (1.5 ml, 10.7 mmol) and TMSOTf (1.9 ml, 10.7 mmol) were added at -78° C to a suspension of K[H₂B(Pz)₂] (2.0 g, 10.7 mmol) in CH₂Cl₂ (10 ml) and the mixture was allowed to warm up to r.t. overnight. Then the solvent was filtered off and the white solid left washed with CH₂Cl₂ (2 x 5 ml). The crude product was then extracted with CH₃CN (2 x 5 ml) at 0 °C and the combined solvent removed *in vacuo* to afford **63** as a white solid (2.5 g, 57%). Colourless crystals suitable for X–ray crystallography were obtained from a CH₃CN/Et₂O at – 30 °C. m.p.: 101 °C (dec.). ¹H NMR (CD₃CN, 400 MHz): $\delta = 8.62$ (dd, J = 3.3 Hz, $J_{H-P} = 3.9$ Hz, 2H), 8.29 (s, 2H), 7.57 (m, 1H), 7.48 (m, 2H), 7.09 (m, 2H), 6.88 (dd, J = 2.4 Hz, $J_{H-P} = 5.1$ Hz, 2H), 3.25 ppm (br, $J_{H-B} = 138$ Hz). ¹³C NMR (CD₃CN, 100 MHz): $\delta = 145.8$, 144.0 (d, $J_{C-P} = 26.7$ Hz), 133.3, 131.6 (d, $J_{C-P} = 17.4$ Hz), 130.7 (d, $J_{C-P} = 19.4$ Hz), 130.3 (d, $J_{C-P} = 5.6$ Hz), 122.2 (q, $J_{C-F} = 319.7$ Hz), 110.7 ppm (d, $J_{C-P} = 5.2$ Hz). ³¹P NMR (CD₃CN, 162 MHz): $\delta = 87.1$ ppm. ¹¹B NMR (CD₃CN, 128 MHz): $\delta = -7.1$ ppm (t, $J_{B-H} = 105$ Hz). ¹⁹F

NMR (CD₃CN, 282 MHz): $\delta = -79.3$ ppm. IR $\tilde{v} = 416, 443, 465, 517, 633, 690, 746, 780, 950, 983,1027, 1061, 1092,1139, 1252, 1388, 1419, 2461, 3020, 3138 cm⁻¹. Elemental analysis for C₁₃H₁₃BF₃N₄O₃PS (404.05)$ *calcd.*for: C 38.64%, H 3.24%, N 13.86%,*found*: C 37.78%, H 2.89%, N 13.65%.

Compound 64



CyPCl₂ (0.21 ml, 1.3 mmol) and TMSOTf (0.24 ml, 1.300 mmol) were added at -78° C to a suspension of K[H₂B(Pz)₂] (250.0 mg, 1.301 mmol) in CH₂Cl₂ (5 ml) and the mixture was allowed to warm up to r.t. overnight. Then the solvent was filtered off and the white solid obtained washed with CH₂Cl₂ (2 x 5 ml). Then the crude product was extracted with CH₃CN (2 x 5 ml) at 0 °C and the organic solvent removed *in vacuo* to afford **64** as a white solid (302.1 mg, 55%). mp: 113 °C (dec), ¹H NMR (CD₃CN, 400 MHz): $\delta = 8.42$ (dd, J = 3.3 Hz, $J_{H-P} = 3.3$ Hz, 2H), 8.3702 (s, 2H), 6.32 (dd, J = 2.7 Hz, $J_{H-P} = 4.6$, Hz, 2H), 4.01 (br, $J_{H-B} = 128$ Hz), 3.16 (m, 2H), 1.79 (m, 3H), 1.35 (m, 7H) ppm, ¹³C NMR (CD₃CN, 100 MHz): $\delta = 145.5$, 143.7 (d, $J_{C-P} = 25.3$ Hz), 122.1 (q, $J_{C-F} = 320.9$ Hz), 110.6 (d, $J_{C-P} = 5.4$ Hz), 39.5 (d, $J_{C-P} = 20.5$ Hz), 25.9, 25.8, 25.7, 25.6, 25.5 ppm. ³¹P NMR (CD₃CN, 162 MHz): $\delta = -79.3$ ppm. ¹¹B NMR (CD₃CN, 128 MHz): $\delta = -8.1$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -79.3$ ppm. IR $\tilde{v} = 6$ 35, 697, 792, 875, 1027, 1073, 1137, 1222, 1263, 1414, 2425, 2490, 2859, 2928, 3105, 3137 cm⁻¹. Elemental analysis for C₁₃H₁₉BF₃N₄O₃PS (410.16): *calcd*. for C 38.07%, H 4.67%, N 13.66%, *found*: C 38.03%, H 4.23%, N 13.12%.

Compound 67



PhPCl₂ (1.8 ml, 13.5 mmol) and TMSOTf (4.9 ml, 27.0 mmol) were added at -78° C to a solution of [H₂C(Pz)₂] (2.0 g, 13.500 mmol) in CH₂Cl₂ (10 ml) and the mixture allowed to warm up to r.t. overnight. Then the solvent was filtered off and the white solid thus obtained washed with CH₂Cl₂ (2 x 5 ml). The crude product was dissolved in CH₃CN (5 ml), precipitated with Et₂O (15 ml) and dried *in vacuo* to afford **67** as a white solid (2.83 g, 38%). Colourless crystals suitable for X–ray crystallography were obtained from a CH₃CN/Et₂O at – 30°C. m.p.: 86 °C (dec.). ¹H NMR (CD₃CN, 400 MHz): $\delta = 8.98$ (dd, J = 2.5 Hz, $J_{H-P} = 2.5$

Hz, 2H), 8.75 (s, 2H), 7.70 (m, 1H), 7.60 (m, 2H), 7.39 (m, 2H), 7.29 (d, J = 14.9 Hz, 1H), 7.10 (m, 2H), 5.87 (d, J = 14.9 Hz, 1H) ppm. ¹³C NMR (CD₃CN, 100 MHz): $\delta = 147.9$ (d, $J_{C-P} = 19.4$ Hz), 145.1, 134.7, 131.9 (d, $J_{C-P} = 18.7$ Hz), 131.0 (d, $J_{C-P} = 5.5$ Hz), 128.3 (d, $J_{C-P} = 24.3$ Hz), 121.9 (q, $J_{C-F} = 320.3$ Hz), 111.7 (d, $J_{C-P} = 2.2$ Hz), 63.3 ppm. ³¹P NMR (CD₃CN, 162 MHz): $\delta = 85.8$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -79.3$ ppm. IR $\tilde{v} = 675$, 838, 894, 1029, 1162, 1220, 1241, 1377, 1563, 1580, 2827, 3136 cm⁻¹. Elemental analysis for C₁₅H₁₃F₆N₄O₆PS₂ (554.38): *calcd.* for C 32.50%, H 2.36%, N 10.11%, *found*: C 32.11%, H 2.76%, N 10.60%.

Compound 68



CyPCl₂ (0.26 ml, 1.7 mmol) and TMSOTf (0.61 ml, 3.4 mmol) were added to a suspension of $[H_2C(P_z)_2]$ (250.0 mg, 1.7 mmol) in CH₂Cl₂ (5 ml) at – 78°C and the mixture allowed to warm up to r.t. overnight. The solvent was then evaporated *in vacuo* and the resulting solid dissolved in CH₃CN (2 ml). Then Et₂O (10 ml) was added to precipitate the product **68** as a white solid (433.3 mg, 46%). m.p.: 93 °C (dec.). ¹H NMR (CD₃CN, 400 MHz): δ = 8.80 (s, 2H), 8.76 (s, 2H), 7.56 (s, 1H), 7.05 (s, 2H), 6.84 (s, 1H), 2.97 (m, 1H), 1.94 (m, 2H), 1.85 (m, 1H), 1.54 (m, 4H), 1.34 ppm (m, 3H). ¹³C NMR (CD₃CN, 100 MHz): δ = 147.3 (d, *J*_{*C*-*P*} = 20.9 Hz), 144.9 (d, *J*_{*C*-*P*} = 2.8 Hz), 121.9 (q, *J*_{*C*-*F*} = 320.4 Hz), 112.1 (d, *J*_{*C*-*P*} = 5.4 Hz), 63.4, 40.5 (d, *J*_{*C*-*P*} = 26.9 Hz), 25.6, 25.5, 25.4, 25.3, 25.2 ppm. ³¹P NMR (CD₃CN, 162 MHz): δ = 110.1 ppm.¹⁹F NMR (CD₃CN, 282 MHz): δ = – 79.3 ppm. IR $\tilde{\upsilon}$ = 573, 609, 759, 1023, 1159, 1246, 1567, 2744, 2853, 3039, 3121 cm⁻¹. Elemental analysis for C₁₅H₁₉F₆N₄O₆PS₂ (560.42): *calcd.* for C 32.15%, H 3.24%, N 10.00%, *found*: C 31.18%, H 3.34%, N 9.68%.

Compound 69



 $(Et_2N)PCl_2$ (0.29 ml, 2.0 mmol) and TMSOTf (0.73 ml, 4.0 mmol) were added to a solution of $[H_2C(Pz)_2]$ (296.0 mg, 2.0 mmol) in CH₂Cl₂ (4 ml) at – 78°C and the mixture was allowed to warm up to r.t. overnight. The solvent was then filtered off and the white solid thus obtained washed with CH₂Cl₂ (2 x 5 ml). Crude **69** was then dissolved in CH₃CN and

precipitated with Et₂O (362.1 mg, 33%). Colourless crystals suitable for X–ray crystallography were obtained from CH₃CN/Et₂O at – 30°C. m.p.: 103 °C (dec.). ¹H NMR (CD₃CN, 400 MHz): $\delta = 8.69$ (s, 2H), 8.61 (s, 2H), 7.27 (d, J = 11.36 Hz, 1H), 7.08 (t, J = 2.88 Hz, 1H), 7.08 (d, 11.36 Hz, 1H), 3.38 (m, 4H), 1.23 ppm (t, J = 7.1 Hz, 6H). ¹³C NMR (CD₃CN, 75 MHz): $\delta = 143.7$ (d, $J_{C-P} = 9.0$ Hz), 142.1, 111.7, 63.2, 43.9, 43.7, 13.8, 13.7 ppm. ³¹P NMR (CD₃CN, 162 MHz): $\delta = 107.8$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -79.3$ ppm. IR $\tilde{\upsilon} = 515$, 574, 632, 759, 1023, 1100, 1158, 1347, 1391, 1445, 1522, 1567, 2854, 2997, 3120 cm⁻¹. Elemental analysis for C₁₃H₁₈F₆N₅O₆PS₂ (549.40): *calcd.* for C 28.42%, H 3.40%, N 12.75%, *found*: C 28.23%, H 3.28%, N 12.75%.

Compound 73



PhPCl₂ (0.75 ml, 5.4 mmol) and TMSOTf (2.0 ml, 10.8 mmol) were added at – 78°C to a suspension of bisoxazoline **72** (1.28 g, 5.4 mmol) in CH₂Cl₂ (20 ml) and the mixture allowed to warm up to r.t. overnight. Filtration of the solvent afforded a white solid that was subsequently washed with CH₂Cl₂ (2 x 10 ml). Crude **73** was then dissolved in CH₃CN at 0°C and precipitated with Et₂O to afford the desired product as a white solid (1.55 g, 45%). m.p.: 65.2–67.8 °C. ¹H NMR (CD₃CN, 300 MHz): $\delta = 8.11 - 8.05$ (m, 2H), 7.94 – 7.90 (m, 1H), 7.80 – 7.74 (m, 2H), 5.08 – 5.04 (m, 4H), 2.19 (s, 3H), 2.04 (s, 3H), 1.85 (s, 6H), 1.08 (s, 6H) ppm. ¹³C NMR (CD₃CN, 75 MHz): $\delta = 175.7$ (d, *J_{C-P}* = 6.9 Hz), 138.1 , 135.9 (d, *J_{C-P}* = 33.9 Hz), 131.7 (d, *J_{C-P}* = 11.1 Hz), 129.3 (d, *J_{C-P}* = 29.2 Hz), 86.3 , 75.6 (d, 12.9), 41.9 (d, *J* = 1.1 Hz), 29.6, 26.5 (d, *J* = 2.1 Hz), 25.6 (d, *J* = 10.0 Hz), 22.7 ppm (d, *J* = 1.9 Hz). ³¹P NMR (CD₃CN, 162 MHz): $\delta = 88.8$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -79.17$ ppm. IR $\tilde{v} = 435$, 493, 516, 573, 634, 693, 739, 934, 1026, 1149, 1245, 1329, 1382, 1495, 1599, 1656, 2941 cm⁻¹. Elemental analysis for C₂₁H₂₇F₆N₂O₈PS₂ (644.54): *calcd*. for C 39.13%, H 4.22%, N 4.35%, *found*: C 38.33%, H 4.22%, N 4.35%.



PCl₃ (0.56 ml, 6.4 mmol) and TMSOTf (2.3 ml, 12.8 mmol) were added at – 78°C to a suspension of K[HB(3,5– Me₂Pz)₃] (2.05 g, 6.1 mmol) in CH₂Cl₂ (10 ml) and the mixture was allowed to warm up to r.t. overnight. Filtration of the solid afforded a white solid that was subsequently washed with CH₂Cl₂ (2 x 5 ml). The crude product was extracted with CH₃CN (2 x 10 ml) and the solvent evaporated *in vacuo* to afford **76** as a white solid (1.134 g, 24%). Colourless crystals suitable for X–ray crystallography were obtained from CH₃CN/Et₂O solution at – 30°C. m.p.: 118 °C (dec), ¹H NMR (CD₃CN, 300 MHz): δ = 6.44 (d, *J*_{*H–P*} =4.4, Hz, 3H), 4.79 (br, *J*_{*H–B*} = 162 Hz), 2.70 (s, 9H), 2.57 ppm (s, 9H). ³C NMR (CD₃CN, 101 MHz): δ = 158.3, 156.2 (d, *J*_{*C–P*} = 19.3 Hz), 122.0 (d, *J*_{*C–F*} = 320.7 Hz), 111.2 (q, *J*_{*C–P*} = 2.2 Hz), 13.1 (d, *J*_{*C–P*} = 8.8 Hz), 12.8 ppm. ³¹P NMR (CD₃CN, 121 MHz): δ = 7.3 ppm. ¹¹B NMR (CD₃CN, 128 MHz): δ = - 9.9 (d, *J*_{*B–H*} = 129 Hz) ppm. ¹⁹F NMR (CD₃CN, 282 MHz): δ = - 79.3 ppm. IR $\tilde{\upsilon}$ = 516, 573, 605, 633, 691, 756, 789, 906, 1023, 1099, 1160, 1223, 1435, 1522, 2700, 3040, 3142 cm⁻¹. Elemental analysis for C₁₇H₂₂BF₆N₆O₆PS₂ (626.29): *calcd*. for C 32.60%, H 3.54%, N 13.42%, *found*: C 32.11%, H 3.52%, N 12.95%.

Compound 79



PCl₃ (0.16 ml, 1.8 mmol) and TMSOTf (0.65 ml, 3.6 mmol) were added at -78° C to a solution of K[B(Pz)₄] (572 mg, 1.8 mmol) in CH₂Cl₂ (5 ml) and the mixture was allowed to warm up to r.t. overnight. After filtration of the supernatant the white solid obtained washed with CH₂Cl₂ (2 x 5 ml) and extracted with CH₃CN (2 x 10 ml). Evaporation of the solvent *in vacuo* afforded the desired product **79** as a white solid (588 mg, 43%). Colourless crystals suitable for X–ray crystallography were obtained from a CH₃CN/Et₂O solution at 5 °C. m.p.: 122 °C (dec.). ¹H NMR (CD₃CN, 300 MHz): $\delta = 8.86$ (s, 3H), 8.61 (s, 3H), 8.28 (s, 1H), 8.08 (s, 1H), 6.85 (d, $J_{H-P} = 2.6$, 3H), 6.82 (s, 1H). ¹³C NMR (CD₃CN, 75 MHz): $\delta = 146.5$ (d, $J_{C-P} = 19.3$ Hz), 145.5, 136.3, 121.8 (q, $J_{C-F} = 320.2$ Hz), 110.8, 110.7 (d, $J_{C-P} = 3.2$ Hz) ppm.

³¹P NMR (CD₃CN, 121 MHz): $\delta = -0.4$ ppm. ¹¹B NMR (CD₃CN, 128 MHz): $\delta = -1.3$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -79.3$ ppm. IR $\tilde{\upsilon} = 567, 594, 766, 864, 1065, 1109, 1157, 1243, 1392, 1157, 2659, 3133$ cm⁻¹. Elemental analysis for C₁₄H₁₂BF₆N₈O₆PS₂ (608.20): *calcd.* for C 27.65%, H 1.99%, N 18.42%, *found*: C 27.96%, H 1.67%, N 18.14%.

Compound 82



PCl₃ (0.23 ml, 2.6 mmol) and TMSOTf (1.4 ml, 7.9 mmol) were added to a solution of [HC(3,5–Me₂Pz)₃] (790 mg, 2.6 mmol) in CH₂Cl₂ (5 ml) at – 78°C and the mixture was allowed to warm up to r.t. overnight. Filtration of the solvents afforded a white solid that washed with CH₂Cl₂ (2 x 5 ml). Crude **82** was then dissolved in CH₃CN (5 ml) and precipitated with Et₂O (15 ml) to afford a white solid (608 mg, 29%). m.p.: 102 °C (dec.). ¹H NMR (CD₃CN, 400 MHz): δ = 9.60 (s, 1H), 6.75 (d, *J*_{H–P} =4.8 Hz, 3H), 2.89 (s, 9H), 2.88 ppm (s, 9H). ¹³C NMR (CD₃CN, 101 MHz): δ = 161.6 (d, *J*_{C–P} = 15.2 Hz), 158.5, 121.8 (q, *J*_{C–F} = 320.2 Hz), 112.6, 70.8 (d, *J*_{C–P} = 3.6 Hz), 15.1 (d, *J*_{C–P} = 5.4 Hz), 13.6 ppm. ³¹P NMR (CD₃CN, 121 MHz): δ = -9.9 ppm. ¹⁹F NMR (CD₃CN, 282 MHz): δ = -79.2 ppm. IR \tilde{v} = 447, 515, 573, 631, 707, 760, 844, 944, 1022, 1078, 1160, 1207, 1417, 1584, 2709, 2940, 3135 cm⁻¹. Elemental analysis for C₁₉H₂₂F₉N₆O₉PS₃ (776.56): *calcd*. for C 29.39%, H 2.86%, N 10.82%, *found*: C 29.52%, H 3.02%, N 10.50%.





To a solution of [2-(diphenylphosphino)phenyl]phosphine (200.0 mg, 0.340 mmol) in THF (10 ml) was added with chlorocyclopropenium salt (243.7 mg, 0.680 mmol) and Et_3N (0.1 ml, 0.710 mmol). The resulting mixture was stirred at 60 °C overnight. After cooling to r.t., the solvent was removed *in vacuo*, the left was dissolved in CH₂Cl₂ and the resulting solution washed three times with sat. NaBF₄. Once dried over Na₂SO₄, the organic phase was concentrated and the left was crystallized from CH₂Cl₂/Et₂O to afford compound **91** as a

white solid (146.0 mg, 46%). Colourless crystals suitable for X-ray crystallography were obtained from CH₂Cl₂/Et₂O at r.t. ¹H NMR (CD₂Cl₂, 500 MHz): $\delta = 8.19 - 8.16$ (m, 1H), 7.92 -7.80(m, 1H), 7.71 - 7.67 (m, 2H), 7.42 - 7.38 (m, 2H), 4.47 (d, J = 2.70 Hz, 1H), 3.86 (br, J = 2.70 Hz, 1H), 31H), 3.67 - 7.62 (m, 1H), 3.35 - 7.32 (m, 1H), 2.84 - 2.81 (m, 1H), 1.48 - 0.90 (m, 48H), 0.50 ppm (d, J = 6.80 Hz, 3H). ¹³C NMR (CD₃CN, 125 MHz): $\delta = 178.5$ (dd, J = 90.6 Hz, J =1.7 Hz), 143.5 (d, J = 22.5 Hz), 137.2 (d, J = 5.6 Hz), 136.3 (d, J = 5.2 Hz), 136.2 (dd, J = 5.2 20.2 Hz, J = 3.0 Hz), 135.5 (dd, J = 20.6 Hz, J = 2.9 Hz), 134.3 (d, J = 11.4 Hz), 133.3 (d, J = 11.3 Hz), 133.2 (d, *J* = 11.4 Hz), 132.9 (dd, *J* = 65.4 Hz, *J* = 8.9 Hz), 132.3 (d, *J* = 14.0 Hz), 131.4 (d, *J* = 12.5 Hz), 131.0 (d, *J* = 13.0 Hz), 121.4 (d, *J* = 84.2 Hz), 120,1 (d, *J* = 80.9 Hz), 107.6 (d, J = 91.9 Hz), 81.2, 69.5 (dd, J = 8.7 Hz, J = 4.2 Hz), 52.1, 50.0, 46.8 (dd, J = 81.2Hz, J = 22.0 Hz), 44.1, 27.0, 26.0, 25.1, 24.4 (d, J = 8.5 Hz), 23.5 (d, J = 6.0 Hz), 22.92, 22.86, 21.4, 20.1 ppm. ³¹P NMR (CD₃CN, 121 MHz): δ = 31.9 (d, *J* = 24.8 Hz), - 16.2 ppm (d, J = 24.8 Hz). ¹¹B NMR (CD₃CN, 96 MHz): $\delta = -1.1$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -152.5$ ppm. HRMS calcd. for C₄₈H₇₀N₄BF₄P₂⁺: 851.510320, found 851.509943. IR $\tilde{\upsilon} =$ 491, 528, 585, 646, 690, 724, 911, 1050, 1099, 1149, 1205, 1249, 1353, 1376, 1440, 1462, 1543, 1568, 1856, 2129, 2262, 2880, 2938, 2974 cm^{-1} .

Compound 92a



2–Chloro–1,3–dimethylimidazolidinium tetrafluoroborate (150.0 mg, 0.680 mmol) and Et₃N (0.100 ml, 0.710 mmol) were added to a solution of [2-(diphenylphosphino)phenyl]phosphine (100.0 mg, 0.340 mmol) in THF (5 ml) and the resulting mixture stirred at 60 °C overnight. After cooling to r.t., the solvent was filtered and the left washed with CHCl₃ to afford a white solid. This solid was stirred with NaBF₄ (149.6 mg, 1.360 mmol) in CH₃CN (5 ml) overnight. Subsequently the solvent was removed *in vacuo* and the resulting white solid extracted with CH₂Cl₂ (3 × 20 ml). The combined organic phase thus obtained was evaporated *in vacuo* to afford **92a** as a white solid (146.3 mg, 65%). ¹H NMR (CD₃CN, 400 MHz): δ = 7.76 – 7.68 (m, 3H), 7.53 – 7.45 (m, 6H), 7.42 – 7.38 (m, 1H), 7.34 – 7.30 (m, 4H), 3.84 – 3.80 (m, 8H), 2.98 ppm (s, 12H). ¹³C NMR (CD₃CN, 100 MHz): δ = 164.4 (dd, *J* = 47.5 Hz, *J* = 18.0 Hz), 144.3 (dd, *J* = 35.6 Hz, *J* = 5.1 Hz), 137.1 (d, *J* = 7.8 Hz), 136.6 (d, *J* = 8.2 Hz), 135.2 (d, *J* = 1.4 Hz), 134.5, 134.3, 134.0 (dd, *J* = 6.0 Hz, *J* = 1.0 Hz), 133.2, 131.3, 130.4, (d, *J* = 7.3 Hz), 127.3 (dd, *J* = 39.5 Hz, *J* = 3.1 Hz), 53.4, 36.8 ppm (d, *J* = 8.7 Hz). ³¹P NMR (CD₃CN, 121

MHz): $\delta = -12.3$ (d, $J_{P-P} = 211.6$ Hz), -47.6 ppm (d, $J_{P-P} = 212.6$ Hz). ¹¹B NMR (CD₃CN, 96 MHz): $\delta = -1.2$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -151.8$ ppm. HRMS *calcd*. for C₂₈H₃₄N₄BF₄P₂⁺: 575.228360, *found* 575.228243. IR $\tilde{v} = 425$, 457, 522, 653, 699, 741, 762, 936, 998, 1094, 1111, 1300, 1337, 1418, 1434, 1445, 1523, 1579, 3105 cm⁻¹.

Compound 92b



2-Chloro-1,3-dimethylimidazolidinium tetrafluoroborate (150.0 mg, 0.680 mmol) and Et₃N (0.100 ml, 0.710 mmol) were added to a solution of [2-(diphenylphosphino)phenyl]phosphine (100.0 mg, 0.340 mmol) in THF (5 ml) and the resulting mixture stirred at 60 °C overnight. After cooling to r.t., the solvent was filtered and the left washed with CHCl₃ to afford a white solid. This solid was stirred with NaSbF₆ (352.0 mg, 1.360 mmol) in CH₃CN (5 ml) overnight. Subsequently the solvent was removed in vacuo and the resulting white solid extracted with CH_2Cl_2 (3 \times 10 ml). The combined organic phase thus obtained was evaporated in vacuo to afford 92b as a white solid (234.9 mg, 72%). Colourless crystals suitable for X-ray crystallography were obtained from CH₂Cl₂/Et₂O at - 20 °C. ¹H NMR $(CD_3CN, 400 \text{ MHz}): \delta = 7.76 - 7.68 \text{ (m, 3H)}, 7.53 - 7.45 \text{ (m, 6H)}, 7.42 - 7.38 \text{ (m, 1H)}, 7.34$ -7.30 (m, 4H), 3.84 - 3.80 (m, 8H), 2.98 ppm (s, 12H). ¹³C NMR (CD₃CN, 100 MHz): $\delta =$ 164.4 (dd, J = 47.5 Hz, J = 18.1 Hz), 144.3 (dd, J = 30.0 Hz, J = 4.9 Hz), 137.1 (d, J = 7.2Hz), 136.6 (d, J = 8.4 Hz), 135.0, 134.4 (d, J = 18.6 Hz), 134.0 (dd, J = 6.0 Hz, J = 1.0 Hz), 133.2, 131.3, 130.4, (d, J = 7.3 Hz), 127.3 (dd, J = 40.6 Hz, J = 4.2 Hz), 53.4, 36.8 ppm (d, J = 8.7 Hz). ³¹P NMR (CD₃CN, 121 MHz): δ = -10.7 (d, J_{P-P} = 212.4 Hz), -46.1 ppm (d, J_{P-P} = 212.4 Hz). ¹⁹F NMR (CD₃CN, 376 MHz): δ = - 124.0 ppm (sextet, $J_{F-Sb(I=5/2)}$ = 1933 Hz, octet, $J_{F-Sb(I=7/2)} = 1049$ Hz). HRMS calcd. for $C_{28}H_{34}N_4SbF_6P_2^+$: 723.119040, found 723.119040. IR $\tilde{v} = 422, 456, 518, 653, 699, 745, 767, 934, 998, 1090, 1107, 1300, 1335,$ 1412, 1434, 1445, 1521, 1576, 3103 cm⁻¹.

Compound 92c



92b (96.0 mg, 0.100 mmol) and KB(Ar^F)₄ (143.6 mg, 0.2 mmol) in CH₂Cl₂ (2 ml) stirred for 10 min at r.t. After filtration, the filtrate was evaporated *in vacuo* to afford the desired compound **92c** as a white solid (183.0 mg, 99%). ¹H NMR (CD₂Cl₂, 400 MHz): $\delta = 7.82 -$ 7.77 (m, 1H), 7.64 – 7.59 (m, 1H), 7.57 – 7.51 (m, 3H), 7.50 – 7.45 (m, 4H), 7.36 – 7.31 (m, 1H), 7.28 – 7.22 (m, 4H), 3.87 – 3.80 (m, 8H), 3.04) ppm (s, 12H). ¹³C NMR (CD₂Cl₂, 125 Mz): $\delta = 164.1$ (dd, J = 54.8 Hz, J = 23.9 Hz), 149.4 (br), 147.6 (br), 144.3 (dd, J = 35.7 Hz, J =1.8 Hz), 139.7 (m), 137.7 (m), 135.8 (d, J = 1.8 Hz), 135.7 (m), 133.9 (d, J = 9.2 Hz), 133.6, 133.5, 133.4, 131.6, 131.5, 130.2 (d, J = 8.0 Hz), 125.1 (dd, J = 42.6 Hz, J = 7.0 Hz), 52.8, 36.5 ppm (d, J = 8.7 Hz). ³¹P NMR (CD₂Cl₂, 162 MHz): $\delta = -9.8$ (d, $J_{P-P} = 213.8$ Hz), – 49.1 ppm (d, $J_{P-P} = 213.8$ Hz). ¹⁹F NMR (CD₂Cl₂, 282 MHz): $\delta = -133$ (m), -163.2 (t, $J_{F-F} =$ 20.2 Hz), -167.3 ppm (t, $J_{F-F} = 18.1$ Hz). ¹¹B NMR (CD₂Cl₂, 96 MHz): $\delta = -16.7$ ppm. HRMS *calcd*. for C₂₈H₃₄N₄P₂⁺: 244.112390, *found* 244.112387. IR $\tilde{v} = 489$, 501, 573, 610, 661, 683, 713, 756, 774, 930, 954, 976, 1084, 1274, 1297, 1374, 1413, 1460, 1513, 1577, 1643 cm⁻¹.

Compound 99



^{*n*}BuLi (1.6 M in hexanes, 2.92 ml, 4.672 mmol) was added dropwise to *Rac*–**98** (2.3 g, 4.672 mmol) in THF (25 ml) at – 78 °C and the mixture stirred for 1 h at – 78 °C. Then CIP(O)(OEt)₂ (0.680 ml, 4.672 mmol) in THF (5 ml) was added dropwise and the mixture was allowed to warm to r.t. overnight. After that all volatiles were removed *in vacuo* and the crude phosphate was purified by column chromatography (SiO₂, hexane:EtOAc = 3:1) to afford the *rac*–phosphate **99** (1.1 g, 47%). ¹H NMR (CDCl₃, 400 MHz): δ = 7.90 (dd, *J* = 15.2 Hz, *J* = 7.12 Hz, 1H), 7.38 – 7.34 (m, 1H), 7.32 – 7.18 (m, 14H), 3.99 – 3.12 (m, 4H), 1.97 (s, 3H), 1.27 (s, 3H), 1.15 ppm (q, *J* = 5.8 Hz, 6H). ¹³C NMR (CDCl₃, 100 MHz): δ = 145.5 (dd, *J* = 33.5 Hz, *J* = 4.1 Hz), 143.4 (d, *J* = 8.2 Hz), 143.3 (d, *J* = 9.0 Hz), 139.7 (d, *J* = 13.9 Hz), 138.4 (dd, *J* = 15.3 Hz, *J* = 2.3 Hz), 138.0 (d, *J* = 11.4 Hz), 137.0 (d, *J* = 6.5 Hz), 136.9 (d, *J* = 1.8 Hz), 131.1 (d, *J* = 9.2 Hz), 130.5, 129.0, 128.4 (d, *J* = 7.7 Hz), 128.0 (d, *J* = 4.9 Hz), 127.5 (d, *J* = 10.4 Hz), 127.3 (d, *J* = 15.6 Hz), 127.1 (d, *J* = 2.8 Hz), 61.8 (t, *J* = 5.4 Hz), 20.5 (d, *J* = 2.7 Hz), 19.4, 16.4 ppm (dd, *J* = 11.7 Hz, *J* = 6.0 Hz). ³¹P NMR (CDCl₃, 121 MHz): δ = 17.7, – 16.2 ppm. HRMS *calcd*, for C₃₀H₃₂O₃P₂Na⁺: 525.171490, *found*

Compound 100



To LiAlH₄ (135.9 mg, 3.582 mmol) in Et₂O (5 ml) at -78 °C was added the previously prepared rac-phosphate 99 (600.0 mg, 1.194 mmol) in Et₂O (5 ml) over the course of ca. 0.5 h. This gray suspension stirred at -78 °C for an additional 15 min, allowed to warm to r.t. overnight. After this time, the reaction mixture was cooled to 0 °C. Deoxygenated water was carefully added and stirred until gas evolution ceased. The organic layer was then transferred into a schlenk and the solid was extracted with Et_2O (2 × 15 ml). Subsequently, the combined organic phases were dried with Na₂SO₄, filtered through Celite and the solvent removed in *vacuo* to afford **100** as a white solid (404.1 mg, 85%). ¹H NMR (CDCl₃, 400 MHz): $\delta = 7.43$ $(t, J = 6.8 \text{ Hz}, 1\text{H}), 7.27 - 7.15 \text{ (m, 13H)}, 7.12 - 7.10 \text{ (m, 1H)}, 7.10 - 7.03 \text{ (m, 1H)}, 3.72 \text{ (dd, 1H)}, 7.10 - 7.03 \text{ (m, 1H$ *J* = 31.6 Hz, *J* = 12.0 Hz, 1H), 3.21 (dd, *J* = 31.6 Hz, *J* = 12.0 Hz, 1H), 1.93 (s, 3H), 1.48 ppm (s, 3H). ¹³C NMR (CDCl₃, 400 MHz): $\delta = 146.4$ (dd, J = 31.4 Hz, J = 3.7 Hz), 144.1 (dd, J =16.2 Hz, J = 7.0 Hz), 137.9 (d, J = 12.3 Hz), 137.5 (d, J = 9.8 Hz), 137.2 (t, J = 3.0 Hz), 136.7 (d, J = 12.3 Hz), 136.4 (d, J = 6.3 Hz), 134.6 (d, J = 21.1 Hz), 133.6 (d, J = 19.2 Hz), 132.5(d, J = 9.8 Hz), 132.2 (d, J = 2.0 Hz), 131.1, 130.,0, 129.9 (d, J = 2.9 Hz), 128.8, 128.4 (d, J = 4.1 Hz), 128.36 (d, J = 2.7 Hz), 128.30, 127.9, 127.6 (d, J = 4.7 Hz), 20.1, 19.8 ppm. ³¹P NMR (CDCl₃, 121 MHz): $\delta = -15.0$ (d, $J_{P-P} = 20.1$ Hz), -125.6 ppm (d, $J_{P-P} = 20.1$ Hz). HRMS calcd. for C₂₆H₂₅P₂⁺: 399.142680, found 399.142604, IR $\tilde{v} = 438, 490, 506, 537, 553$, 573, 743, 768, 787, 827, 914, 998, 1026, 1067, 1094, 1147, 1206, 1261, 1306, 1379, 1400, 1434, 1475, 1566, 1584, 2294, 2851, 2913, 3001, 3048 cm⁻¹.

Compound 101a



2–Chloro–1,3–dimethylimidazolidinium tetrafluoroborate (110.0 mg, 0.502 mmol) and Et_3N (0.070 ml, 0.527 mmol) were added to a solution of **100** (100.0 mg, 0.251 mmol) in THF (5
ml). The resulting mixture was stirred at 60 °C overnight. After cooling to r.t., the solvent was filtered and the left washed with CHCl₃, affording a white solid. This solid was stirred with NaBF₄ (220.0 mg, 2.008 mmol) in CH₃CN (5 ml) overnight. Subsequently the solvent was removed in vacuo and the resulting white solid extracted with CH₂Cl₂. The combined organic phase thus obtained was evaporated *in vacuo* to afford **101a** as a white solid (78.9 mg, 41%). Colourless crystals suitable for X-ray crystallography were obtained from CH₃COCH₃/Et₂O at r.t. ¹H NMR (CD₃CN, 400 MHz): $\delta = 7.71 - 7.70$ (m, 1H), 7.56 - 7.50 (m, 2H), 7.47 - 7.26(m, 10H), 7.16 - 7.09 (m, 3H), 4.07 (d, J = 2.4 Hz, 4H), 3.95 - 3.90 (m, 2H), 3.83 - 3.79 (m, 2H), 3.13 (s, 6H), 2.78 (s, J = 0.6 Hz, 6H), 1.81 (s, 3H), 1.20 ppm (m, 3H). ¹³C NMR $(CD_3CN, 100 \text{ MHz})$: $\delta = 166.1 \text{ (dd, } J = 47.6 \text{ Hz}, J = 0.8 \text{ Hz}), 163.2 \text{ (dd, } J = 53.2 \text{ Hz}, J = 4.9 \text{ Hz})$ Hz), 145.7 (dd, J = 34.8 Hz, J = 5.7 Hz), 142.2 (dd, J = 8.2 Hz, J = 1.9 Hz), 141.5 (d, J = 7.2 Hz), 141.2 (d, J = 7.0 Hz), 140.0 (dd, J = 6.2 Hz, J = 1.4 Hz), 139.7 (dd, J = 34.8 Hz, J = 5.7 Hz), 137.1 (d, J = 8.9 Hz), 136.3 (d, J = 22.4 Hz), 135.9, 134.6, 133.8 (dd, J = 8.0 Hz, J = 3.9 Hz), 133.6 (d, J = 1.8 Hz), 133.4 (d, J = 3.4 Hz), 133.3 (d, J = 2.8 Hz), 132.8, 131.2, 131.1 (d, J = 0.9 Hz), 130.3 (d, J = 2.4 Hz), 129.9 (d, J = 5.9 Hz), 129.8 (d, J = 8.6 Hz), 54.5, 52.6, 38.0 (dd, J = 11.2 Hz, J = 3.5 Hz), 37.2 (d, J = 10.8 Hz), 19.5 (d, J = 2.3 Hz), 18.9 ppm (d, J = 3.2 Hz). ³¹P NMR (CD₃CN, 121 MHz): $\delta = -14.6$ (d, $J_{P-P} = 87.0$ Hz), -44.3 ppm (d, $J_{P-P} = 87.0$ Hz). ¹¹B NMR (CD₃CN, 96 MHz): $\delta = -1.2$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -151.8$ ppm. HRMS calcd. for C₃₆H₄₂N₄BF₄P₂⁺: 679.290520, found 679.290843. IR $\tilde{\upsilon}$ = 438, 461, 480, 493, 506, 531, 576, 633, 646, 698, 746, 754, 767, 787, 931, 1024, 1047, 1223, 1297, 1332, 1363, 1411, 1435, 1447, 1526, 1579, 1709, 2923, 3504 cm⁻¹.

Compound 101b



2–Chloro–1,3–dimethylimidazolidinium tetrafluoroborate (110.0 mg, 0.502 mmol) and Et₃N (0.070 ml, 0.527 mmol) were added to a solution of **100** (100.0 mg, 0.251 mmol) in THF (5 ml). The resulting mixture was stirred at 60 °C overnight. After cooling to r.t., the solvent was filtered and the left washed with CHCl₃, affording a white solid. This solid was stirred with NaSbF₆ (517.5 mg, 2.000 mmol) in CH₃CN (5 ml) overnight. Subsequently the solvent was removed *in vacuo* and the resulting white solid extracted with CH₂Cl₂. The combined organic phase thus obtained was evaporated *in vacuo* to afford **101b** as a white solid (162.9 mg, 61%).

¹H NMR (CD₃CN, 400 MHz): $\delta = 7.78 - 7.72$ (m, 1H), 7.58 - 7.52 (m, 2H), 7.49 - 7.26 (m, 10H), 7.18 - 7.12 (m, 3H), 4.10 (s, 4H), 3.98 - 3.92 (m, 2H), 3.85 - 3.80 (m, 2H), 3.15 (s, 6H), 2.79 (s, J = 0.6 Hz, 6H), 1.81 (s, 3H), 1.21 ppm (m, 3H). ¹³C NMR (CD₃CN, 100 MHz): $\delta = 165.7$ (d, J = 47.9 Hz), 163.0 (dd, J = 53.2 Hz, J = 4.9 Hz), 145.5 (dd, J = 34.8 Hz, J = 5.7 Hz), 141.8 (d, J = 8.1 Hz), 141.3 (d, J = 6.8 Hz), 141.0 (d, J = 7.0 Hz), 139.8 (d, J = 6.2 Hz), 139.5 (dd, J = 7.8 Hz, J = 1.7 Hz), 136.9 (d, J = 8.9 Hz), 136.1 (d, J = 22.4 Hz), 135.6, 134.4, 133.6 (dd, J = 8.4 Hz, J = 4.0 Hz), 129.6 (d, J = 8.6 Hz), 54.3, 52.4, 37.8 (dd, J = 11.2 Hz, J = 3.5 Hz), 37.0 (d, J = 10.8 Hz), 19.2 (d, J = 1.8 Hz), 18.7 ppm (d, J = 3.0 Hz). ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -122.4$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1945$ Hz, octet, $J_{F-Sb(I=7/2)} = 1071$ Hz). HRMS *calcd*. for C₃₂H₄₁ONP⁺: 486.292280. HRMS *calcd*. for C₃₆H₄₂N₄SbF₆P₂⁺: 827.182162, *found* 827.1829. IR $\tilde{v} = 438$, 461, 480, 493, 506, 531, 576, 633, 646, 698, 746, 754, 767, 787, 931, 1024, 1047, 1223, 1297, 1332, 1363, 1411, 1435, 1447, 1526, 1579, 1709, 2923, 3504 cm⁻¹.

Compound 102



2–Chloro–1,3–dimethylimidazolidinium tetrafluoroborate (132.6 mg, 0.602 mmol) and Et₃N (0.088 ml, 0.632 mmol) were added to a solution of Diphenyl(2– phosphinophenyl)phosphine (56.0 mg, 0.340 mmol) in THF (5 ml) and the resulting mixture stirred at 60 °C overnight. After cooling to r.t., the solvent filtered off to afford a white powder, which was dissolved in CH₂Cl₂ and washed with sat. NaSbF₆ twice. Evaporation of the organic phase afforded the desired product **102** as a white solid, which could be purified by recrystallization in CH₃CN/Et₂O (60.9 mg, 24%). ¹H NMR (CD₃CN, 400 MHz): δ = 7.84 – 7.79 (m, 1H), 7.66 – 7.57 (m, 6H), 7.43 – 7.41 (m, 2H), 3.96 – 3.82 (m, 8H), 2.88 ppm (s, 12H). ¹³C NMR (CD₃CN, 100 MHz): δ = 164.1 (d, *J* = 47.1 Hz), 150.1 (d, *J* = 34.1 Hz), 139.7 (d, *J* = 8.0 Hz), 135.7, 135.0, 133.0 (d, *J* = 6.0 Hz), 130.8 (d, *J* = 1.4 Hz), 130.5 (d, *J* = 13.8 Hz), 130.3 (d, *J* = 4.0 Hz), 128.9 (d, *J* = 24.1 Hz), 128.6, 53.4, 36.9 ppm (d, *J* = 9.0 Hz). ³¹P NMR (CD₃CN, 121 MHz): δ = - 43.1 ppm. ¹⁹F NMR (CD₃CN, 282 MHz): δ = - 122.4 ppm (sextet, *J*_{*F*-*Sb*(*I*=*5*/2) = 1945 Hz, octet, *J*_{*F*-*Sb*(*I*=*7*/2) = 1071 Hz). HRMS *calcd*. for C₂₂H₂₉N₄F₆PSb⁺: 615.106410, *found*}}

615.106603. IR $\tilde{v} = 435$, 455, 468, 554, 653, 707, 761, 779, 935, 1206, 1301, 1337, 1413, 1447, 1526, 1583 cm⁻¹.

Compound 103



At - 78 °C, PhPH₂ (50.0 mg, 0.454 mmol) in THF (5 ml) was cannulated to chlorodipiperidinocarbenium hexafluoroantimonate (410.1 mg, 0.908 mmol) and KHDMS (181.2 mg, 0.908 mmol) in one schlenk and the resulting mixture was warmed to r.t. overnight. The solvent was removed in vacuo and the left was stirred with NaSbF₆(352.0 mg, 1.360 mmol) in CH₃CN (5 ml) overnight. Subsequently the solvent was removed in vacuo and the resulting white solid extracted with CH₂Cl₂. The combined organic phase thus obtained was evaporated in vacuo and the resulting solid washed with Et₂O and a small amout of CH_2Cl_2 to afford the desired compound 103 as a white solid (155.5 mg, 41%). Colourless crystals suitable for X-ray crystallography were obtained from CH₂Cl₂/Et₂O at r.t. ¹H NMR $(CD_3CN, 400 \text{ MHz}): \delta = 7.91 - 7.36 \text{ (m, 5H)}, 4.22 - 3.21 \text{ (m, 16H)}, 1.82 - 1.37 \text{ ppm (m, 16H)}$ 24H). ¹³C NMR (CD₃CN, 100 MHz): $\delta = 173.9$ (d, J = 25.0 Hz), 137.5 (d, J = 23.6 Hz), 134.8, 132.1 (d, J = 10.3 Hz), 122.8, 56.0, 26.3, 23.3 ppm. ³¹P NMR (CD₃CN, 121 MHz): $\delta =$ -15.3 ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -124.0$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1933$ Hz, octet, $J_{F-Sb(I=7/2)} = 1049$ Hz). HRMS calcd. for $C_{28}H_{45}N_4SbF_6P_1^+$: 703.231110, found 703.231803. IR $\tilde{v} = 460, 496, 586, 654, 752, 859, 1013, 1132, 1255, 1290, 1362, 1441, 1538,$ 1557, 2864, 2945 cm⁻¹.

Compound 104



At – 78 °C, cyclohexylphosphine (50.0 mg, 0.430 mmol) in THF (5 ml) was cannulated to chlorodipiperidinocarbenium hexafluoroantimonate (388.7 mg, 0.861 mmol) and KHDMS (171.8 mg, 0.861 mmol) in one schlenk and the resulting mixture was warmed to r.t. overnight. The solvent was removed *in vacuo* and the left was stirred with NaSbF₆(352.0 mg, 1.360 mmol) in CH₃CN (5 ml) overnight. Subsequently the solvent was removed *in vacuo* and

the resulting white solid extracted with CH₂Cl₂ (3 × 10 ml). The combined organic phase thus obtained was evaporated *in vacuo* and the resulting solid washed with Et₂O and a small amout of CH₂Cl₂ to afford the desired compound **104** as a white solid (297 mg, 73%). ¹H NMR (CD₃CN, 400 MHz): $\delta = 3.68$ (m, 16H), 3.32 - 3.13 (m, 1H), 1.92 - 1.84 (m, 4H), 1.84 - 1.26 ppm (m, 30H). ¹³C NMR (CD₃CN, 100 MHz): $\delta = 174.5$ (d, J = 34.7 Hz), 55.9 (d, J = 5.1 Hz), 38.88 (d, J = 23.2 Hz), 32.83 (d, J = 17.8 Hz), 27.1 (d, J = 15.9 Hz), 26.5, 25.7 (d, J = 2.1 Hz), 23.3 ppm. ³¹P NMR (CD₃CN, 121 MHz): $\delta = -3.7$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -124.0$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1933$ Hz, octet, $J_{F-Sb(I=7/2)} = 1049$ Hz), HRMS *calcd.* for C₂₈H₅₁N₄SbF₆P₁⁺: 709.278630, *found* 709.278753. IR $\tilde{v} = 483$, 578, 653, 780, 860, 1012, 1130, 1255, 1354, 1445, 1533, 2862, 2943 cm⁻¹.

Compound 105

ⁿBuLi (1.6 M in hexanes, 0.340 ml, 0.590 mmol) was added dropwise to (2-Bromophenyl)diphenylphosphine (200.0 mg, 0.586 mmol) in THF (5 ml) at - 78 °C and the mixture stirred for 1 h at -78 °C. (C₆F₅)₂PCl (238.0 mg, 0.590 mmol) in THF (2 ml) was added dropwise. The reaction was then allowed to warm to r.t. overnight and after that all volatiles were removed in vacuo. The crude was purified by column chromatography (SiO₂, hexane: toluene = 5: 1) to afford the desired diphosphine 105 as a white solid (103.5 mg, 28%). ¹H NMR (C₆D₆, 400 MHz): $\delta = 7.32 - 7.30$ (m, 1H), 7.18 - 7.13 (m, 1H), 7.05 - 7.02 (m, 5H), 6.95 - 6.88 ppm (m, 7H). ¹³C NMR (C₆D₆, 100 MHz): $\delta = 149.5$ (m), 146.9 (m), 142.6 (dm, $J_{C-F} = 258.5$ Hz), 138.3 (dd, J = 34.0 Hz, J = 11.4 Hz), 138.2 (d, J = 34.3 Hz, J = 11.4 Hz) 11.4 Hz), 137.7 (q, $J_{C-F} = 252.8$ Hz), 135.9 (q, J = 5.0 Hz), 133.7, 133.5, 132.7 (d, J = 8.9Hz), 130.4, 129.8, 129.0, 128.8 ppm (d, J = 7.0 Hz). ³¹P NMR (C₆D₆, 121 MHz): $\delta = -16.6$ (dt, $J_{P-F} = 184.5$ Hz, $J_{P-P} = 5.1$ Hz), -56.4 ppm (dq, $J_{P-F} = 184.5$ Hz, $J_{P-P} = 30.2$ Hz). ¹⁹F NMR (C₆D₆, 282 MHz): $\delta = -129.2$ (m), -149.8 (m), -160.5 ppm (m). HRMS *calcd*. for $C_{30}H_{14}F_{10}P_2$: 626.040937, found 626.041114. IR $\tilde{v} = 407, 439, 478, 494, 511, 521, 586, 631,$ 675, 745, 800, 840, 972, 1026, 1082, 1260, 1284, 1306, 1378, 1434, 1440, 1514, 1585, 1641, 2859, 2963, 3055 cm⁻¹.

Compound 106



ⁿBuLi (1.6 M in hexanes, 0.689 ml, 1.102 mmol) was added dropwise to (2-Bromophenyl)diphenylphosphine (376.0 mg, 1.102 mmol) in THF (5 ml) at - 78 °C. The mixture stirred for 1 h at - 78 °C and (pyrrolyl)₂PCl (218.9 mg, 1.102 mmol) in THF (2 ml) was added dropwise. The reaction was then allowed to warm to r.t. overnight and after that all volatiles were removed in vacuo. The crude was purified by column chromatography (SiO₂, hexane:toluene = 3:1) to afford the desired diphosphine **106** as a white solid (304.2 mg, 65%). ¹H NMR (C₆D₆, 300 MHz): $\delta = 7.29 - 7.26$ (m, 1H), 7.21 - 7.19 (m, 3H), 7.00 - 7.97 (m, 7H), 6.92 - 6.88 (m, 2H), 6.81 - 6.78 (m, 1H), 6.76 - 6.74 (m, 4H), 6.23 ppm (t, J = 2.1Hz, 4H). ¹³C NMR (C₆D₆, 100 Mz): $\delta = 144.6$ (dd, J_{C-P} = 32.3, J_{C-P} = 12.6 Hz), 141.9 (dd, J_{C-P} = 28.3, $J_{C-P} = 14.2$ Hz), 136.5 (dd, $J_{C-P} = 10.3$, $J_{C-P} = 4.6$ Hz), 135.5 (d, $J_{C-P} = 3.2$ Hz), 133.8 (d, $J_{C-P} = 19.6 \text{ Hz}$, 130.6 (dd, $J_{C-P} = 10.3, 5.3 \text{ Hz}$), 130.5 (d, $J_{C-P} = 73.1 \text{ Hz}$), 128.8, 128.7 (d, J_{C-P} = 73.1 \text{ Hz}), 128.8, 128.7 (d, J_{C-P} = 73.1 \text{ Hz})), 128.8, 1 $_{P}$ = 7.0 Hz), 127.3, 124.6 (d, J_{C-P} = 13.8 Hz), 112.6 ppm (d, J_{C-P} = 3.9 Hz). ³¹P NMR (C₆D₆, 121 MHz): $\delta = 66.1$ (d, $J_{P-P} = 167.3$ Hz), -18.6 ppm (d, $J_{P-P} = 167.3$ Hz). HRMS *calcd*. for $C_{26}H_{22}N_2P_2Na^+$: 447.114760, found 447.115045. IR $\tilde{v} = 419, 474, 498, 546, 616, 662, 693,$ 731, 766, 803, 100, 1057, 1074, 1176, 1241, 1262, 1292, 1389, 1434, 1449, 1478, 1555, 1582, 2924, 2961, 3063 cm⁻¹.

Compound 107a



92b (36.4 mg, 0.038 mmol) and Mo(CO)₆ (10.0 mg, 0.038 mmol) was stirred in THF (2 ml) at 75 °C overnight. After cooling to r.t., the solvent was evaporated *in vacuo* and washed with CH₂Cl₂ to afford the desired compound as a yellow solid (19.9 mg, 49%). Yellow crystals suitable for X– ray analysis were obtained from a saturated solution in CH₃CN/Et₂O at r.t. ¹H NMR (CD₃CN, 400 MHz): $\delta = 8.15 - 8.07$ (m, 1H), 8.04 - 7.89 (m, 3H), 7.68 - 7.27 (m, 10H), 4.01 (s, 8H), 3.14 - 2.92 (br, 12H). ¹³C NMR (CD₃CN, 125 Mz): $\delta = 213.6$ (dd, $J_{C-P} =$ 32.5, $J_{C-P} = 10.0$ Hz), $\delta = 213.1$ (dd, $J_{C-P} = 23.8$, $J_{C-P} = 7.6$ Hz), 208.2 (m), 162.4 (d, $J_{C-P} =$ 22.7Hz), 144.9 (dd, $J_{C-P} = 42.2$, $J_{C-P} = 35.1$ Hz), 138.4 (d, $J_{C-P} = 15.6$ Hz), 136.5 (d, $J_{C-P} =$ 12.1 Hz), 136.2 (dd, $J_{C-P} = 4.7$ Hz, $J_{C-P} = 2.2$ Hz), 135.1 (dd, $J_{C-P} = 5.8$ Hz, $J_{C-P} = 1.7$ Hz), 134.4 (d, $J_{C-P} = 13.2$ Hz), 133.0 (m), 132.4, 130.3 (d, $J_{C-P} = 10.4$ Hz), 129.8 (dd, $J_{C-P} = 41.6$ Hz, 35.9 Hz), 53.5 (m), 53.5 ppm (m). ³¹P NMR (CD₃CN, 162 MHz): $\delta = 60.1$ (d, $J_{P-P} = 13.7$ Hz), 40.2 ppm (d, $J_{P-P} = 13.7.7$ Hz). ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -124.0$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1933$ Hz, octet, $J_{F-Sb(I=7/2)} = 1049$ Hz). HRMS *calcd.* for C₃₂H₃₄N₄F₆MoP₂Sb⁺: 933.004530, *found* 933.004662. IR $\tilde{\upsilon} = 514$, 524, 657, 697, 796, 1016, 1090, 1259, 1297, 1572, 1847, 1938, 1973, 2403, 2963 cm⁻¹.

Compound 107b



(Dipyrrolylphosphino)–2–diphenylphsphine **106** (100.0 mg, 0.236 mmol) and Mo(CO)₆ (62.2mg, 0.236 mmol) in THF (3 ml) was stirred overnight at 70 °C. After cooling to r.t., the solvent was evaporated *in vacuo* to afford the desired compound **107b** as a yellow solid (113.2 mg, 76%). ¹H NMR (CD₂Cl₂, 400 MHz): $\delta = 7.57$ (m, 3H), 7.49 (m, 1H), 7.44 – 7.26 (m, 10H), 6.72 (dt, J = 4.2, J = 2.1 Hz, 4H), 6.32 ppm (td, J = 2.1, J = 1.1 Hz, 4H). ¹³C NMR (CD₂Cl₂, 100 Mz): $\delta = 215.7 - 214.8$ (m), 209.0 – 207.9 (m), 145.0 (dd, $J_{C-P} = 40.9$, $J_{C-P} = 33.8$ Hz), 143.1 (dd, $J_{C-P} = 42.9$, $J_{C-P} = 34.9$ Hz), 135.6 (dd, $J_{C-P} = 37.8$, $J_{C-P} = 2.9$ Hz), 133.9 (d, $J_{C-P} = 14.9$ Hz), 132.6 (dd, $J_{C-P} = 5.0$ Hz, $J_{C-P} = 2.0$ Hz), 132.6 (d, $J_{C-P} = 9.7$ Hz), 131.1 (d, $J_{C-P} = 7.5$ Hz), 113.0 ppm (d, $J_{C-P} = 5.7$ Hz). ³¹P NMR (CD₂Cl₂, 162 MHz): $\delta = 139.2$ (d, $J_{P-P} = 4.7$ Hz), 56.9 ppm (d, $J_{P-P} = 4.7$ Hz). HRMS *calcd*. for C₃₀H₂₂N₂O₄MoP₂Na⁺: 656.999890, *found* 657.000215. IR $\tilde{v} = 416$, 504, 525, 571, 585, 671, 732, 999, 1037, 1067, 1116, 1177, 1234, 1434, 1449, 1481, 1572, 1896, 1936, 2030, 3062, 3251 cm⁻¹.

Compound 107c



(Dipentafluorophenylphosphino)–2–diphenylphsphine **105** (100.0 mg, 0.160 mmol) and $Mo(CO)_6$ (42.2mg, 0.160 mmol) in THF (3 ml) was stirred at 70 °C overnight. After cooling to r.t., the solvent was evaporated *in vacuo* to afford the desired compound **107c** as a white solid (114.6 mg, 86%). ¹H NMR (CD₂Cl₂, 400 MHz): $\delta = 7.76 - 7.72$ (m, 1H), 7.61 – 7.56

(m, 4H), 7.43 – 7.40 ppm (m, 9H). ¹³C NMR (CD₂Cl₂, 100 Mz): $\delta = 216.6$ (dd, $J_{C-P} = 31.8$, $J_{C-P} = 8.7$ Hz), 215.1 (d, $J_{C-P} = 26.0$ Hz), 208.5 (m), 146.5 (dm, $J_{C-F} = 251.0$ Hz), 143.1 (dm, $J_{C-F} = 258.2$ Hz), 142.9 (dd, $J_{C-P} = 43.4$, $J_{C-P} = 35.0$ Hz), 139.5 (m), 137.0 (m), 135.9 (dd, $J_{C-P} = 37.4$, $J_{C-P} = 2.5$ Hz), 134.8 (d, $J_{C-P} = 15.6$ Hz), 133.4 (d, $J_{C-P} = 12.8$ Hz), 132.5 (d, $J_{C-P} = 12.7$ Hz), 131.7 (dd, $J_{C-P} = 16.5$, $J_{C-P} = 2.0$ Hz), 130.5 (d, J = 2.0 Hz), 128.9 (d, J = 9.7 Hz), 111.2 ppm (d, $J_{C-P} = 21.2$ Hz). ³¹P NMR (CD₂Cl₂, 162 MHz): $\delta = 60.5$ (d, $J_{P-P} = 7.3$ Hz), 31.1 ppm (q, $J_{P-F} = 10.6$, $J_{P-F} = 10.1$ Hz). ¹⁹F NMR (CD₂Cl₂, 282 MHz): $\delta = -128.6$ (m), -149.6 (m), -160.0 ppm (m). EI–MS *calcd.* for C₃₄H₁₄O₄F10MoP₂: 834.37, *found* 834.25. IR $\tilde{v} = 424, 542, 585, 631, 665, 693, 729, 799, 976, 1009, 1086, 1190, 1260, 1287, 1322, 1384, 1436, 1470, 1514, 1639, 1911, 2028, 2072, 2963, 3058 cm⁻¹.$

Compound 108



S₈ (2.0 mg, 0.063 mmol) and **92b** (30.0 mg, 0.031 mmol) in DCE (2 ml) were stirred at 70 °C for 48 h. After removal of the solvent *in vacuo*, the remaining solid was washed with Et₂O and pentane to afford **108** as a white solid (23.6 mg, 76%). Colourless crystals suitable for X–ray crystallography were obtained from a saturated solution of the compound in CH₂Cl₂/Et₂O at r.t. ¹H NMR (CD₃CN, 400 MHz): δ = 7.78 – 7.70 (m, 9H), 7.63 – 7.61 (m, 4H), 7.37 – 7.30 (m, 1H), 3.97 – 3.91 (m, 8H), 2.79 ppm (s, 12H). ¹³C NMR (CD₃CN, 100 MHz): δ = 166.0 (d, *J* = 45.2 Hz), 141.7 (dd, *J* = 83.4 Hz, *J* = 32.5 Hz), 142.4 (dd, *J* = 9.6 Hz, *J* = 2.0 Hz), 135.8 (dd, *J* = 8.4 Hz, *J* = 8.4 Hz), 135.1 (d, *J* = 10.5 Hz), 134.9 (d, *J* = 2.6 Hz), 134.2 (d, *J* = 3.0 Hz), 133.7 (d, *J* = 10.9 Hz), 130.4 (d, *J* = 13.0 Hz), 129.7 (dd, *J* = 86.7 Hz, *J* = 0.9 Hz), 123.1 (dd, *J* = 11.0 Hz, *J* = 9.6 Hz), 55.3, 53.3, 36.3, 36.2 ppm. ³¹P NMR (CD₃CN, 121 MHz): δ = 44.3 (d, *J*_{*P*-*P*} = 32.1 Hz), - 51.1 ppm (d, *J*_{*P*-*P*</sup> = 32.1 Hz). ¹⁹F NMR (CD₃CN, 282 MHz): δ = - 122.4 ppm (sextet, *J*_{*F*-*Sb*(*I*=5/2) = 1945 Hz, octet, *J*_{*F*-*Sb*(*I*=7/2) = 1071 Hz). HRMS *calcd.* for C₂₈H₃₄N₄SbF₆P₂S⁺: 755.091860, *found* 755.091565. IR \tilde{v} = 422, 437, 448, 474, 505, 521, 651, 690, 716, 738, 753, 767, 840, 929, 1000, 1105, 1187, 1293, 1329, 1409, 1441, 1484, 1518, 1572, 1715, 2962, 3066 cm⁻¹.}}}

Compound 109a



Ptl₂(PhCN)₂ (20.0 mg, 0.031 mmol) and **92b** (29.5 mg, 0.031 mmol) in CH₂Cl₂ (2 ml) was stirred overnight. After removal of the solvent *in vacuo*, the remaining solid was washed with pentane, affording the desired product as a yellow solid **109a** (40.3 mg, 95%). Yellow crystals suitable for X–ray crystallography were obtained from a saturated solution of CH₃COCH₃/Et₂O at 0 °C. ¹H NMR (CD₃CN, 400 MHz): δ = 8.45 – 8.40 (m, 1H), 7.96 – 7.91 (m, 2H), 7.77 – 7.70 (m, 7H), 7.62 – 7.57 (m, 4H), 4.07 – 4.00 (m, 8H), 3.24 ppm (s, 12H). ¹³C NMR (CD₃CN, 100 MHz): δ = 154.3 (d, *J* = 49.5 Hz), 138.7 (m), 138.5 (m), 136.3 (m), 136.2 (m), 136.1 (m), 135.9 (m), 135.1 (m), 134.9 (d, *J*_{C-P} = 2.8 Hz), 134.5 (d, *J*_{C-P} = 3.6 Hz), 127.6 (d, *J*_{C-P} = 68.7 Hz), 54.5 (d, *J*_{C-P} = 4.6 Hz, *J*_{P-Pt} = 2856.1 Hz), 5.4 ppm (d, *J*_{P-P} = 4.6 Hz, *J*_{P-Pt} = 3457.9 Hz). ¹⁹F NMR (CD₃CN, 282 MHz): δ = – 122.4 ppm (sextet, *J*_{F-Sb(I=5/2)} = 3890 Hz, octet, *J*_{F-Sb(I=7/2)} = 1071 Hz). HRMS *calcd*. for C₂₈H₃₄N₄SbF₆P₂I₂Pt⁺: 1171.893620, *found* 1171.893250. IR \tilde{v} = 452, 503, 543, 598, 645, 689, 750, 922, 998, 1101, 1114, 1300, 1408, 1437, 1520, 1586, 1979, 2220, 3007, 3061 cm⁻¹.

Compound 109b



CH₂Cl₂ (2 ml) was added to a mixture of PtCl₂(CH₃CN)₂ (10.9 mg, 0.031 mmol) and **92b** (30.0 mg, 0.031 mmol) and the mixture stirred overnight. After removal of the solvent *in vacuo*, the solid left washed with pentane and dried, affording the desired product **109b** as a white solid (36.8 mg, 96%).¹H NMR (CD₃CN, 400 MHz): $\delta = 8.28 - 8.23$ (m, 1H), 8.05–7.95 (m, 3H), 7.80 - 7.68 (m, 6H), 7.62 - 7.57 (m, 4H), 4.10 - 4.05 (m, 8H), 3.25 ppm (s, 12H). ¹³C NMR (CD₃CN, 100 MHz): $\delta = 153.1$ (d, J = 53.0 Hz), 143.0 (dd, J = 63.5 Hz, J = 40.9 Hz), 138.9 (dd, J = 7.8 Hz, J = 2.7 Hz), 138.2 (dd, J = 19.3 Hz, J = 4.1 Hz), 137.3 (dd, J = 9.2 Hz, J = 2.2 Hz), 136.6 (dd, J = 1.7 Hz, J = 3.6 Hz), 135.2 (dd, J = 19.9 Hz, J = 8.4 Hz), 134.7 (d, J = 3.0 Hz), 130.6 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz, J = 22.5 Hz), 126.0 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz, J = 22.5 Hz), 126.0 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz, J = 22.5 Hz), 126.0 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz, J = 22.5 Hz), 126.0 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz, J = 22.5 Hz), 126.0 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz, J = 22.5 Hz), 126.0 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz, J = 22.5 Hz), 126.0 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz, J = 22.5 Hz), 126.0 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz), 128.0 (dd, J = 67.5 Hz), 126.0 (d, J = 12.7 Hz), 128.0 (dd, J = 67.5 Hz), 128.

= 71.3 Hz),54.5 (d, *J* = 3.6 Hz), 39.3 ppm (d, *J* = 2.5 Hz). ³¹P NMR (CD₃CN, 121 MHz): δ = 39.5 (t, J_{P-Pt} = 3006.0 Hz), 8.5 ppm (t, J_{P-Pt} = 3893.4 Hz). ¹⁹F NMR (CD₃CN, 376 MHz): δ = - 124.0 ppm (sextet, $J_{F-Sb(I=5/2)}$ = 1933 Hz, octet, $J_{F-Sb(I=7/2)}$ = 1049 Hz). HRMS *calcd*. for C₂₈H₃₄N₄SbF₆P₂Cl₂Pt⁺: 987.022430, *found* 988.022211. IR $\tilde{\upsilon}$ = 472, 505, 525, 654, 690, 735, 748, 767, 922, 997, 1102, 1117, 1205, 1294, 1437, 1521, 1581 cm⁻¹.

Compound 109c and 109d



[RhCl(COD)]₂ (5.0 mg, 0.013 mmol) and **92b** (24.7 mg, 0.026 mmol) in CH₂Cl₂ (2 ml) was stirred overnight. After removal of the solvent *in vacuo*, the solid left washed with pentane, affording the desired product **109c** as an orange solid (26.3 mg, 92%). The compound **109c** in CD₃CN is equilibrium between **109c** and **109d**, which can be proved by the related ³¹P NMR Spectra. Mixing of the solution of **92b** and [RhCl(COD)]₂ in CH₂Cl₂ at -78 °C, orange crystals of **109c** suitable for X–ray crystallography were obtained by slowly warming up the solution. Orange crystals of **109d** suitable for X–ray crystallography were directly obtained from solutions of the title compound in CH₃CN/CH₂Cl₂/Et₂O at r.t.

Compound 109e



PdCl₂(PhCN)₂ (7.2 mg, 0.019 mmol) and **92b** (18.0 mg, 0.019 mmol) in CH₂Cl₂ (2 ml) was stirred overnight. After removal of the solvent *in vacuo*, the solid left washed with pentane and dried, affording the desired product **109e** as a white solid (19.4 mg, 91%). ¹H NMR (CD₃CN, 400 MHz): $\delta = 8.28 - 8.23$ (m, 1H), 8.10 - 8.06 (m, 2H), 8.00 - 7.90 (m, 1H), 7.85 - 7.72 (m, 6H), 7.64 - 7.59 (m, 4H), 4.11 - 4.06 (m, 8H), 3.24 ppm (s, 12H). ¹³C NMR (CD₃CN, 100 MHz): $\delta = 155.4$ (d, J = 41.8 Hz), 139.8 (dd, J = 6.9 Hz, J = 2.2 Hz), 138.6 (dd, J = 23.6 Hz, J = 2.9 Hz), 137.5 (d, J = 1.7 Hz), 137.4 (d, J = 2.1 Hz), 137.3 (d, J = 1.5 Hz), 137.2, 135.3 (d, J = 11.5 Hz), 135.0 (d, J = 3.3 Hz), 130.7 (d, J = 12.8 Hz), 126.9 (d, J = 64.5 Hz), 54.7 (d, J = 3.4 Hz), 39.4 ppm (d, J = 2.8 Hz). ³¹P NMR (CD₃CN, 121 MHz): $\delta = 63.7$

(d, $J_{P-P} = 5.9$ Hz), 22.8 ppm (d, $J_{P-P} = 5.9$ Hz). ¹⁹F NMR (CD₃CN, 376 MHz): $\delta = -124.0$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1933$ Hz, octet, $J_{F-Sb(I=7/2)} = 1049$ Hz). HRMS *calcd*. for C₂₈H₃₄N₄SbF₆P₂Cl₂Pd⁺: 898.961130, *found* 898.960595. IR $\tilde{v} = 426, 452, 495, 507, 525, 678, 699, 746, 767, 938, 987, 1102, 1117, 1205, 1265, 1294, 1437, 1489, 1521, 1581, 2935 cm⁻¹.$

Compound 109f



(Me₂S)AuCl (9.2 mg, 0.031 mmol) and **92b** (30.0 mg, 0.031 mmol) in CH₂Cl₂ (2 ml) were stirred overnight. After removal of the solvent *in vacuo*, the solid left washed with pentane and dried, affording the desired product **109f** as a white solid (34.6 mg, 93%). Colorless Crystals suitable for X–ray crystallography were obtained from CH₃CN/CH₂Cl₂/Et₂O. ¹H NMR (CD₃CN, 400 MHz): δ = 7.88 – 7.81 (m, 2H), 7.75 – 7.70 (m, 3H), 7.70 – 7.61 (m, 8H), 7.36 – 7.30 (m, 1H), 4.01 (d, *J* = 1.3, 8H), 2.83 ppm (s, 12H). ¹³C NMR (CD₃CN, 100 MHz): δ = 163.7 (dd, *J* = 39.6 Hz, *J* = 3.1 Hz), 140.8 (dd, *J* = 8.2 Hz, *J* = 1.8 Hz), 138.6 (dd, *J* = 59.6 Hz, *J* = 37.2 Hz), 137.6 (dd, *J* = 9.8 Hz, *J* = 6.0 Hz), 136.9 (d, *J* = 8.3 Hz), 135.9 (d, *J* = 14.2 Hz), 135.5, 134.5 (d, *J* = 2.8 Hz), 131.1 (d, *J* = 12.3 Hz), 126.0 (dd, *J* = 65.4 Hz, *J* = 3.0 Hz), 120.6 (d, *J* = 2.3 Hz), 53.7, 36.3 ppm (d, *J* = 9.1 Hz). ¹⁹F NMR (CD₃CN, 282 MHz): δ = -122.4 ppm (sextet, *J_{F-Sb(1=5/2})* = 1945 Hz, octet, *J_{F-Sb(1=7/2})* = 1071 Hz). HRMS *calcd.* for C₂₈H₃₄N₄P₂F₆ClSbAu⁺: 955.054890, *found* 955.054898. IR \tilde{v} = 454, 498, 509, 549, 645, 693, 796, 930, 1023, 1100, 1206, 1261, 1296, 1334, 1411, 1438, 1482, 1520, 1578, 2921, 2962 cm⁻¹.





 $[RhCl(COD)]_2$ (6.4 mg, 0.013 mmol) and **101a** (20.0 mg, 0.026 mmol) in CH₃CN (2 m l) were stirred overnight. After removal of the solvent *in vacuo*, the solid left washed with CH₂Cl₂ and pentane, and dried, affording **110** as a yellow solid (21.6 mg, 86%). Yellow

crystals suitable for X–ray crystallography were obtained from CH₃CN/CH₂Cl₂/Et₂O at r.t. ¹H NMR (CD₃CN, 400 MHz): $\delta = 7.75 - 8.60$ (m, 3H), 7.59 - 7.42 (m, 7H), 7.42 - 7.35 (m, 3H), 7.33 - 7.28 (m, 1H), 7.26 - 7.16 (m, 1H), 7.14 - 7.10 (m, 1H), 4.32 - 4.20 (m, 2H), 4.16 (s, 3H), 4.02 (s, 3H), 3.96 - 3.90 (m, 2H), 3.81 - 3.89 (m, 1H), 3.78 - 3.66 (m, 2H), 3.45 - 3.33 (m, 1H), 3.03 (s, 3H), 2.75 (s, 3H), 1.74 (s, 3H), 1.62 ppm (s, 3H). ¹³C NMR (CD₃CN, 125 MHz): $\delta = 164.8$ (d, J = 33.6 Hz), 154.8, 143.1 (d, J = 9.5 Hz), 142.5 (d, J = 7.6 Hz), 140.5 (d, J = 18.2 Hz, J = 4.0 Hz), 137.0 (d, J = 52.9 Hz), 136.9 (dd, J = 11.5 Hz, J = 6.1 Hz), 135.9, 135.7 (d, $J_{C-P} = 10.4$ Hz), 135.5 (d, J = 12.9 Hz), 134.8, 132.7, 132.3 (d, J = 50.0 Hz), 132.0, 131.2 (d, J = 7.6 Hz), 129.4 (d, J = 9.7 Hz), 127.8 (d, J = 51.0 Hz), 121.7 (d, J = 59.1 Hz), 55.4, 53.7, 53.6, 51.5, 42.6 (d, J = 4.4 Hz), 39.4 (d, J = 11.0 Hz), 39.0, 37.4, 20.7, 19.8 ppm. ³¹P NMR (CD₃CN, 121 MHz): $\delta = 38.1$ (dd, $J_{P-Rh} = 153.9$ Hz, $J_{P-P} = 50.2$ Hz). ¹¹B NMR (CD₃CN, 96 MHz): $\delta = -1.2$ ppm, ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -151.9$ ppm. IR $\tilde{\nu} = 463$, 698, 754, 792, 868, 936, 1052, 1292, 1401, 1661, 2112, 2325, 3205, 3369 cm⁻¹.

Compound 112b



Pd(C₆F₅)₂(cod) (50.0 mg, 0.031 mmol) and 1,2–bis(diphenylphosphino)benzene (30.4 mg, 0.031 mmol) were stirred overnight in CH₂Cl₂ (2 ml). After removal of the solvent *in vacuo*, the solid left washed with pentane and dried, affording the desired product as a white solid **112b** (76.8 mg, 95%). Colorless crystals suitable for X–ray crystallography were obtained from CH₂Cl₂. ¹H NMR (CD₂Cl₂, 600 MHz): $\delta = 7.75 - 7.72$ (m, 2H), 7.61 – 7.60 (m, 2H), 7.51 – 7.49 (m, 4H), 7.47 – 7.44 (m, 8H), 7.39 – 7.37 ppm (m, 8H). ¹³C NMR (CD₂Cl₂, 150 MHz): $\delta = 146.3$ (dm, $J_{C-F} = 230.4$), 142.5 (t, $J_{C-P} = 43.0$ Hz), 137.5 (dm, $J_{C-F} = 241.9$ Hz), 136.5 (dm, $J_{C-F} = 237.4$ Hz), 133.9 (t, $J_{C-P} = 8.6$ Hz), 133.7 (t, $J_{C-P} = 8.6$ Hz), 133.1, 131.8, 130.6 (d, J = 47.9 Hz), 129.2 ppm (t, J = 4.5 Hz). ³¹P NMR (CD₂Cl₂, 121 MHz): $\delta = 52.3$ ppm. ¹⁹F NMR (CD₂Cl₂, 282 MHz): $\delta = -113.7$ (m), -161.2 (t, $J_{F-F} = 20.7$ Hz), -163.1 (tm, $J_{F-F} = 20.7$ Hz) ppm. MS–EI *calcd*. for C₄₂H₂₄F₁₀P₂Pd: 886.02, *found* 886.90, IR $\tilde{\upsilon} = 411$, 422, 445, 498, 544, 602, 617, 668, 687, 741, 760, 774, 950, 1000, 1027, 1055, 1098, 1159, 1186, 1254, 1281, 1308, 1346, 1432, 1496, 1608, 1633, 3062 cm⁻¹.



 $Pd(C_6F_5)_2(cod)$ (43.8 mg, 0.080 mmol) and the diphosphine **105** (50.0 mg, 0.080 mmol) were stirred overnight in CH₂Cl₂ (2 ml). After removal of the solvent in vacuo, the remaining solid was washed with pentane and dried, affording the desired product 112c as a white solid (81.7 mg, 96%). ¹H NMR (CD₂Cl₂, 400 MHz): $\delta = 8.07 - 7.96$ (m, 1H), 7.84 - 7.82 (m, 1H), 7.76 -7.65 (m, 2H), 7.63 – 7.54 (m, 2H), 7.36 – 7.52 ppm (m, 8H). 13 C NMR (CD₂Cl₂, 100 MHz): δ = 147.6 (dm, J_{C-F} = 81.4 Hz), 147.3 (dm, J_{C-F} = 252.3 Hz), 144.9, 144.4 (dm, J_{C-F} = 258.2 Hz), 141.4 (dd, $J_{C-P} = 50.8$ Hz, $J_{C-P} = 44.5$ Hz), 138.5 (dm, $J_{C-F} = 243.4$ Hz), 138.1 (dm, J_{C-F} = 243.4 Hz), 138.1 (dm, J_{C = 216.5 Hz), 136.2 (J_{C-F} = 253.6 Hz), 134.7 (dd, J_{C-P} = 19.9 Hz, J_{C-P} = 1.1 Hz), 134.5 (dd, J_{C-P} $_{P} = 5.5 \text{ Hz}, J_{C-P} = 2.0 \text{ Hz}), 134.3 \text{ (dd, } J_{C-P} = 6.3 \text{ Hz}, J_{C-P} = 1.8 \text{ Hz}), 133.7 \text{ (d, } J_{C-P} = 12.5 \text{ Hz}),$ 133.3 (d, J_{C-P} = 15.7 Hz), 132.3 (d, J_{C-P} = 2.6 Hz), 129.8, 129.4 ppm (d, J_{C-P} = 11.1 Hz). ³¹P NMR (CD₂Cl₂, 121 MHz): $\delta = 51.0$ (m), 16.9 ppm (m). ¹⁹F NMR (CD₂Cl₂, 282 MHz): $\delta = -$ 115.0 (m), -118.1 (m), -127.1 (m), -145.7 (m), -159.0 (m), -160.7 (t, $J_{F-F} = 19.7$ Hz), -161.4 (t, J_{F-F} = 19.7 Hz), - 163.5 (td, J_{F-F} = 20.1 Hz, J_{F-P} = 9.4 Hz), - 164.0 ppm (td, J_{F-F} = 20.1 Hz, $J_{F-P} = 10.4$ Hz). HRMS calcd. for $C_{42}H_{14}F_{20}P_2PdNa^+$: 1088.917860, found 1088.917765. IR $\tilde{v} = 458, 483, 519, 536, 631, 670, 692, 745, 797, 954, 977, 1017, 1091,$ 1260, 1297, 1360, 1455, 1475, 1499, 1519, 1642, 2963 cm⁻¹.





ppm (t, J = 6.7 Hz, 4H). ¹³C NMR (CD₂Cl₂, 100 MHz): $\delta = 151.4$ (t, J = 3.1 Hz), 132.2, 130.6, 129.7, 125.6, 122.2, 26.1 ppm (dd, J = 42.1 Hz, J = 19.5 Hz). ³¹P NMR (CD₂Cl₂, 121 MHz): $\delta = 207.2$ ppm. HRMS *calcd*. for C₂₆H₂₀O₄P₂: 458.083314, *found* 458.083689. IR $\tilde{\upsilon} = 416, 429, 480, 516, 591, 669, 703, 762, 883, 939, 978, 1036, 1060, 1094, 1202, 1245, 1268, 1400, 1435, 1474, 1496, 1595, 1713, 2404, 2943, 3023, 3070, 3185 cm⁻¹.$

Pd(C₆F₅)₂(cod) (53.8 mg, 0.098 mmol) and bis(1,2–biphenylphosphino)ethane (45.0 mg, 0.098 mmol) were dissolved in CH₂Cl₂ (2 ml) and stirred overnight. After removal of the solvent *in vacuo*, the solid left was washed with pentane and dried, affording **112d** as a white solid (82.1 mg, 93%). ¹H NMR (CD₂Cl₂, 400 MHz): δ = 7.48 – 7.45 (m, 4H), 7.36 – 7.34 (m, 8H), 7.15 – 7.13 (m, 4H), 2.41 ppm (d, *J* = 23.0 Hz, 4H). ¹³C NMR (CD₂Cl₂, 100 MHz): δ = 148.23 (d, *J*_{*C*-*P*} = 11.3 Hz), 148.22, 146.1 (dm, *J* = 226.3 Hz), 137.4 (dm, *J*_{*C*-*F*} = 245.2 Hz), 136.1 (dm, *J*_{*C*-*F*} = 252 Hz), 130.5, 129.6, 129.2, 126.6, 121.0, 26.8 ppm (t, *J* = 23.2 Hz). ³¹P NMR (CD₂Cl₂, 121 MHz): δ = 202.2 ppm (m). ¹⁹F NMR (CD₂Cl₂, 282 MHz): δ = – 114.5 (m), – 161.9 (t, *J*_{*F*-*F*} = 19.9 Hz), – 163.1 (td, *J*_{*F*-*F*} = 19.9 Hz, *J*_{*F*-*P*} = 9.1 Hz) ppm. HRMS *calcd*. for C₃₈H₂₀O₄F₁₀P₂PdNa⁺: 920.960310, *found* 920.960340. IR \tilde{v} = 435, 493, 523, 536, 595, 654, 716, 755, 772, 823, 871, 912, 954, 1012, 1045, 1094, 1191, 1248, 1274, 1361, 1403, 1456, 1498, 1532, 1606, 1633, 2916, 3067 cm⁻¹.

Compound 112e



(Dipyrrolylphosphino)–2–diphenylphosphine (38.7 mg, 0.091 mmol) and Pd(C₆F₅)₂(cod) (50.0 mg, 0.091 mmol) were dissolved in CH₂Cl₂ (1 ml) and stirred overnight. Then, the solvent was evaporated *in vacuo* and washed with Et₂O to afford the desired compound **112e** as a white solid (73.3 mg, 93%). ¹H NMR (CD₂Cl₂, 500 MHz): $\delta = 7.50 - 7.91$ (m, 1H), 7.85 – 7.81 (m, 1H), 7.80 – 7.75 (m, 2H), 7.53 – 7.49 (m, 2H), 7.46 – 7.33 (m, 8H), 6.86 – 6.84 (m, 5H), 6.40 – 6.38 ppm (m, 4H). ¹³C NMR (CD₂Cl₂, 125 Mz): $\delta = 147.2$ (dm, $J_{C-F} = 68.6$ Hz), 145.3 (dm, $J_{C-F} = 72.8$ Hz), 141.8 (dd, $J_{C-P} = 49.6$, $J_{C-P} = 37.0$ Hz), 140.8 (dd, $J_{C-P} = 52.1$, $J_{C-P} = 43.2$ Hz), 138.1 (dm, $J_{C-F} = 241.6$ Hz), 136.8 (d, $J_{C-F} = 250.6$ Hz), 135.62 (d, $J_{C-P} = 6.0$ Hz), 134.23 (d, $J_{C-P} = 19.3$ Hz), 132.1 (dd, $J_{C-P} = 12.6$ Hz), 133.3 (dd, $J_{C-P} = 5.9$ Hz, $J_{C-P} = 1.6$ Hz), 132.2 (d, $J_{C-P} = 2.5$ Hz), 132.1 (dd, $J_{C-P} = 15.8$, $J_{C-P} = 2.4$ Hz), 129.4 (d, $J_{C-P} = 10.9$ Hz), 128.9 (d, $J_{C-P} = 49.7$ Hz), 124.1 (d, $J_{C-P} = 8.2$ Hz), 114.8 ppm (d, $J_{C-P} = Hz$). ³¹P NMR

(CD₂Cl₂, 162 MHz): $\delta = 109.1$ (br), 47.9 ppm (br). ¹⁹F NMR (CD₂Cl₂, 282 MHz): - 115.02 (m), - 161.59 (m), - 163.57 (dm, $J_{F-P} = 139.0$ Hz). HRMS *calcd*. for C₃₈H₂₂N₂F₁₀P₂PdNa⁺: 887.002710, *found* 887.002477. IR $\tilde{v} = 421$, 450, 478, 511, 537, 566, 608, 627, 672, 702, 725, 776, 953, 1001, 1055, 1100, 1115, 1237, 1350, 1360, 1436, 1498, 1531, 3060 cm⁻¹.

Compound 112f



2-Diphenylphosphino-2'-(N,N-dimethylamino)biphenyl (30.0 mg, 0.055 mmol) and $Pd(C_6F_5)_2(cod)$ (20.8 mg, 0.055 mmol) were stirred in CH_2Cl_2 (2 ml) for 2 d. Then the solvent was evaporated in vacuo and washed with Et₂O to afford compound 112f as a pale yellow solid (41.4 mg, 92%). Yellow crystals suitable for X- ray analysis were obtained from saturated CH₂Cl₂/pentane solution. ¹H NMR (CD₂Cl₂, 300 MHz): $\delta = 8.05 - 7.99$ (m, 2H), 7.70 - 7.65 (m, 1H), 7.55 - 7.46 (m, 4H), 7.42 - 7.32 (m, 2H), 7.23 - 7.16 (m, 3H), 6.98 -6.75 (m, 5H), 6.59 – 6.56 (m, 1H), 3.04 ppm (s, 6H). ¹³C NMR (CD₂Cl₂, 125 Mz): δ = 155.33 (m), 150.5 (d, $J_{C-P} = 22.0$ Hz), 147.2 (m), 145.8 (m), 144.6 (m), 138.2 (m), 135.5 (d, $J_{C-P} = 22.0$ Hz) 13.3 Hz), 133.7, 132.5 (m), 131.9, 131.6, 131.4 (d, $J_{C-P} = 11.4$ Hz), 130.5, 129.4 (d, $J_{C-P} = 11.4$ Hz) 10.6 Hz), 128.4 (d, $J_{C-P} = 10.2$ Hz), 128.2 (d, $J_{C-P} = 5.6$ Hz), 122.4 (br), 116.6 (br), 47.3 ppm (m). ³¹P NMR (CD₂Cl₂, 162 MHz): $\delta = 23.2$ ppm (m). ¹⁹F NMR (CD₂Cl₂, 282 MHz): $\delta = -$ 112.92 (m), -114.28 (m), -115.26 (m), -117.93 (m), -162.35 (t, $J_{F-F} = 19.8$ Hz), -162.95 $(t, J_{F-F} = 19.8 \text{ Hz}), -163.64 \text{ (m)}, -163.88, -164.43 \text{ (m)}, -164.94 \text{ ppm (m)}.$ HRMS calcd. for $C_{38}H_{24}NF_{10}PPdNa^+$: 844.041910, found 884.041289. IR $\tilde{\upsilon} = 433, 450, 494, 538, 692, 760,$ 788, 852, 949, 1041, 1058, 1099, 1213, 1274, 1344, 1362, 1435, 1493, 1577, 2965, 3067 cm⁻ 1

Compound 112g



 $Pd(C_6F_5)_2(cod)$ (100.0 mg, 0.182 mmol) and **92a** (120.3 mg, 0.182 mmol) were dissolved in CH_2Cl_2 (4 ml) and stirred overnight. After removal of the solvent *in vacuo*, the remaining solid was washed with CH_2Cl_2 and pentane, and dried, affording **112g** as a white solid (168.8

mg, 84%). Colorless crystals suitable for X–ray crystallography were obtained from saturated CH₃CN/CH₂Cl₂/Et₂O solutions of the title compound. ¹H NMR (CD₃CN, 400 MHz): $\delta = 8.25 - 8.20$ (m, 1H), 8.16 – 8.11(m, 1H), 8.10 – 8.05 (m, 2H), 7.68 – 7.65 (m, 2H), 7.53 – 7.50 (m, 8H), 4.14 – 4.10 (m, 8H), 3.03 ppm (s, 12H). ¹³C NMR (CD₃CN, 125 MHz): $\delta = 157.2$ (dd, $J_{C-P} = 26.2$ Hz, $J_{C-P} = 1.1$ Hz), 147.6 (dm, $J_{C-F} = 194.2$ Hz), 146.0 (dm, $J_{C-F} = 191.3$ Hz), 144.2 (dd, $J_{C-P} = 52.0$ Hz, $J_{C-P} = 44.5$ Hz), 140.6 (br), 138.8 (dd, $J_{C-P} = 5.6$ Hz, $J_{C-P} = 2.3$ Hz), 138.3 (d, $J_{C-P} = 20.2$ Hz), 137.8 (dm, $J_{C-F} = 256.1$ Hz), 137.5 (d, $J_{C-P} = 13.4$ Hz), 137.2 (dd, $J_{C-P} = 7.2$ Hz, $J_{C-P} = 1.7$ Hz), 134.4 (d, $J_{C-P} = 12.5$ Hz), 134.1 (d, $J_{C-P} = 2.8$ Hz), 130.6 (d, $J_{C-P} = 1.4$ Hz), 127.9 (d, $J_{C-P} = 53.4$ Hz), 126.3 (dd, $J_{C-P} = 50.3$ Hz, $J_{C-P} = 33.7$ Hz), 54.3 (d, $J_{C-P} = 2.1$ Hz), 38.3 ppm (d, $J_{C-P} = 3.4$ Hz). ³¹P NMR (CD₃CN, 121 MHz): $\delta = 49.0$ (m), 11.9 ppm (m). ¹¹B NMR (CD₃CN, 96 MHz): $\delta = -1.1$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -116.8$ (m), -117.6 (m), -157.9 (t, $J_{F-F} = 19.7$ Hz), -159.9 (t, $J_{F-F} = 19.2$ Hz), -161.8 (dt, $J_{F-F} = 8.7$ Hz), -163.6 ppm (dt, $J_{F-F} = 20.3$, $J_{F-P} = 8.3$ Hz). HRMS *calcd*. for C₄₀H₃₄N₄BF₁₄P₂Pd⁺: 1015.119220, *found* 1015.115674. IR $\tilde{v} = 465$, 499, 518, 536, 643, 691, 735, 775, 1300, 1363, 1440, 1458, 1501, 1589, 1600 cm⁻¹.

Compound 112h



Pd(C₆F₅)₂(cod) (50.0 mg, 0.065 mmol) and **101a** (35.8 mg, 0.065 mmol) were dissolved in CH₃COCH₃ (3 ml) and stirred for 48 h. After removal of the solvent *in vacuo*, the solid left was washed with CH₂Cl₂ and pentane, and dried, to afford **112h** as a light yellow solid (57.5 mg, 73%). ¹H NMR (CD₃COCD₃, 400 MHz): $\delta = 8.08 - 8.04$ (m, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.93 - 7.78 (m, 3H), 7.71 - 7.62 (m, 2H), 7.56 - 7.44 (m, 3H), 7.43 - 4.40 (m, 1H), 7.36 - 7.29 (m, 3H), 7.20 - 7.12 (m, 2H), 4.49 - 4.31 (m, 4H), 3.84 - 3.74 (m, 8H), 3.59 - 3.54 (m, 2H), 3.25 (s, 3H), 3.23 (s, 3H), 1.89 (s, 3H), 1.50 ppm (s, 3H). ¹³C NMR (CD₃COCD₃, 100 MHz): $\delta = 158.3$ (dd, $J_{C-P} = 24.4$ Hz, $J_{C-P} = 3.6$ Hz), 156.6 (d, $J_{C-P} = 14.3$ Hz), 144.3 (d, $J_{C-P} = 8.3$ Hz), 144.0 (d, $J_{C-P} = 10.8$ Hz), 142.3 (dd, $J_{C-P} = 23.3$ Hz, d, $J_{C-P} = 3.0$ Hz), 138.1 (d, $J_{C-P} = 2.0$ Hz), 137.7(dd, $J_{C-P} = 13.5$ Hz, $J_{C-P} = 5.5$ Hz), 136.8 (dd, $J_{C-P} = 12.5$ Hz, $J_{C-P} = 2.8$ Hz), 136.4 (d, $J_{C-P} = 7.3$ Hz), 131.9 (d, $J_{C-P} = 2.5$ Hz), 131.6 (d, $J_{C-P} = 41.8$ Hz), 131.3 (d, $J_{C-P} = 8.7$ Hz), 130.5 (d, $J_{C-P} = 8.6$ Hz), 130.4 (d, $J_{C-P} = 11.3$ Hz), 129.2 (d, $J_{C-P} = 5.5$ Hz), 130.4 (d, $J_{C-P} = 5.5$ Hz), 129.2 (d, $J_{C-P} = 5.5$ Hz), 130.4 (d, $J_{C-P} = 5.5$ Hz), 129.2 (d, $J_{C-P} = 5.5$ Hz), 120.4 Hz), 129.2 (d, $J_{C-P} = 5.5$ Hz), 120.5 Hz), 129.2 (d, $J_{C-P} = 5.5$ Hz), 120.4 (d, $J_{C-P} = 5.5$ Hz), 120.2 (d, $J_{C-P} = 5.5$ Hz), 120.4 (d, $J_{C-P} = 5.5$ Hz), 120.2 (d, $J_{C-P} = 5.5$ Hz), 120.4 (d, $J_{C-P} = 5.5$ Hz), 120.2 (d, $J_{C-P} = 5.5$ Hz), 120.4 (d, $J_{C-P} = 5.5$ Hz), 120.4 (d, $J_{C-P} = 5.5$ Hz), 120.2 (d, J_{C

10.7 Hz), 128.6 (t, $J_{C-P} = 24.6$ Hz), 126.5 (dd, $J_{C-P} = 51.8$ Hz, $J_{C-P} = 1.8$ Hz), 125.3 (d, $J_{C-P} = 48.6$ Hz), 56.1 (d, $J_{C-P} = 1.5$ Hz), 54.1 (d, $J_{C-P} = 2.2$ Hz), 53.6 (d, $J_{C-P} = 2.2$ Hz), 53.4, 42.5 (dd, $J_{C-P} = 6.2$ Hz, $J_{C-P} = 5.1$ Hz), 39.7 (t, $J_{C-P} = 9.4$ Hz), 37.6, 37.3 (d, $J_{C-P} = 6.3$ Hz), 20.9 (d, $J_{C-P} = 2.5$ Hz), 19.9 ppm (d, $J_{C-P} = 1.6$ Hz). ³¹P NMR (CD₃COCD₃, 121 MHz): $\delta = 15.3$ (m), 12.6 ppm (m). ¹¹B NMR (CD₃COCD₃, 96 MHz): $\delta = -1.0$ ppm. ¹⁹F NMR (CD₃COCD₃, 282 MHz): $\delta = -110.8$ (m), -111.0 (m), -113.7 (m), -114.2 (m), -156.7 (t, $J_{F-F} = 19.9$ Hz), -160.7 (m), -161.6 (t, $J_{F-F} = 19.9$ Hz), -163.4 (m), -163.9 ppm (m). HRMS *calcd*. for C₄₈H₄₂N₄BF₁₄P₂Pd⁺: 1119.178050, *found* 1119.178274. IR $\tilde{\upsilon} = 420$, 458, 468, 501, 521, 544, 696, 747, 766, 783, 924, 956, 1056, 1298, 1442, 1504, 1580 cm⁻¹.

Compound 113



Compound **92b** (20.0 mg, 0.021 mmol) and Pd(dba)₂ (12.0 mg, 0.021 mmol) in CH₂Cl₂ (2 ml) were stirred at r.t. for 2 h and then the solvent was evaporated in vacuo. The resulting solid was extracted with CH₃CN and recrystallized from CH₃CN, CH₂Cl₂ and Et₂O to afford the desired compound 113 as a yellow solid (4.9 mg, 21%). The colorless crystals suitable for Xray analysis were obtained from CH₃CN/CH₂Cl₂/Et₂O. ¹H NMR (CD₃CN, 600 MHz): $\delta =$ 7.69 - 7.55 (m, 13H), 7.55 - 7.50 (m, 1H), 3.90 - 3.84 (m, 2H), 3.83 - 3.76 (m, 2H), 3.75 -3.66 (m, 4H), 3.35 (s, 3H), 3.04 (s, 3H), 2.94 ppm (s, 6H). ¹³C NMR (CD₃CN, 125 Mz): $\delta =$ 196.5 (dd, $J_{C-P} = 126.7$ Hz, $J_{C-P} = 16.4$ Hz), 176.6 (dd, $J_{C-P} = 80.7$ Hz, $J_{C-P} = 1.7$ Hz), 146.2 (dd, $J_{C-P} = 40.9$ Hz, $J_{C-P} = 20.9$ Hz), 135.4 (dd, $J_{C-P} = 56.0$ Hz, $J_{C-P} = 15.8$ Hz), 135.1 (d, $J_{C-P} = 15.8$ Hz), 135.1 (d, J_{C-P} = 15.8 Hz), = 2.4 Hz), 134.6 (dd, J_{C-P} = 4.4 Hz, J_{C-P} = 1.8 Hz), 134.21, 134.20 (d, J_{C-P} = 9.3 Hz), 134.1 (d, $J_{C-P} = 11.3$ Hz), 134.0 (d, $J_{C-P} = 21.8$ Hz), 133.4 (d, $J_{C-P} = 2.6$ Hz), 130.8 (dd, $J_{C-P} = 11.0$ Hz, $J_{C-P} = 2.4$ Hz), 130.7 (d, $J_{C-P} = 1.7$ Hz), 130.4 (d, $J_{C-P} = 47.5$ Hz), 129.7 (d, $J_{C-P} = 96.8$ Hz), 128.6 (d, J_{C-P} = 48.2 Hz), 52.8 (d, J_{C-P} = 5.2 Hz), 52.5 (d, J_{C-P} = 4.6 Hz), 52.4 (d, J_{C-P} = 1.0 Hz), 37.7, 37.6, 37.4, 37.3, 37.2 ppm (m). ³¹P NMR (CD₃CN, 162 MHz): $\delta = 49.4$, 15.9 ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -124.0$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1933$ Hz, octet, $J_{$ $_{Sb(I=7/2)} = 1049$ Hz). HRMS calcd. for C₂₈H₃₄N₄F₆P₂SbPd⁺: 829.022380, found 829.022889. IR $\tilde{\upsilon} = 426, 495, 507, 534, 591, 652, 699, 752, 774, 920, 940, 1103, 1203, 1291, 1333, 1407,$ 1438, 1546, 1567, 2301, 2929 cm⁻¹.



Compound **92b** (50.0 mg, 0.052 mmol) and Ni(cod)₂ (14.3 mg, 0.052 mmol) were stirred overnight in CH₂Cl₂ (2 ml). A yellow precipitate was separated from the solution. 2,6dimethylphenyl isocyanide (16.7 mg, 0.128 mmol) was added in CH₂Cl₂ (2 ml) and the mixture stirred overnight. After evaporation of the solvent, the solid was washed with Et₂O and recrystallized from CH₂Cl₂/Et₂O to afford the desired compound 114 as a yellow solid (22.1 mg, 37%). The yellow crystal suitable for X- ray analysis was obtained from a saturated solution of the title compound in CH₂Cl₂/Et₂O. ¹H NMR (CD₂Cl₂, 600 MHz): $\delta = 7.74 - 7.48$ (m, 13H), 7.37 (t, J = 8.2 Hz, 1H), 7.32 (t, J = 7.7 Hz, 1H), 7.14 (d, J = 7.7 Hz, 2H), 3.98 (s, J = 4H), 3.88 - 3.71 (m, 4H), 3.33 (s, 6H), 3.01 (s, 6H), 1.98 (s, 6H). 13 C NMR (CD₂Cl₂, 125) Mz): $\delta = 199.2$ (dd, $J_{C-P} = 71.0$ Hz, $J_{C-P} = 22.3$ Hz), 176.7 (dd, $J_{C-P} = 76.9$ Hz, $J_{C-P} = 3.7$ Hz), 146.2 (m), 144.7 (dd, $J_{C-P} = 39.7$ Hz, $J_{C-P} = 15.4$ Hz), 136.2, 135.4 (dd, $J_{C-P} = 59.0$ Hz, $J_{C-P} = 20.0$ Hz), 135.0, 134.1, 133.5, 133.3, 133.2, 132.8 (dd, $J_{C-P} = 35.4$ Hz, $J_{C-P} = 17.5$ Hz), 131.7, 130.7 (d, $J_{C-P} = 11.4$ Hz), 130.4 (d, $J_{C-P} = 8.3$ Hz), 129.0, 125.6, 52.7, 51.7, 37.43, 37.41, 37.34, 37.28, 18.3 ppm (m). ³¹P NMR (CD₂Cl₂, 162 MHz): $\delta = 56.9$ (d, $J_{P-P} = 4.3$ Hz), 23.7 ppm (d, $J_{P-P} = 4.3$ Hz). ¹⁹F NMR (CD₂Cl₂, 282 MHz): $\delta = -124.0$ ppm (sextet, J_{F-} $_{Sb(I=5/2)}$ = 1933 Hz, octet, $J_{F-Sb(I=7/2)}$ = 1049 Hz). HRMS calcd. for C₃₇H₄₃N₅F₆P₂Sb⁺: 912.128170, found 912.128332. IR $\tilde{v} = 442, 487, 515, 530, 651, 693, 713, 752, 773, 791, 939,$ 957, 1097, 1205, 1287, 1438, 1536, 1566, 2164 cm⁻¹.





Indole (25.8 mg, 0.220 mmol) and phenyl 1,3–butadiene (26.0 mg, 0.200 mmol) were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 20:1) to afford the desired compound **118** as a colorless oil (41.0 mg, 86% yield). ¹H NMR (CDCl₃, 400 MHz): δ = 7.95 (br, 1H), 7.69 (dd, J = 7.9 Hz, J = 0.6 Hz, 1H), 7.40 – 7.35 (m, 3H), 7.31 – 7.27 (m, 2H), 7.23 – 7.17 (m, 2H), 7.10 (ddd, J = 7.9 Hz, J = 7.8 Hz, J = 0.6 Hz, 1H), 7.03 (dd, J = 2.3 Hz, J = 0.6 Hz, 1H), 6.51 – 6.48 (m, 2H), 3.95 (p, J = 6.8 Hz, 1H), 1.58 ppm (d, J = 7.0 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): $\delta = 137.9$, 136.7, 135.6, 128.6, 128.3, 127.0, 126.9, 126.3, 122.1, 120.6, 120.5, 119.8, 119.4, 111.2, 34.4, 20.8 ppm. HRMS *calcd.* for C₁₈H₁₈N⁺: 248.143420, *found* 248.143374. IR $\tilde{v} = 424$, 497, 581, 693, 742, 765, 807, 928, 966, 1009, 1095, 1221, 1244, 1337, 1417, 1455, 1492, 1598, 1618, 2869, 2927, 2963, 3024, 3055, 3417 cm⁻¹.

Compound 119



5–Bromoindole (43.1 mg, 0.220 mmol) and phenyl 1,3–butadiene^[165] (26.0 mg, 0.200 mmol) were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 20:1) to afford the desired compound **119** as a light yellow oil (53.5 mg, 82% yield). ¹H NMR (CDCl₃, 400 MHz): δ = 8.00 (br, 1H), 7.78 (m, 1H), 7.40 – 7.35 (m, 2H), 7.31 – 7.28 (m, 2H), 7.27 – 7.25 (m, 2H), 7.23 – 7.17 (m, 2H), 7.03 (d, *J* = 2.0 Hz, 1H), 6.51 – 6.39 (m, 1H), 3.88 (p, *J* = 6.7 Hz, 1H), 1.55 ppm (d, *J* = 7.0 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ = 137.7, 135.3, 135.0, 128.7, 128.6, 128.6, 127.1, 126.3, 125.0, 122.3, 121.8, 120.4, 112.7, 34.2, 20.9 ppm. HRMS *calcd.* for C₁₈H₁₅NBr⁺: 324.039610, *found* 324.039349. IR $\tilde{\upsilon}$ = 421, 488, 583, 696, 749, 795, 865, 996, 1045, 1096, 1260, 1373, 1458, 1493, 1599, 1721, 2927, 2962, 3025, 3421 cm⁻¹.



1–Methyl–2–phenylindole (45.6 mg, 0.220 mmol) and diene (26.0 mg, 0.200 mmol) were added to a solution of **92b** (9.6 mg, 0.010 mmol), $[RhCl(CO)_2]_2$ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for

18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 20:1) to afford the desired compound **120** as a colorless oil (39.1 mg, 57% yield). ¹H NMR (CDCl₃, 400 MHz): $\delta = 7.76$ (dm, J = 8.0 Hz, 1H), 7.53 – 7.45 (m, 3H), 7.44 – 7.40 (m, 2H), 7.37 (dm, J = 8.0 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.28 (m, 3H), 7.17 (tm, J = 7.1 Hz, 1H), 7.11 (tm, J = 7.4 Hz, 1H), 6.62 (dd, J = 15.9 Hz, J = 5.8 Hz, 1H), 6.39 (dd, J = 15.9 Hz, J = 1.5 Hz, 1H), 3.80 (m, 1H), 3.58 (s, 3H), 1.56 ppm (d, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): $\delta = 138.1$, 137.5, 135.7, 132.3, 131.0, 128.6, 128.5, 128.4, 128.3, 128.0, 126.9, 126.4, 126.2, 121.6, 120.7, 119.2, 116.3, 116.2, 109.6, 34.4, 30.9, 21.1 ppm. HRMS *calcd*. for C₂₅H₂₃NNa⁺: 360.172400, *found* 360.172268. IR $\tilde{v} = 435$, 486, 520, 592, 582, 601, 722, 735, 805, 921, 964, 1017, 1098, 1135, 1157, 1247, 1264, 1335, 1362, 1397, 1429, 1466, 1492, 1600, 2926, 2963, 3025 cm⁻¹.

Compound 121



5–Methylindol (28.9 mg, 0.220 mmol) and phenyl 1,3–butadiene (26.0 mg, 0.200 mmol) were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 100:1 to 20:1) to afford the desired compound **121** as a light yellow oil (41.2 mg, 76% yield). ¹H NMR (CDCl₃, 400 MHz): δ = 7.86 (br, 1H), 7.45 (m, 1H), 7.38 – 7.35 (m, 2H), 7.30 – 7.25 (m, 3H), 7.19 (tm, *J* = 8.4 Hz, 1H), 7.2 (dd, *J* = 8.3 Hz, *J* = 1.2 Hz, 1H), 7.00 (d, *J* = 2.3 Hz, 1H), 6.49 – 6.43 (m, 2H), 3.95 – 3.88 (m, 1H), 2.44 (s, 3H), 1.56 ppm (d, *J* = 7.0 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ = 138.0, 135.7, 135.0, 128.6, 128.2, 127.1, 127.0, 126.3, 126.9, 123.7, 120.7, 120.1, 119.3, 110.9, 34.3, 21.7, 20.9 ppm. HRMS *calcd*. for C₁₉H₁₉NNa⁺: 284.141150, *found* 284.140968. IR \tilde{v} = 423, 460, 493, 589, 696, 748, 793, 698, 920, 996, 1012, 1029, 1073, 1096, 1182, 1224, 1320, 1369, 1419, 1448, 1493, 1580, 1598, 2867, 2925, 2962, 3023, 3414 cm⁻¹.



1–Methylindol (28.8 mg, 0.220 mmol) and phenyl 1,3–butadiene (26.0 mg, 0.200 mmol) were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 20:1) to afford the desired compound **122** as colorless oil (32.1 mg, 63% yield). ¹H NMR (CDCl₃, 400 MHz): δ = 7.67 (dm, *J* = 7.9 Hz, 1H), 7.38 – 7.25 (m, 2H), 7.31 – 7.27 (m, 2H), 7.24 – 7.21 (m, 1H), 7.21 – 7.16 (m, 1H), 7.01 – 7.06 (m, 1H), 6.88 (s, 1H), 6.54 – 6.43 (m, 2H), 3.93 (p, *J* = 6.8 Hz, 1H), 3.76 (s, 3H), 1.56 ppm (d, *J* = 7.0 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ = 137.9, 137.4, 135.7, 128.6, 128.1, 127.3, 127.0, 126.3, 125.4, 121.7, 119.8, 119.0, 118.8, 109.3, 34.3, 32.8, 21.0 ppm. HRMS *calcd.* for C₁₉H₁₉NNa⁺: 284.141100, *found* 284.140968. IR \tilde{v} = 424, 497, 581, 698, 746, 968, 992, 1093, 1242, 1373, 1470, 1493, 1528, 1613, 1712, 1778, 2930, 2961, 3026, 3055 cm⁻¹.

Compound 123



5–Fluoroindole (29.7 mg, 0.220 mmol) and phenyl 1,3–butadiene (26.0 mg, 0.200 mmol) were added to a solution of **122b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 100:1 to 20:1) to afford the desired compound **123** as light yellow oil (34.4 mg, 65% yield). ¹H NMR (CDCl₃, 400 MHz): $\delta = 8.00$ (br, 1H), 7.36 – 7.33 (m, 2H), 7.28 – 7.25 (m, 2H), 7.18 – 7.17 (m, 1H), 7.14 – 7.11 (m, 1H), 7.09 – 7.05 (m, 1H), 6.96 – 6.95 (m, 1H), 6.76 – 71 (m, 1H), 6.54 – 6.42 (m, 2H), 4.08 (p, *J* = 6.8 Hz, 1H), 1.53 ppm (d, *J* = 6.9 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): $\delta = 152.3$ (d, *J* = 247.0 Hz), 139.4 (d, *J* = 11.9), 138.1, 135.6 (d, *J* = 0.8), 128.6, 128.4 (d, *J* = 7.6), 128.2 (d, *J* = 1.0), 127.0, 126.3, 125.8 (d, *J* = 35.1), 122.7 (d, *J* = 8.0), 120.5 (d, *J* = 1.3), 120.3 (d, *J* = 3.9 Hz), 115.7 (d, *J* = 20.2), 115.7 (d, *J* = 20.2),

107.3 (d, J = 3.6), 104.9 (d, J = 20.2), 34.8 (d, J = 1.4), 21.5 ppm (d, J = 1.9). ¹⁹F NMR (CDCl₃, 282 MHz): $\delta = -120.8$ ppm. HRMS *calcd*. for C₁₈H₁₅NF⁺: 264.119600, *found* 264.119402. IR $\tilde{v} = 483$, 649, 696, 732, 780, 908, 996, 1035, 1224, 1348, 1446, 1494, 1578, 1628, 1628, 1694, 2962, 3025, 3416 cm⁻¹.

Compound 124



1,3–Dimethoxybenzene (30.4 mg, 0.220 mmol) and phenyl 1,3–butadiene (26.0 mg, 0.200 mmol) were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 20:1) to afford the desired compound **124** as colorless oil (33.6 mg, 63% yield). ¹H NMR (CDCl₃, 400 MHz): δ = 7.37 – 7.34 (m, 2H), 7.30 – 7.27 (m, 2H), 7.20 – 7.15 (m, 1H), 7.10 (d, *J* = 8.2 Hz, 1H), 6.47 – 6.40 (m, 4H), 4.00 – 3.97 (m, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 1.39 ppm (d, *J* = 7.0 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ = 159.3, 157.9, 138.1, 135.4, 128.6, 128.1, 128.0, 126.9, 126.7, 126.2, 104.3, 98.9, 55.6, 55.5, 34.8, 20.3 ppm. HRMS *calcd*. for C₁₈H₂₁O₂⁺: 269.153580, *found* 269.135605. IR \tilde{v} = 495, 634, 692, 737, 798, 909, 966, 1034, 1117, 1156, 1179, 1206, 1259, 1290, 1417, 1453, 1503, 1586, 1610, 2835, 2928, 2959, 3024 cm⁻¹.

Compound 125



1–Methyl–2–phenylindole (45.6 mg, 0.220 mmol) and 1–phenyl–1,3–pentadiene (E/Z = 1:1, 26.0 mg, 0.200 mmol)^[165] were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 100:1 to 20:1) to afford the desired compound **125** as colorless yellow oil (23.1 mg, 33% yield). ¹H NMR (CDCl₃, 400 MHz): δ = 7.72 (d, *J* = 8.0 Hz, 1H), 7.49 – 7.38 (m, 3H), 7.38 – 7.30 (m, 3H), 7.28 – 7.25 (m, 2H), 7.24 – 7.19 (m,

3H), 7.15 – 7.04 (m, 2H), 6.58 (dd, J = 15.8, J = 7.0 Hz, 1H), 6.30 (d, J = 15.8 Hz, 1H), 3.52 (s, 3H), 3.43 (q, J = 8.1, 7.6 Hz, 1H), 1.92 (qt, J = 13.7, J = 7.1 Hz, 2H), 0.75 ppm (t, J = 7.4 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): $\delta = 138.45$, 138.12, 134.56, 132.45, 131.11, 128.75, 128.49, 128.43, 128.27, 126.84, 126.37, 126.22, 121.54, 120.68, 119.07, 114.70, 109.59, 42.66, 30.92, 28.17, 12.83. HRMS *calcd*. for C₂₆H₂₅NNa⁺: 374.187880, *found* 374.187918. IR $\tilde{v} = 701$, 741, 808, 908, 964, 1019, 1072, 1134, 1157, 1246, 1334, 1365, 1397, 1429, 1446, 1467, 1601, 2869, 2928, 2959, 3025, 3056 cm⁻¹.

Compound 126



1,3–Dimethoxybenzene (30.4 mg, 0.220 mmol) and 1–phenyl–1,3–pentadiene (E/Z = 1:1, 28.8 mg, 0.200 mmol)^[165] were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 20:1) to afford the desired compound **126** as colorless oil (24.3 mg, 43% yield). ¹H NMR (CDCl₃, 400 MHz): δ = 7.28 – 7.25 (m, 2H), 7.21 – 7.17 (m, 2H), 7.11 – 7.07 (m, 1H), 7.03 – 7.01 (m, 1H), 6.41 – 6.38 (m, 2H), 6.29 – 6.28 (m, 2H), 3.74 (s, 3H), 3.73 (s, 3H), 3.63 (p, *J* = 6.4 Hz, 1H), 1.70 (m, 2H), 0.82 ppm (t, *J* = 7.4, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ = 159.1, 158.2, 138.1, 134.3, 129.1, 128.5, 128.3, 126.9, 126.2, 125.5, 104.3, 98.8, 55.6, 55.5, 43.0, 28.1, 12.4 ppm. HRMS *calcd*. for C₁₉H₂₃O₂⁺: 283.169380, *found* 283.169255. IR \tilde{v} = 634, 694, 747, 797, 834, 936, 966, 1037, 1133, 1157, 1179, 1207, 1259, 1289, 1438, 1463, 1504, 1586, 1610, 2834, 2871, 2931, 2959, 2998, 3024 cm⁻¹.





Indole (25.8 mg, 0.220 mmol) and 1–(*p*–methoxyphenyl)–1,3–butadiene (E/Z = 2.1:1, 32.0 mg, 0.200 mmol)^[165] were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture

was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 20:1) to afford the desired compound **127** as colorless yellow oil (19.4 mg, 35% yield). ¹H NMR (CD₂Cl₂, 400 MHz): $\delta = 8.10$ (s, 1H), 7.66 (dd, J = 7.9, 1.0 Hz, 1H), 7.37 (dt, J = 8.2, 1.0 Hz, 1H), 7.32 – 7.27 (m, 2H), 7.16 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.10 – 7.04 (m, 2H), 6.85 – 6.79 (m, 2H), 6.51 – 6.41 (m, 1H), 6.32 (dd, J = 15.8, 7.0 Hz, 1H), 3.91 (tt, J = 7.1, 1.1 Hz, 1H), 3.78 (s, 3H), 1.55 ppm (d, J = 7.0 Hz, 3H). ¹³C NMR (CD₂Cl₂, 100 MHz): $\delta = 159.17$, 136.98, 133.75, 130.89, 129.60, 127.77, 127.49, 122.19, 120.84, 120.82, 119.83, 119.43, 114.19, 111.47, 55.59, 34.67, 20.98 ppm. HRMS *calcd.* for C₁₉H₁₉NONa⁺: 300.135910, *found* 300.135883, IR $\tilde{v} = 424$, 488, 743, 815, 850, 967, 1010, 1032, 1096, 1175, 1246, 1298, 1337, 1418, 1456, 4510, 1606, 2838, 2930, 2960, 3415 cm⁻¹.

Compound 128



1,3–Dimethoxybenzene (30.4 mg, 0.220 mmol) and 1–(*p*–trifluoromethylphenyl)–1,3– butadiene (E/Z = 1.8:1, 39.6 mg, 0.200 mmol)^[166] were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 100:1 to 20:1) to afford the desired compound **128** as a colorless yellow oil (14.1 mg, 21% yield). ¹H NMR (CDCl₃, 400 MHz): δ = 7.52 (d, *J* = 8.2 Hz, 2H), 7.43 (d, *J* = 8.1 Hz, 2H), 7.13 – 7.04 (m, 1H), 6.56 – 6.44 (m, 3H), 6.44 – 6.35 (m, 1H), 4.01 (p, *J* = 6.3 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 1.40 ppm (d, *J* = 7.0 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ = 159.44, 157.85, 141.62 (d, *J_{C-F}* = 1.5 Hz), 138.28, 128.73 (q, *J_{C-F}* = 32.4 Hz), 127.93, 126.86, 126.32, 126.02, 125.81, 125.50 (q, *J_{C-F}* = 3.8 Hz), 104.33, 98.90, 55.60, 55.51, 34.98, 20.03 ppm. ¹⁹F NMR (CDCl₃, 376 MHz): δ = - 62.35 ppm. HRMS *calcd*. for C₁₉H₁₉O₂F₃Na⁺: 359.122850, *found* 359.122934. IR $\tilde{\nu}$ = 502, 596, 636, 798, 820, 864, 969, 1015, 1036, 1066, 1106, 1116, 1157, 1207, 1322, 1415, 1464, 1504, 1586, 1612, 2837, 2935, 2962 cm⁻¹.

Compound 129



1,3–Dimethoxybenzene (E/Z = 1:1, 30.4 mg, 0.220 mmol) and 4–(1*E or Z*)–1,3–butadien–1– yl–methyl ester^[165] (37.6 mg, 0.200 mmol) were added to a solution of **92b** (9.6 mg, 0.010 mmol), [RhCl(CO)₂]₂ (1.9 mg, 0.005 mmol) and KB(Ar^F)₄ (14.3 mg, 0.020) in DCE (1 ml), and the reaction mixture was stirred at 70 °C for 18 h. The resulting oil was purified by column chromatography (SiO₂, Hexane:EtOAc = 100:1 to 20:1) to afford the desired compound **129** as a colorless yellow oil (15.0 mg, 23% yield). ¹H NMR (CD₂Cl₂, 400 MHz): $\delta = 7.89 - 7.79$ (m, 2H), 7.37 – 7.29 (m, 2H), 7.00 (dt, *J* = 8.0, 0.6 Hz, 1H), 6.47 (dd, *J* = 16.0, 6.4 Hz, 1H), 6.41 – 6.29 (m, 3H), 3.95 – 3.86 (m, 1H), 3.78 (s, 3H), 3.74 (s, 3H), 3.69 (s, 3H), 1.30 ppm (d, *J* = 7.1 Hz, 3H). ¹³C NMR (CD₂Cl₂, 100 MHz): $\delta = 167.10$, 159.74, 158.13, 142.91, 138.69, 130.07, 128.77, 128.09, 127.39, 126.25, 126.14, 104.59, 98.89, 55.81, 55.66, 52.23, 35.37, 20.04 ppm. HRMS *calcd.* for C₂₀H₂₂O₄Na⁺: 349.141170, *found* 349.141029. IR $\tilde{v} = 699$, 768, 833, 871, 936, 970, 1016, 1157, 1178, 1207, 1276, 1414, 1435, 1455, 1504, 1586, 1607, 1644, 1717, 2836, 2954, 2996 cm⁻¹.

Compound 133a



To a solution of carbene **137** (1 g, 2.260 mmol) in THF (10 ml), Ph₂PCl (0.418 ml, 2.26 mmol) was added and the resulting mixture stirred at r.t. overnight. The initial pale yellow solution changed to a bright yellow suspension. Then the solution was filtered off and the remaining yellow solid washed with Et₂O and dried *in vacuo*. The yellow solid thus obtained was dissolved in CH₃CN, NaSbF₆ (1.020 g, 3.95 mmol) was added to that solution and the resulting suspension stirred overnight at r.t. Removal of the solvents and the extraction with CH₂Cl₂ afforded the desired product **138a** as a yellow solid, which can be further purified by recrystallization from CH₂Cl₂/Et₂O (1.03 g, 66%). ¹H NMR (400 MHz, CD₂Cl₂): δ = 7.59 – 7.51 (m, 3H) , 7.50 – 7.44 (m, 4H), 7.43 – 7.31 (m, 6H), 2.54 – 2.43 (m, 4H), 1.59 (s, 6H), 1.41 (s, 6H), 1.31 (d, *J* = 6.5 Hz, 6H), 0.90 ppm (d, *J* = 6.5 Hz, 6H). ¹³C NMR (100 MHz,

CD₂Cl₂): $\delta = 215.3$ (d, J = 58.5 Hz), 144.7 (d, J = 2.4 Hz), 136.2 (d, J = 23.5 Hz), 132.4, 132.8 (d, J = 4.9 Hz), 132.5 (d, J = 0.94 Hz), 130.4 (d, J = 9.4 Hz), 128.8 (d, J = 6.6 Hz), 127.2, 83.1 (d, J = 3.4 Hz), 56.5 (d, J = 4.6 Hz), 52.7, 30.2, 29.6 (d, J = 2.2 Hz), 29.1 (d, J =1.1 Hz), 26.1, 24.7 ppm (d, J = 5.9 Hz). ³¹P NMR (162 MHz, CD₂Cl₂): $\delta = 0.0$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -122.4$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1945$ Hz, octet, $J_{F-Sb(I=7/2)} = 1071$ Hz). HRMS *calcd*. for C₃₂H₄₁NP⁺: 470.296970, *found*: 470.297113. IR $\tilde{\upsilon} = 427$, 481, 499, 569, 651, 696, 752, 807, 931, 999, 1052, 1090, 1130, 1197, 1338, 1377, 1391, 1437, 1469, 1520, 1586, 2944, 2977 cm⁻¹.

Compound 138b



To a solution of carbene 137 (1 g, 2.26 mmol) in THF (10 ml), Cy₂PCl (0.5 ml, 2.26 mmol) was added and the resulting mixture stirred at r.t. overnight. The pale yellow solution changed to a bright yellow suspension. Then the solution was filtered off and the remaining yellow solid washed with diethyl ether and dried in vacuo. The yellow solid was dissolved in CH₃CN, NaSbF₆ (1.27 g, 4.92 mmol) was added to the solution and the resulting suspension stirred overnight at r.t. Removal of the solvents and extraction with CH₂Cl₂ afforded the desired product 138b as a yellow solid, which was purified yf by recrystallization from CH_2Cl_2/Et_2O (1.06 g, 65%). ¹H NMR (500 MHz, CD_2Cl_2) δ = 7.60 (t, J = 7.8 Hz, 1H), 7.41 (d, J = 7.8 Hz, 2H), 2.53 (hept, J = 6.5 Hz, 2H), 2.40 (s, 2H), 2.25 - 2.15 (m, 2H), 1.89 - 1.81 (s, 2H), 2.25 - 2.15 (m, 2H), 1.89 - 1.81 (m, 2H), 1.89 -(m, 8H), 1.80 (s, 6H), 1.76 - 1.69 (m, 2H), 1.56 - 1.47 (m, 5H), 1.46 (s, 6H), 1.37 (d, J = 6.5Hz, 6H), 1.29 (d, J = 6.6 Hz, 6H), 1.28 – 1.21 ppm (m, 5H). ¹³C NMR (126 MHz, CD₂Cl₂) δ = 214.5 (d, J = 70.7 Hz), 144.9 (d, J = 2.7 Hz), 132.1, 131.7 (d, J = 2.5 Hz), 126.5, 83.1 (d, J = 2.7 Hz), 57.5 (d, J = 4.0 Hz), 52.1, 35.8 (d, J = 19.0 Hz), 32.9 (d, J = 13.1 Hz), 29.7, 29.5 (d, J = 2.9 Hz), 27.7 (d, J = 11.5 Hz), 26.7 (d, J = 3.6 Hz), 25.9, 24.7 ppm. ³¹P NMR (122) MHz, CDCl₃) δ = 21.6 ppm. ¹⁹F NMR (CD₃CN, 282 MHz): δ = - 122.4 ppm (sextet, J_{F-} $_{Sb(I=5/2)} = 1945$ Hz, octet, $J_{F-Sb(I=7/2)} = 1071$ Hz). HRMS calcd. for C₃₂H₅₃NP⁺: 482.391013, found: 482.391350. IR $\tilde{v} = 420, 463, 567, 606, 654, 774, 808, 849, 996, 1051, 1130, 1201,$ 1337, 1389, 1459, 1518, 2866, 2935, 2971 cm⁻¹.



To a solution of carbene **137** (0.500 g, 1.132 mmol) in THF (5 ml), [(p-CF₃)Ph]₂PCl (403.9 mg, 1.132 mmol) was added and the resulting mixture stirred at r.t. overnight. The initial pale yellow solution changed to a bright yellow suspension. Then the solvent was removed in vacuo and the remaining yellow solid washed with pentane and dried in vacuo. The solid thus obtained was dissolved in CH_2Cl_2 (20 ml) and $NaSbF_6$ (732.6 g, 2.831 mmol) was added to a yellow suspension and stirred overnight at r.t. After that the solvent was filtered and the remaining solid was extracted with CH_2Cl_2 . Evaporation of the organic solvents in vacuo afforded a yellow solid, which was purified by recrystallization from CH₂Cl₂/Et₂O to afford the desired product **138c** (610.0 mg, 64%). ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): $\delta = 7.82 - 100$ 7.72 (m, 4H), 7.65 – 7.48 (m, 5H), 7.36 (d, J = 7.8 Hz, 2H), 2.53 (s, 2H), 2.48 (p, J = 6.5 Hz, 2H), 1.63 (s, 6H), 1.46 (d, J = 0.7 Hz, 6H), 1.34 (d, J = 6.5 Hz, 6H), 0.92 ppm (d, J = 6.6 Hz, 6H). ¹³C NMR (CD₂Cl₂, 100 MHz, 298 K): δ = 213.03 (d, J_{C-P} = 57.2 Hz), 144.69 (d, J_{C-P} = 2.3 Hz), 136.63 (d, J = 23.8 Hz), 134.40 (q, $J_{C-F} = 33.4$ Hz), 133.36 - 132.58 (m), 132.52 -132.11 (m), 128.48 – 126.53 (m), 123.69 (d, J_{C-F} = 272.9 Hz), 84.34 (d, J_{C-P} = 3.2 Hz), 56.79 (d, $J_{C-P} = 4.7$ Hz), 52.56, 30.22, 29.69 (d, $J_{C-P} = 1.9$ Hz), 29.21, 25.97, 24.86 ppm (d, $J_{C-P} = 1.9$ Hz) 5.7 Hz). ³¹P NMR (CD₂Cl₂, 121 MHz, 298K): $\delta = -4.29$ ppm. ¹⁹F NMR (CD₂Cl₂, 282 MHz, 298K): $\delta = -63.81$ ppm. HRMS *calcd*. for C₃₄H₃₉NF₆P⁺ 606.272470, *found*: 606.271884. IR $\tilde{\upsilon} = 413, 514, 602, 654, 695, 711, 807, 836, 954, 1014, 1059, 1110, 1127, 1170, 1262, 1320,$ 1396, 1461, 1607, 2966 cm⁻¹.

Compound 139a



(Me₂S)AuCl (42.0 mg, 0.140 mmol) was added to a solution of compound **138a** (100.2 mg, 0.140 mmol) in CH₂Cl₂ (2 ml) and the resulting suspension stirred for 1 hour at r.t. After evaporation of the solvent, the resulting solid was dissolved in CH₃CN and filtered. Removal of the solvent *in vacuo* afforded the desired product **139a** as a yellow solid, which could be

further purified by recrystallization from CH₂Cl₂/Et₂O (95.8 mg, 72%). ¹H NMR (300 MHz, CD₃CN): $\delta = 7.81 - 7.64$ (m, 11H) , 7.52 (d, J = 7.8 Hz, 2H), 1.66 (s, 6H), 2.64 – 2.49 (m, 4H), 1.35 (d, J = 6.6 Hz, 12H), 1.19 ppm (d, J = 6.6 Hz, 6H). ¹³C NMR (126 MHz, CD₃CN): $\delta = 202.3$ (d, J = 12.8 Hz), 145.4, 135.8 (d, J = 15.2 Hz), 135.4 (d, J = 2.8 Hz), 133.7, 131.4 (d, J = 12.7 Hz), 128.6, 124.4 (d, J = 60.0 Hz), 90.3 (d, J = 1.9 Hz), 59.5 (d, J = 2.2 Hz), 50.5 (d, J = 2.2 Hz), 30.4 (d, J = 7.4 Hz), 29.8, 27.4, 25.0 ppm. ³¹P NMR (122 MHz, CD₂Cl₂): $\delta = 29.5$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -122.4$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1945$ Hz, octet, $J_{F-Sb(I=7/2)} = 1071$ Hz). HRMS *calcd*. for C₃₂H₄₁AuClNP⁺: 702.232519, *found*: 702.232490. IR $\tilde{v} = 426$, 452, 504, 537, 562, 609, 648, 657, 692, 744, 800, 999, 1052, 1091, 1191, 1342, 1378, 1392, 1438, 1464, 1481, 1538, 1588, 2962 cm⁻¹.

Compound 139b



(Me₂S)AuCl (42.0 mg, 0.140 mmol) was added to a solution of compound 138b (101.1 mg, 0.140 mmol) in CH₂Cl₂ (2 ml) and the resulting suspension stirred for 1 hour at r.t. After evaporation of the solvent, the resulting solid dissolved in CH₃CN and filtered. Removal of the solvents afforeded the desired solid 139b dried in vacuo to yield the new gold complex (90.0 mg, 90%). ¹H NMR (300 MHz, CD₃CN) δ = 7.63 (t, J = 7.8 Hz, 1H), 7.41 (d, J = 7.9 Hz, 2H), 2.74 - 2.58 (m, 2H), 2.34 (hept, J = 6.6 Hz, 2H), 2.43 (s, 2H), 2.22 - 2.09 (m, 2H), 1.82 (m, , 3H), 1.78 (s, 6H), 1.72 - 1.47 (m, 9H), 1.43 (d, J = 6.6 Hz, 6H), 1.41 - 1.38 (m, 6H), 1.35 (d, J = 12.0 Hz, 3H), 1.28 (d, J = 6.3 Hz, 6H), 1.26 – 1.16 ppm (m, 3H). ¹³C NMR $(150 \text{ MHz}, \text{CD}_3\text{CN}) \delta = 204.7 \text{ (d}, J = 3.4 \text{ Hz}), 145.3, 27.0 \text{ (d}, J = 14.1 \text{ Hz}), 133.5, 128.2, 90.2,$ 58.9 (d, J = 1.6 Hz), 50.9 (d, J = 2.3 Hz), 38.7 (d, J = 23.9 Hz), 34.9 (d, J = 3.4 Hz), 32.7 (d, J = 2.2 Hz), 30.2 (d, J = 16.3 Hz), 29.0 (d, J = 17.3 Hz), 27.4 (d, J = 15.3 Hz), 25.9 (d, J = 2.1Hz), 25.0 ppm. ³¹P NMR (121 MHz, CD₃CN) δ = 54.97 ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -122.4$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1945$ Hz, octet, $J_{F-Sb(I=7/2)} = 1071$ Hz). HRMS calcd. for $C_{32}H_{53}AuCINP^+$: 714.326419, found: 714.326670. IR $\tilde{v} = 431, 472, 527, 561, 605, 654, 771,$ 799, 814, 851, 885, 919, 999, 1053, 1128, 1187, 1264, 1341, 1378, 1452, 1520, 2858, 2932 cm^{-1} .



(Me₂S)AuCl (17.5 mg, 0.059 mmol) was added to a solution of compound **138c** (50.0 mg, 0.059 mmol) in CH₂Cl₂ (1 ml) and the resulting suspension stirred for 1 hour at r.t. After evaporation of the solvent, the resulting solid was recrystallized from CH₂Cl₂/Et₂O to afford the desired compound **139c** as a yellow solid (45.6 mg, 70%). ¹H NMR (CD₂Cl₂, 300 MHz, 298 K): $\delta = 7.99$ (m, 4H), 7.94 – 7.75 (m, 5H), 7.50 (d, J = 7.9 Hz, 2H), 2.72 (s, 2H), 2.53 (p, J = 6.6 Hz, 2H), 1.75 (s, 6H), 1.44 (s, 6H), 1.40 (d, J = 6.4 Hz, 6H), 1.22 ppm (d, J = 6.6 Hz, 6H). ¹³C NMR (CD₂Cl₂, 100 MHz, 298 K): $\delta = 200.1$ (d, $J_{C-P} = 14.3$ Hz), 144.8, 136.78 (qd, $J_{C-F} = 33.8$, $J_{C-P} = 2.9$ Hz), 135.9 (d, $J_{C-P} = 15.9$ Hz), 134.0, 132.5 (d, $J_{C-P} = 6.6$ Hz), 128.5, 128.1 (dq, $J_{C-F} = 13.0$, $J_{C-P} = 3.6$ Hz), 127.4 (d, $J_{C-P} = 1.7$ Hz), 123.4 (q, $J_{C-F} = 273.3$ Hz), 90.6 (d, $J_{C-P} = 1.8$ Hz), 59.4 (d, $J_{C-P} = 2.1$ Hz), 50.5 (d, $J_{C-P} = 2.2$ Hz), 30.7, 30.4, 30.1, 27.5, 25.3 ppm. ³¹P NMR (CD₂Cl₂, 121 MHz, 298K): $\delta = 27.40$ ppm. ¹⁹F NMR (CD₂Cl₂, 282 MHz, 298K): $\delta = - 64.02$ ppm. HRMS *calcd.* for C₃₂H₅₃AuClNP⁺: 838.207200, *found*: 838.207290. IR $\tilde{v} = 421$, 437, 517, 539, 563, 605, 652, 710, 771, 802, 833, 954, 1011, 1062, 1117, 1138, 1318, 1337, 1399, 1464, 2308, 2854, 2925, 2962, 3104 cm⁻¹.

Compound 140a



Potassium graphite (74.6 mg, 0.552 mmol) was added to a solution of **138a** (390.0 mg, 0.552 mmol) in THF (2 ml) at -78 °C and the resulting suspension stirred for 5 min. Then the reaction was allowed to warm up to r.t and further stirred for 1 h. The solvent was removed *in vacuo* and the resulting solid extracted with pentane to afford, after the evaporation of pentane, the desired product **140a** as a black solid (81%, 212.0 mg). Crystals suitable for X–ray analysis were obtained from a saturated solution of **140a** in pentane at -20 °C. Elemental analysis *calcd*. for C₃₂H₄₁NP⁺: C: 81.66%, H: 8.78%, N: 2.98%, *found*: C: 81.75%, H: 8.84%, N: 2.97%. UV– visible absorption bands *found* at 213 and 265 nm (in CH₂Cl₂). HRMS *calcd*. for C₃₂H₄₁NP⁺: 470.296830, *found*: 470.297113.



Potassium graphite (21.5 mg, 0.159 mmol) was added to a solution of **138b** (114.0 mg, 0.159 mmol) in THF (2 ml) at -78 °C and the resulting suspension stirred for 5 min. Then the reaction was allowed to warm up to r.t and further stirred for 1 h. The solvent was removed *in vacuo* and the resulting solid extracted with pentane to afford, after the evaporation of the solvent, the desired product **140b** as a orange solid (70%, 54.0 mg). UV–visible absorption bands *found* at 285 and 321 nm (in CH₂Cl₂). HRMS *calcd*. for C₃₂H₅₃NP⁺: 482.391500, *found*: 482.391013.





Potassium graphite (18.8 mg, 0.126 mmol) was added to a solution of **138c** (106.0 mg, 0.126 mmol) in THF (2 ml) at -78 °C and the resulting suspension stirred for 5 min. Then the reaction was allowed to warm up to r.t and further stirred for 1 h. The solvent was removed *in vacuo* and the resulting solid extracted with pentane to afford, after the evaporation of pentane, the desired product **140c** as a black solid (60%, 46.0 mg). Crystals suitable for X–ray analysis were obtained from a saturated solution of **140c** in pentane at -20 °C. UV–visible absorption bands *found* at 250 and 276 nm (in CH₂Cl₂). HRMS *calcd*. for C₃₄H₃₉NPF⁺: 606.272470, *found*: 606.271884.

Compound 141



(Me₂S)AuCl (12.5 mg, 0.043 mmol) was added to a solution of **140a** (20.0 mg, 0.043 mmol) in THF (1 ml) at -78 °C and the resulting solution stirred for 5 min. Then, the reaction was

warmed up to r.t and further stirred for 1 h. Removal of the solvents *in vacuo* afforded a red solid, which was washed with pentane to afforded the desired product **141** as red solid (87%, 24.0 mg). Red crystals suitable for X–ray analysis were obtained from CH_2Cl_2 /pentane at r.t. Elemental analysis *calcd*. for $C_{32}H_{41}NPAuCl$: C: 54.67%, H: 5.88%, N: 1.99%, *found*: C: 51.99%, H: 6.09%, N: 2.02%. UV– visible absorption bands *found* at 234 and 246 nm (in CH_2Cl_2). HRMS *calcd*. for $C_{32}H_{41}NPAuCl^+$: 702.233360, *found*: 702.232519.

Compound 142



(THT)Au(C₆F₅) (19.2 mg, 0.043 mmol) was added to **140a** (20.0 mg, 0.043 mmol) in THF (1 ml) at -78 °C and and the resulting mixture was stirred for 5 min. Then the reaction was warmed up to r.t and further stirred for 1 h. Removal of the solvents *in vacuo* and afforded a red solid, which was washed with pentane to afford the desired product **142** as yellow solid (76%, 27.0 mg). Red crystals suitable for X– ray analysis were obtained from a solution of **142** in benzene/pentane at r.t. UV– visible absorption bands *found* at 234 and 246 nm (in CH₂Cl₂). HRMS *calcd.* for C₃₈H₄₁NPAuF₅⁺: 834.256130, *found*: 834.255683.

Compound 143



(Me₂S)AuCl (12.2 mg, 0.041 mmol) was added to **140b** (20.0 mg, 0.041 mmol) in THF (1 ml) at -78 °C and the mixture stirred for 5 min. Then the reaction was warmed up to r.t and further stirred for 1 h. Removal of the solvents *in vacuo* afforded a solid, which was washed with pentane to afford the desired product **143** as a red solid (88%, 26.0 mg). Red crystals suitable for X– ray analysis were obtained from a solution of **143** in benzene/pentane at 4 °C. Elemental analysis *calcd*. for C₃₂H₄₁NPAuCl[:] C: 57.54%, H: 7.50%, N: 1.77%, *found*: C: 54.49%, H: 7.21%, N: 1.69%. UV– visible absorption bands *found* at 229 and 276 nm (in CH₂Cl₂). HRMS *calcd*. for C₃₂H₄₁AuClNP⁺: 702.232514, *found*: 702.232490.



m–CPBA (63.5 mg, 0.283 mmol) was added to a solution of phosphine **138a** (200.0 mg, 0.283 mmol) in CH₂Cl₂ (2 ml), and the resulting mixture stirred for 1 h. Partly removal of the solvent to approximately 2 ml and addition of Et₂O (10 ml) resulted in precipitation of the desired product, which was further washed with Et₂O to afford clean **146** as a white solid (97%, 200.0 mg). ¹H NMR (CD₃CN, 300 MHz): $\delta = 7.91 - 7.63$ (m, 10H), 7.53 (dd, J = 8.5, 7.0 Hz, 1H), 7.44 – 7.35 (m, 2H), 2.67 (p, J = 6.5 Hz, 2H), 2.56 (s, 2H), 1.53 (s, 6H), 1.38 (d, J = 6.4 Hz, 6H), 1.27 (s, 6H), 1.00 ppm (d, J = 6.6 Hz, 6H), ¹³C NMR (CD₃CN, 100 MHz): $\delta = 202.6$ (d, J = 43.3 Hz), 143.5, 134.5 (d, J = 3.0 Hz), 132.9 (d, J = 11.2 Hz), 130.7, 130.5, 129.2 (d, J = 13.3 Hz), 128.2 (d, J = 110.1 Hz), 125.2, 87.7 (d, J = 5.2 Hz), 54.2 (d, J = 8.4 Hz), 48.8 (d, J = 3.8 Hz), 29.3, 28.4, 27.9, 25.5, 22.9 ppm. ³¹P NMR (CD₃CN, 121 MHz) $\delta = 24.50$ ppm. ¹⁹F NMR (CD₃CN, 282 MHz): $\delta = -122.4$ ppm (sextet, $J_{F-Sb(I=5/2)} = 1945$ Hz, octet, $J_{F-Sb(I=7/2)} = 1071$ Hz). HRMS *calcd*. for C₃₂H₄₁ONP⁺: 486.292280, *found*: 486.292028. IR $\tilde{v} = 447, 472, 502, 536, 655, 697, 732, 754, 799, 807, 1098, 1114, 1219, 1378, 1438, 1471, 2979 cm⁻¹.$

Compound 147



Potassium graphite (10.3 mg, 0.069 mmol) was added to **146** (50.0 mg, 0.069 mmol) in THF (2 ml) at -78 °C and the resulting suspension stirred for 5 min. Then, the reaction was warmed up to r.t and further stirred for 1 h. Removal of the solvents *in vacuo*, followed by extraction with pentane afforded the desired product 147 as a black solid (84%, 28.3 mg). Crystals suitable for X–ray analysis were obtained from a solution of **147** in pentane at -20 °C. Elemental analysis *calcd*. for C₃₂H₄₁NOP: C: 78.98%, H: 8.48%, N: 2.88%, *found*: C: 77.34%, H: 8.86%, N: 2.68%. UV– visible absorption bands *found* at 228 and 270 nm (in CH₂Cl₂). HRMS *calcd*. for C₃₂H₄₁NOP⁺: 486.292230, *found*: 486.292028.

6 Appendix

6.1 NMR Spectra of Representative Compounds

¹H NMR (CD₃CN, 300 MHz) (Compound 62)



¹³C NMR (CD₃CN, 75 MHz) (Compound 62)



³¹P NMR (CD₃CN, 162 MHz) (Compound 62)



¹¹B NMR (CD₃CN, 128 MHz) (Compound 62)

н



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 62)



¹H NMR (CD₃CN, 400 MHz) (Compound 63)





¹³C NMR (CD₃CN, 101 MHz) (Compound 63)

190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm

³¹P NMR (CD₃CN, 162 MHz) (Compound 63)

 $\begin{array}{c} H, -, H\\ \swarrow, B, N, B, N\\ \swarrow, 2+, N\\ TfO - P\\ P\\ D\\ P\\ H\end{array}$


¹¹B NMR (CD₃CN, 128 MHz) (Compound 63)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 63)







¹³C NMR (CD₃CN, 100 MHz) (Compound 64)



¹H NMR (CD₃CN, 400 MHz) (Compound 64)

³¹P NMR (CD₃CN, 162 MHz) (Compound 64)



¹¹B NMR (CD₃CN, 128 MHz) (Compound 64)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 64)



¹H NMR (CD₃CN, 400 MHz) (Compound 67)



¹³C NMR (CD₃CN, 100 MHz) (Compound 67)



³¹P NMR (CD₃CN, 162 MHz) (Compound 67)





¹⁹F NMR (CD₃CN, 282 MHz) (Compound 67)





³¹P NMR (CD₃CN, 162 MHz) (Compound 68)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 68)







¹³C NMR (CD₃CN, 75 MHz) (Compound 69)



³¹P NMR (CD₃CN, 121 MHz) (Compound 69)



¹¹F NMR (CD₃CN, 282 MHz) (Compound 69)



¹H NMR (CD₃CN, 300 MHz) (Compound 73)



¹³C NMR (CD₃CN, 100 MHz) (Compound 73)



³¹P NMR (CD₃CN, 162 MHz) (Compound 73)





¹⁹F NMR (CD₃CN, 282 MHz) (Compound 73)



¹H NMR (CD₃CN, 400 MHz) (Compound 76)







---7.31

³¹P NMR (CD₃CN, 162 MHz) (Compound 76)



200 150 100 50 0 -50 ppm





¹H NMR (CD₃CN, 300 MHz) (Compound 79)



¹³C NMR (CD₃CN, 75 MHz) (Compound 79)





¹¹B NMR (CD₃CN, 96 MHz) (Compound 79)



¹¹F NMR (CD₃CN, 282 MHz) (Compound 79)



¹H NMR (CD₃CN, 300 MHz) (Compound 82)







³¹P NMR (CD₃CN, 121 MHz) (Compound 82)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 82)



¹H NMR (CD₂Cl₂, 500 MHz) (Compound 91)





¹³C NMR (CD₃CN, 125 MHz) (Compound 91)

³¹P NMR (CD₃CN, 121 MHz) (Compound 91)







³¹P NMR (CDCl₃, 121 MHz) (Compound 92a)



¹³C NMR (CD₃CN, 100 MHz) (Compound 92a)

¹¹B NMR (CD₃CN, 96 MHz) (Compound 92a)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 92a)







³¹P NMR (CD₃CN, 121 MHz) (Compound 92b)

¹⁹F NMR (CD₃CN, 282 MHz) (Compound 92b)

| \sim | 0 | ப | ~ | $^{\circ}$ | ∞ | \sim | \leftarrow | 0 | - | 4 | \sim | σ |
|--------------|--------|--------|---|--------------|----------|--------|--------------|--------|--------------|------------|------------|--------|
| \leftarrow | \sim | \sim | σ | \sim | m | £ | $^{\circ}$ | S | \leftarrow | σ | \sim | \sim |
| • | • | | • | • | | | • | • | | • | • | |
| \leftarrow | 4 | 6 | Q | σ | - | \sim | S | Q | 00 | 0 | $^{\circ}$ | 9 |
| \leftarrow | - | - | - | \leftarrow | \sim | \sim | \sim | \sim | \sim | $^{\circ}$ | m | (n) |
| Ч | Ч | - | Ч | Ч | ч | Ч | Ч | ч | - | - | Ч | H |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| | | | | | | | | | | | | |





10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 ppm



³¹P NMR (CD₂Cl₂, 162 MHz) (Compound 92c)



¹⁹F NMR (CD₂Cl₂, 282 MHz) (Compound 92c)





¹H NMR (CDCl₃, 400 MHz) (Compound 99)





³¹P NMR (CDCl₃, 121 MHz) (Compound 99)





¹³C NMR (CDCl₃, 100 MHz) (Compound 100)







¹H NMR (CD₃CN, 400 MHz) (Compound 101a)





¹³C NMR (CD₃CN, 100 MHz) (Compound 101a)

³¹P NMR (CD₃CN, 121 MHz) (Compound 101a)





¹¹B NMR (CD₃CN, 96 MHz) (Compound 101a)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 101a)

 $\begin{array}{c} & & \\ & &$



¹H NMR (CD₃CN, 400 MHz) (Compound 101b)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 101b)

| 72 57 72 72 72 72 72 72 72 72 72 72 72 72 | 42 15 85 97 | | | | | | | |
|--|----------------------|--|--|--|--|--|--|--|
| 106. 114. 114. 114. 120. 22. 25. 27. | 29 33 46 40 | | | | | | | |
| | | | | | | | | |







¹H NMR (CD₃CN, 400 MHz) (Compound 102)

+ Me^{-N}

Ph_/ Me

9.5

9.0

`Me Me

 $2 \, \text{SbF}_6$

8.0

8.5

7.5

2.05



7.0

6.5



5.5

6.0

5.0

4.5

4.0

8.03

3.5

з.о

12.01

2.5

2.0

1.5

1.0 ppm
³¹P NMR (CD₃CN, 121 MHz) (Compound 102)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 102)



¹H NMR (CD₃CN, 400 MHz) (Compound 103)



250 200 150 100 50 0

ppm

³¹P NMR (CD₃CN, 121 MHz) (Compound 103)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 103)



¹H NMR (CD₃CN, 400 MHz) (Compound 104)



¹³C NMR (CD₃CN, 100 MHz) (Compound 104)



³¹P NMR (CD₃CN, 121 MHz) (Compound 104)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 104)





¹H NMR (C₆D₆, 400 MHz) (Compound 105)

¹³C NMR (C₆D₆, 100 MHz) (Compound 105)







¹⁹F NMR (C₆D₆, 282 MHz) (Compound 105)



¹H NMR (C₆D₆, 300 MHz) (Compound 106)



¹³C NMR (C₆D₆, 100 Mz) (Compound 106)



³¹P NMR (C₆D₆, 121 MHz) (Compound 106)



¹H NMR (CD₃CN, 400 MHz) (Compound 107a)







³¹P NMR (CD₃CN, 162 MHz) (Compound 107a)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 107a)



¹H NMR (CD₂Cl₂, 400 MHz) (Compound 107b)





³¹P NMR (CD₂Cl₂, 162 MHz) (Compound 107b)





¹H NMR (CD₂Cl₂, 400 MHz) (Compound 107c)

³¹P NMR (CD₂Cl₂, 162 MHz) (Compound 107c)



¹⁹F NMR (CD₂Cl₂, 282 MHz) (Compound 107c)





¹³H NMR (CD₃CN, 400 MHz) (Compound 108)

³¹P NMR (CD₃CN, 121 MHz) (Compound 108)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 108)





¹H NMR (CD₃CN, 400 MHz) (Compound 109a)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 109a)

Ph

| | -106.88 -111.00 -1114.78 -114.78 -114.78 -122.17 -122.17 -122.17 -123.56 -123.56 -123.35 -123.17 -124.28 -124. |
|---|---|
| N_{+} $Pt_{-}I$ Ph_{-} $2 SbE_{-}$ | |
| | |



³¹P NMR (CD₃CN, 121 MHz) (Compound 109a)



¹H NMR (CD₃CN, 400 MHz) (Compound 109b)

¹³C NMR (CD₃CN, 100 MHz) (Compound 109b)



³¹P NMR (CD₃CN, 121 MHz) (Compound 109b)



¹⁹F NMR (CD₃CN, 376 MHz) (Compound 109b)





¹H NMR (CD₃CN, 400 MHz) (Compound 109e)

³¹P NMR (CD₃CN, 121 MHz) (Compound 109e)



¹⁹F NMR (CD₃CN, 376 MHz) (Compound 109e)

| 12 | 25 | 200 | 52 | 31 | 21 | 94 | 72 | |
|-------|------------|-----|----|-----|-----|----|-----|--|
| -1 57 | 10 10 | | | | · … | | m | |
| H H | H H | H C | 0 | 010 | 101 | ě | m m | |
| 77 | 11 | 11 | 님 | 75 | 1 1 | T | 77 | |
| | | | | | | | | |





³¹P NMR (CD₃CN, 121 MHz) (Compound 109f)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 109f)











¹¹B NMR (CD₃CN, 96 MHz) (Compound 110)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 110)



¹H NMR (CD₂Cl₂, 600 MHz): (Compound 112b)





³¹P NMR (CD₂Cl₂, 121 MHz) (Compound 112b)





¹H NMR (CD₂Cl₂, 400 MHz) (Compound 112c)







240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 ppm

³¹P NMR (CD₂Cl₂, 121 MHz) (Compound 112c)

| 6 0 0 | m |
|-----------|---|
| 000 | 0 |
| | |
| 100 | 9 |
| ഗഗവ | H |
| \forall | |



¹⁹F NMR (CD₂Cl₂, 282 MHz) (Compound 112c)



¹H NMR (CD₂Cl₂, 400 MHz)

| 1128 128 128 128 128 128 128 128 | | 1.95 | |
|---|------------------------|------------------|-------|
| | | | |
| | | | |
| 8.5 8.0 7.5 7.0 6.5 6.0 | 5.5 5.0 4.5 4.0 3.5 3. | 0 2.5 2.0 1.5 1. | 0 ppm |

¹³C NMR (CD₂Cl₂, 100 MHz)



³¹P NMR (CD₂Cl₂, 121 MHz)





¹H NMR (CD₂Cl₂, 400 MHz) (Compound 112d)

³¹P NMR (CD₂Cl₂, 121 MHz) (Compound 112d)



200 150 100 50 0 -50 -100 -150 -200 ppm

¹⁹F NMR (CD₂Cl₂, 282 MHz) (Compound 112d)

| 46 48 50 | 52 | 57 | 61 | 60 | 94 49 | 52 56 | 59 63 |
|----------------|----|----|----|------|--------------|--------------|--------------|
| L14. | 14 | 14 | 61 | 161. | 161. 164. | 164. 164. | 164. 164. |
| | | | | | 51 | | |





¹³C NMR (CD₂Cl₂, 125 Mz) (Compound 112e)





¹⁹F NMR (CD₂Cl₂, 282 MHz) (Compound 112e)



^{150 100 50 0 -50 -100 -150 -200 -250} ppm


 ^{13}C NMR (CD₂Cl₂, 125 Mz) (Compound 112f)



³¹P NMR (CD₂Cl₂, 162 MHz) (Compound 112f)



¹⁹F NMR (CD₂Cl₂, 282 MHz) (Compound 112f)







160 150 140 130 120 0 ppm

¹H NMR (CD₃CN, 400 MHz) (Compound 112g)

³¹P NMR (CD₃CN, 121 MHz) (Compound 112g)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 112g)



¹¹B NMR (CD₃CN, 96 MHz) (Compound 112g)





¹³C NMR (CD₃COCD₃, 100 MHz) (Compound 112h)

³¹P NMR (CD₃COCD₃, 121 MHz) (Compound 112h)



¹¹B NMR (CD₃COCD₃, 96 MHz) (Compound 112h)



¹⁹F NMR (CD₃COCD₃, 282 MHz) (Compound 112h)





¹H NMR (CD₃CN, 600 MHz) (Compound 113)

240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm

³¹P NMR (CD₃CN, 162 MHz) (Compound 113)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 113)

| 000 00 00 00 00 00 00 00 00 00 00 00 00 | 18 |
|---|----|
| | • |
| 94040000000040 | - |
| 000000000000000000000000000000000000000 | 4 |
| ананананана | - |
| | 1 |
| | _ |







¹H NMR (CD₂Cl₂, 600 MHz) (Compound 114)

³¹P NMR (CD₂Cl₂, 162 MHz) (Compound 114)



¹⁹F NMR (CD₂Cl₂, 282 MHz) (Compound 114)







¹³C NMR (CDCl₃, 100 MHz) (Compound 119)







230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 ppm



¹³C NMR (CDCl₃, 100 MHz) (Compound 121)





¹H NMR (CDCl₃, 400 MHz) (Compound 122)

230 220 210 200 190 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm



¹H NMR (CDCl₃, 400 MHz) (Compound 123)



¹H NMR (CDCl₃, 400 MHz) (Compound 124)













¹H NMR (CD₂Cl₂, 400 MHz) (Compound 127)







¹H NMR (CDCl₃, 400 MHz) (Compound 128)

| 0 / 4 / 0 / 4 / 0 / 0 / 0 / 0 / 0 / 0 / | 4 M H O B M O | 10 |
|---|---------------|--------|
| 0 0 4 4 4 0 0 0 0 4 4 4 4 0 | 0000000 | 4 M |
| | | |
| | タタタののの | |
| AV V MA | | \vee |





239

¹³C NMR (CDCl₃, 100 MHz) (Compound 128)

¹⁹F NMR (CDCl₃, 376 MHz) (Compound 128)



-62.35



¹H NMR (CD₂Cl₂, 400 MHz) (Compound 129)

¹³C NMR (CD₂Cl₂, 100 MHz) (Compound 129)





¹H NMR (CD₂Cl₂, 400 MHz) (Compound 138a)

³¹P NMR (CD₂Cl₂, 162 MHz) (Compound 138a)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 138a)





¹H NMR (CD₂Cl₂, 400 MHz) (Compound 138b)

³¹P NMR (CD₂Cl₂, 162 MHz) (Compound 138b)



¹⁹F NMR (CD₂Cl₂, 282 MHz) (Compound 138b)





¹H NMR (CD₂Cl₂, 300 MHz) (Compound 138c)



¹⁹F NMR (CD₂Cl₂, 282 MHz) (Compound 138c)



-63.81



¹³C NMR (CD₃CN, 125 MHz) (Compound 139a)



230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm

¹H NMR (CD₃CN, 300 MHz) (Compound 139a)

³¹P NMR (CD₃CN, 121 MHz, 298K) (Compound 139a)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 139a)

| 60 | 15 | 21 | 61 | 64 | 96 | 74 | 36 | 55 | 33 | 51 | 10 | 92 | 64 | 70 | 27 | 3 5 | 2 | 82 |
|--------------|----|--------------|--------------|--------------|----|--------------|--------------|--------|--------|--------|--------|------------|------------|------------|------------|-----|----|----|
| • | • | • | • | | • | | • | • | • | | | | • | • | • | | ٠ | |
| - | 4 | 9 | 9 | 6 | 9 | 5 | \leftarrow | \sim | S | Q | 00 | 0 | Ч | $^{\circ}$ | 9 | 5 | + | - |
| \leftarrow | - | \leftarrow | \leftarrow | \leftarrow | - | \leftarrow | \sim | \sim | \sim | \sim | \sim | $^{\circ}$ | $^{\circ}$ | $^{\circ}$ | $^{\circ}$ | Lí | 7 | ഹ |
| - | - | Ч | L - | e d | - | - | \leftarrow | - | L - | e d | L - | - | Ч | Ч | - | 5 | ۰. | - |
| 1 | 1 | 1 | 1 | | 1 | 1 | 1 | - 1 | 1 | | 1 | 1 | 1 | 1 | 1 | 1 | | 1 |
| 5 | - | 1 | 111 | 1 | 1 | | 1 | Ζ, | 1/ | 2 | 1 | 2 | 2 | / | / | 1 | | 1 |





¹H NMR (CD₃CN, 300 MHz) (Compound 139b)

¹³C NMR (CD₃CN, 125 MHz) (Compound 139b)



230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm

³¹P NMR (CD₃CN, 121 MHz) (Compound 139b)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 139b)

| W04L0001L00W |
|-------------------|
| 00200104001 |
| |
| 0H0400000747H |
| |
| |
| |
| ししししし ノノノノノ |
| |
| |
| 1 1 0 100 10 10 1 |
| |
| |
| |
| |







¹H NMR (CH₂Cl₂, 300 MHz) (Compound 139c)

³¹P NMR (CH₂Cl₂, 121 MHz) (Compound 139c)



¹⁹F NMR (CH₂Cl₂, 282 MHz) (Compound 139c)




³¹P NMR (CD₃CN, 161 MHz) (Compound 146)



¹⁹F NMR (CD₃CN, 282 MHz) (Compound 146)

| [-110.68 | //r-113.56 | <i>∥r</i> −114.56 | <i>PLL -118.28</i> | W/120.44 | 1/2-122.00 | 125.77 | -127.33 | -129.49 | -133.26 | N-134.23 | L-135.92 | N136.95 | L-141.10 | L-145.79 | L-145.97 | |
|----------|------------|-------------------|--------------------|----------|------------|--------|---------|---------|---------|----------|----------|---------|----------|----------|----------|--|
| | | | _ | 7 | 1 | 1 | Л | 6 | - | - | - | | | | | |



6.2 X-ray Strutures

6.2.1 Crystal Data and Structure Refinement of Compound 63

| F2 G | | |
|---|--|-------------------------|
| Empirical formula | $C_{13} H_{13} B F_3 N_4 O_3 P S$ | |
| Color | colourless | |
| Formula weight | 404.11 g · mol-1 | |
| Temperature | 100 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | ORTHORHOMBIC | |
| Space group | Pna2 ₁ , (no. 33) | |
| Unit cell dimensions | a = 20.258(2) Å | <i>α</i> = 90°. |
| | b = 10.0335(10) Å | β= 90°. |
| | c = 8.2844(8) Å | $\gamma = 90^{\circ}$. |
| Volume | 1683.9(3) Å3 | |
| Z | 4 | |
| Density (calculated) | 1.594 mg · m-3 | |
| Absorption coefficient | 0.341 mm-1 | |
| F(000) | 824 e | |
| Crystal size | 0.48 x 0.07 x 0.05 mm3 | |
| θ range for data collection θ | 2.01 to 28.39°. | |
| Index ranges | $-27 \le h \le 27, -13 \le k \le 13, -11 \le l \le 11$ | |
| Reflections collected | 39971 | |
| Independent reflections | 4204 [Rint = 0.0253] | |
| Reflections with I>2s(I) | 4118 | |
| Completeness to $\theta = 27.50^{\circ}$ | 100.00% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.98 and 0.91 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 4204 / 1 / 243 | |
| Goodness-of-fit on F2 | 1.063 | |
| Final R indices [I>2s(I)] | R1 = 0.0222 | wR2 = 0.0599 |
| R indices (all data) | R1 = 0.0229 | wR2 = 0.0604 |
| Absolute structure parameter | -0.03(5) | |
| Largest diff. peak and hole | 0.3 and -0.2 e·Å-3 | |

6.2.2 Crystal Data and Structure Refinement of Compound 65

| F3 (F C12 C11 | | |
|--|--|---------------------------------|
| Empirical formula | $C_{15}H_{13}F_6N_4O_6PS_2$ | |
| Color | colourless | |
| Formula weight | 554.38 g · mol-1 | |
| Temperature | 100 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | TRICLINIC | |
| Space group | P ⁻ 1, (no. 2) | |
| Unit cell dimensions | a = 9.1777(11) Å | $\alpha = 102.624(3)^{\circ}$. |
| | b = 9.9125(12) Å | β=98.632(3)°. |
| | c = 13.419(2) Å | $\gamma = 112.612(2)^{\circ}$. |
| Volume | 1061.9(3) Å3 | |
| Z | 2 | |
| Density (calculated) | 1.734 mg · m-3 | |
| Absorption coefficient | 0.421 mm-1 | |
| F(000) | 560 e | |
| Crystal size | 0.11 x 0.07 x 0.03 mm3 | |
| θ range for data collection | 2.34 to 31.16°. | |
| Index ranges | $-13 \le h \le 13, -14 \le k \le 14, -19 \le l \le 19$ | |
| Reflections collected | 31528 | |
| Independent reflections | 6834 [Rint = 0.0306] | |
| Reflections with I>2s(I) | 5721 | |
| Completeness to $\theta = 31.16^{\circ}$ | 99.50% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.99and 0.95 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 6834 / 0 / 307 | |
| Goodness-of-fit on F2 | 1.035 | |
| Final R indices [I>2s(I)] | R1 = 0.0385 | wR2 = 0.0975 |
| R indices (all data) | R1 = 0.0491 | wR2 = 0.1039 |
| Largest diff. peak and hole | 1.2 and -0.6 $e \cdot A$ -3 | |



| Empirical formula | $C_{13}H_{18}F_6N_5O_6PS_2$ | |
|--|--|-----------------------|
| Color | colourless | |
| Formula weight | 549.41 g⋅mol ⁻¹ | |
| Temperature | 100 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | MONOCLINIC | |
| Space group | p 2 ₁ /n, (no. 14) | |
| Unit cell dimensions | a = 12.814(3) Å | α= 90° |
| | b = 12.704(3) Å | β=113.697(4)° |
| | c = 14.321(3) Å | $\gamma = 90^{\circ}$ |
| Volume | 2134.8(9) Å ³ | |
| Z | 4 | |
| Density (calculated) | $1.709 \text{ mg} \cdot \text{m}^{-3}$ | |
| Absorption coefficient | 0.419 mm-1 | |
| F(000) | 1120 e | |
| Crystal size | $0.31 \ge 0.27 \ge 0.20 \text{ mm}^3$ | |
| θ range for data collection | 1.80 to 31.38°. | |
| Index ranges | $-18 \le h \le 18, -18 \le k \le 18, -20 \le l \le 20$ | |
| Reflections collected | 58788 | |
| Independent reflections | 6998 [R _{int} = 0.0543] | |
| Reflections with I>2s(I) | 5519 | |
| Completeness to $\theta = 31.38^{\circ}$ | 99.60% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.92807 and 0.86261 | |
| Refinement method | Full-matrix least-squares on F ² | |
| Data / restraints / parameters | 6998 / 0 / 300 | |
| Goodness-of-fit on F ² | 1.075 | |
| Final R indices [I>2s(I)] | R1 = 0.0342 | wR2 = 0.0847 |
| R indices (all data) | R1 = 0.0524 | wR2 = 0.09 |
| Largest diff. peak and hole | 0.733 and -0.555 $e \cdot Å^{-3}$ | |

6.2.4 Crystal Data and Structure Refinement of Compound 76



6.2.5 Crystal Data and Structure Refinement of Compound 79

Color



6.2.6 Crystal Data and Structure Refinement of Compound 91

Color

Temperature

Wavelength

Space group

Volume

F(000)

Crystal size

Index ranges



6.2.7 Crystal Data and Structure Refinement of Compound 92b



Empirical formula Color Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions

Volume Ζ Density (calculated) Absorption coefficient F(000) Crystal size θ range for data collection Index ranges Reflections collected Independent reflections Reflections with $I \ge 2\sigma(I)$ Completeness to $\theta = 67.679^{\circ}$ Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices $[I \ge 2\sigma(I)]$ R indices (all data) Extinction coefficient Largest diff. peak and hole

 $C_{28} H_{34} F_{12} N_4 P_2 Sb_2 \cdot 0.25 CH_2 Cl_2$ colorless 981.26 g · mol-1 150 K 1.54178 Å MONOCLINIC $P2_1/c$, (no. 14) a = 15.3374(6) Å $\alpha = 90^{\circ}$. b = 37.0863(14) Å $\beta = 104.8921(17)^{\circ}$. c = 13.4231(5) Å $\gamma = 90^{\circ}$. 7378.7(5) Å3 8 1.767 mg · m-3 13.564 mm-1 3844 e 0.20 x 0.11 x 0.03 mm3 2.383 to 65.082°. $-18 \le h \le 17, -43 \le k \le 43, -15 \le l \le 15$ 172322 12440 [Rint = 0.0844] 10497 93.10% Gaussian 0.68 and 0.08 Full-matrix least-squares on F2 12440 / 0 / 895 1.028 R1 = 0.0724wR2 = 0.1879R1 = 0.0840wR2 = 0.19720.00034(3)

1.8 and -1.6 e \cdot Å-3

6.2.8 Crystal Data and Structure Refinement of Compound 101a



| Empirical formula | $C_{37} H_{44} B_2 Cl_2 F_8 N_4 P_2$ | |
|---|--|-------------------------------|
| Color | yellow | |
| Formula weight | 851.22 g · mol-1 | |
| Temperature | 100.15 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | MONOCLINIC | |
| Space group | P2 ₁ /c, (no. 14) | |
| Unit cell dimensions | a = 19.5245(8) Å | $\alpha = 90^{\circ}$. |
| | b = 12.1720(11) Å | $\beta = 102.298(4)^{\circ}.$ |
| | c = 17.6079(10) Å | $\gamma = 90^{\circ}$. |
| Volume | 4088.5(5) Å3 | |
| Z | 4 | |
| Density (calculated) | 1.383 mg · m-3 | |
| Absorption coefficient | 0.306 mm-1 | |
| F(000) | 1760 e | |
| Crystal size | 0.18 x 0.18 x 0.17 mm3 | |
| θ range for data collection | 2.713 to 33.139°. | |
| Index ranges | $-30 \le h \le 30, -18 \le k \le 18, -27 \le l \le 27$ | |
| Reflections collected | 123046 | |
| Independent reflections | 15544 [Rint = 0.0289] | |
| Reflections with $I \ge 2\sigma(I)$ | 13476 | |
| Completeness to $\theta = 25.242^{\circ}$ | 99.60% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.75 and 0.68 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 15544 / 0 / 502 | |
| Goodness-of-fit on F2 | 1.052 | |
| Final R indices [I>2 σ (I)] | R1 = 0.0342 | wR2 = 0.0892 |
| R indices (all data) | R1 = 0.0420 | wR2 = 0.0949 |
| Largest diff. peak and hole | 0.6 and -0.5 e · Å-3 | |

6.2.9 Crystal Data and Structure Refinement of Compound 103



6.2.10 Crystal Data and Structure Refinement of Compound 107a



| Empirical formula | $C_{33}H_{35.50}F_{12}MoN_{4.50}O_4P_2Sb_2$ | |
|---|--|--------------------------------|
| Color | yellow | |
| Formula weight | 1188.54 g · mol-1 | |
| Temperature | 100 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | TRICLINIC | |
| Space group | P ⁻ 1 , (no. 2) | |
| Unit cell dimensions | a = 10.5620(5) Å | $\alpha = 99.497(8)^{\circ}$. |
| | b = 14.8442(13) Å | $\beta = 92.181(6)^{\circ}$. |
| | c = 14.9641(14) Å | $\gamma = 92.074(6)^{\circ}$. |
| Volume | 2310.2(3) Å3 | |
| Z | 2 | |
| Density (calculated) | 1.709 mg ⋅ m-3 | |
| Absorption coefficient | 1.584 mm-1 | |
| F(000) | 1158 e | |
| Crystal size | 0.15 x 0.08 x 0.03 mm3 | |
| θ range for data collection | 2.633 to 32.031°. | |
| Index ranges | $15 \le h \le -15, 21 \le k \le -22, 22 \le l \le 0$ | |
| Reflections collected | 53813 | |
| Independent reflections | 15951 [Rint = 0.0520] | |
| Reflections with $I \ge 2\sigma(I)$ | 14303 | |
| Completeness to $\theta = 25.242^{\circ}$ | 99.20% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.75 and 0.44 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 15951 / 0 / 544 | |
| Goodness-of-fit on F2 | 1.042 | |
| Final R indices [I>2 σ (I)] | R1 = 0.0631 | wR2 = 0.1740 |
| R indices (all data) | R1 = 0.0683 | wR2 = 0.1784 |
| Largest diff. peak and hole | 7.060 and -3.420 e · Å-3 | |

6.2.11 Crystal Data and Structure Refinement of Compound 108



| Empirical formula | $C_{28}H_{34}F_{12}N_4P_2SSb_2$ | |
|---|--|--------------------------------|
| Color | colorless | |
| Formula weight | 992.09 g · mol-1 | |
| Temperature | 100.15 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | MONOCLINIC | |
| Space group | C2/c, (no. 15) | |
| Unit cell dimensions | a = 39.801(4) Å | $\alpha = 90^{\circ}$. |
| | b = 12.189(5) Å | $\beta = 112.724(12)^{\circ}.$ |
| | c = 17.500(6) Å | $\gamma = 90^{\circ}$. |
| Volume | 7831(4) Å3 | |
| Z | 8 | |
| Density (calculated) | 1.683 mg · m-3 | |
| Absorption coefficient | 1.597 mm-1 | |
| F(000) | 3888 e | |
| Crystal size | 0.10 x 0.04 x 0.04 mm3 | |
| θ range for data collection | 2.640 to 33.168°. | |
| Index ranges | $-61 \le h \le 61, -18 \le k \le 18, -25 \le l \le 26$ | |
| Reflections collected | 77801 | |
| Independent reflections | 14892 [Rint = 0.0550] | |
| Reflections with $I \ge 2\sigma(I)$ | 11755 | |
| Completeness to $\theta = 25.242^{\circ}$ | 99.90% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.95 and 0.86 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 14892 / 0 / 446 | |
| Goodness-of-fit on F2 | 1.056 | |
| Final R indices $[I \ge 2\sigma(I)]$ | R1 = 0.0365 | wR2 = 0.0829 |
| R indices (all data) | R1 = 0.0530 | wR2 = 0.0888 |
| Extinction coefficient | n/a | |
| Largest diff. peak and hole | 0.7 and -1.3 e · Å-3 | |

6.2.12 Crystal Data and Structure Refinement of Compound 109a



0.16 x 0.10 x 0.01 mm3

16334 [Rint = 0.0675]

0.94105 and 0.50116

3.007 and -3.217 e·Å-3

16334 / 0 / 491

R1 = 0.0342

R1 = 0.0420

Full-matrix least-squares on F2

 $-27 \le h \le 27, -21 \le k \le 21, -26 \le l \le 26$

2.717 to 33.132°.

135279

14409 99.90%

1.051

n/a

Gaussian

Empirical formula Color Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions

Volume Ζ Density (calculated) Absorption coefficient F(000) Crystal size θ range for data collection Index ranges Reflections collected Independent reflections Reflections with I>2 σ (I) Completeness to $\theta = 26.000^{\circ}$ Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices $[I \ge 2 \sigma (I)]$ R indices (all data) Extinction coefficient Largest diff. peak and hole

 $\alpha = 90^{\circ}.$ $\beta = 100.40(3)^{\circ}.$ $\gamma = 90^{\circ}.$

wR2 = 0.0832wR2 = 0.0883

6.2.13 Crystal Data and Structure Refinement of Compound 109c



Empirical formula $C_{62}\,H_{80}\,Cl_{14}\,F_{24}\,N_8\,P_4\,Rh_2\,Sb_4$ Color orange 2706.38 g · mol-1 Formula weight Temperature 100.15 K 0.71073 Å Wavelength MONOCLINIC Crystal system Space group $P2_1/n$, (no. 14) $\alpha = 90^{\circ}$. Unit cell dimensions a = 13.2883(12) Å $\beta = 92.308(7)^{\circ}$. b = 13.0485(16) Å c = 26.3951(12) Å $\gamma = 90^{\circ}$. Volume 4573.0(7) Å3 2 Density (calculated) 1.965 mg · m-3 2.088 mm-1 Absorption coefficient F(000) 2632 e 0.10 x 0.07 x 0.04 mm3 Crystal size θ range for data collection 2.727 to 27.500°. Index ranges $-17 \le h \le 17, -16 \le k \le 16, -34 \le l \le 34$ Reflections collected 87023 Independent reflections 10476 [Rint = 0.0536] 9134 Reflections with $I \ge 2\sigma(I)$ Completeness to $\theta = 25.242^{\circ}$ 99.60% Absorption correction Gaussian Max. and min. transmission 0.94 and 0.83 Refinement method Full-matrix least-squares on F2 Data / restraints / parameters 10476 / 0 / 530 Goodness-of-fit on F2 1.054 Final R indices $[I \ge 2 \sigma (I)]$ R1 = 0.0593wR2 = 0.1638R1 = 0.0672R indices (all data) wR2 = 0.17623.6 and -1.8 $e \cdot Å$ -3 Largest diff. peak and hole

6.2.14 Crystal Data and Structure Refinement of Compound 109d



Empirical formula $C_{32}\,H_{34}\,Cl\,D_6\,F_{12}\,N_6\,P_2\,Rh\,Sb_2$ Color orange Formula weight 1186.53 g · mol-1 Temperature 100.15 K Wavelength 0.71073 Å Crystal system MONOCLINIC Space group $P2_1/c$, (no. 14) $\alpha = 90^{\circ}$. Unit cell dimensions a = 17.492(2) Å $\beta = 111.088(2)^{\circ}$. b = 15.774(2) Å $\gamma = 90^{\circ}$. c = 17.985(2) ÅVolume 4629.8(11) Å3 Ζ 4 Density (calculated) $1.702 \text{ mg} \cdot \text{m-3}$ Absorption coefficient 1.716 mm-1 F(000) 2304 e Crystal size 0.1 x 0.1 x 0.1 mm3 θ range for data collection 2.296 to 31.082°. $-25 \le h \le 25, -22 \le k \le 22, -26 \le l \le 26$ Index ranges Reflections collected 129694 Independent reflections 14793 [Rint = 0.0730] Reflections with I>2 σ (I) 11201 Completeness to $\theta = 25.242^{\circ}$ 99.60% Absorption correction Gaussian Max. and min. transmission 0.89 and 0.83 Refinement method Full-matrix least-squares on F2 Data / restraints / parameters 14793 / 0 / 511 Goodness-of-fit on F2 1.059 R1 = 0.0511Final R indices $[I \ge 2 \sigma (I)]$ wR2 = 0.1030R1 = 0.0748R indices (all data) wR2 = 0.1098Largest diff. peak and hole 3.4 and -2.0 $e \cdot Å$ -3

F11 P C27 Sb2 F10 Ð Ð F12 F2 C10 C28 6 F8 © C24 C7 CI1 Cf Au1 С F3 C11 C16 C17 C21 C12 C15 Ø 64 C18 C20 C13 (C19 C14

| Empirical formula | $C_{28} H_{34} Au Cl F_{12} N_4 P_2 Sb_2$ | |
|---|--|--------------------------------|
| Color | colorless | |
| Formula weight | 1192.45 g · mol-1 | |
| Temperature | 100 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | MONOCLINIC | |
| Space group | C 2/c, (no. 15) | |
| Unit cell dimensions | a = 36.725(5) Å | $\alpha = 90^{\circ}$. |
| | b = 12.1334(15) Å | $\beta = 108.584(2)^{\circ}$. |
| | c = 17.956(2) Å | $\gamma = 90^{\circ}$. |
| Volume | 7584.1(16) Å3 | |
| Z | 8 | |
| Density (calculated) | 2.089 mg⋅m-3 | |
| Absorption coefficient | 5.514 mm-1 | |
| F(000) | 4528 e | |
| Crystal size | 0.06 x 0.05 x 0.03 mm3 | |
| θ range for data collection | 2.393 to 31.060°. | |
| Index ranges | $-53 \le h \le 53, -17 \le k \le 17, -25 \le l \le 26$ | |
| Reflections collected | 110234 | |
| Independent reflections | 12111 [Rint = 0.0641] | |
| Reflections with $I \ge 2\sigma(I)$ | 10022 | |
| Completeness to $\theta = 25.242^{\circ}$ | 99.90% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.83 and 0.65 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 12111 / 0 / 455 | |
| Goodness-of-fit on F2 | 1.021 | |
| Final R indices $[I>2\sigma(I)]$ | R1 = 0.0253 | wR2 = 0.0464 |
| R indices (all data) | R1 = 0.0387 | wR2 = 0.0501 |
| Largest diff. peak and hole | 2.3 and -1.4 e·Å-3 | |

6.2.15 Crystal Data and Structure Refinement of Compound 109f

6.2.16 Crystal Data and Structure Refinement of Compound 110



Empirical formula Color Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions

Volume Ζ Density (calculated) Absorption coefficient F(000) Crystal size θ range for data collection Index ranges Reflections collected Independent reflections Reflections with $I \ge 2\sigma(I)$ Completeness to $\theta = 25.242^{\circ}$ Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices $[I \ge 2 \sigma (I)]$ R indices (all data) Largest diff. peak and hole

 $C_{38}\,H_{45}\,B_2\,Cl\,F_8\,N_5\,P_2\,Rh$ yellow 945.71 g · mol-1 100 K 0.71073 Å MONOCLINIC $P2_1/n$, (no. 14) $\alpha = 90^{\circ}$. a = 17.7583(18) Å $\beta = 91.115(2)^{\circ}$. b = 12.1947(12) Å c = 18.3067(18) Å $\gamma = 90^{\circ}$. 3963.7(7) Å3 4 1.585 mg · m-3 0.654 mm-1 1928 e 0.34 x 0.10 x 0.03 mm3 1.582 to 26.818°. $-22 \le h \le 22, -15 \le k \le 15, -23 \le l \le 23$ 76406 8461 [Rint = 0.0750] 6803 100.00% Gaussian 0.99 and 0.87 Full-matrix least-squares on F2 8461 / 0 / 521 1.138 R1 = 0.0332wR2 = 0.0890R1 = 0.0517wR2 = 0.11140.8 and -0.9 $e \cdot Å$ -3

6.2.17 Crystal Data and Structure Refinement of Compound 112b



Empirical formula Color Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions

Volume Ζ Density (calculated) Absorption coefficient F(000) Crystal size θ range for data collection Index ranges Reflections collected Independent reflections Reflections with $I \ge 2\sigma(I)$ Completeness to $\theta = 25.242^{\circ}$ Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices $[I \ge 2 \sigma(I)]$ R indices (all data) Extinction coefficient Largest diff. peak and hole

C42 H24 F10 P2 Pd colourless 886.95 g·mol-1 100 K 0.71073 Å monoclinic P $2_1/n$, (no. 14) a = 15.061(3) Å $\alpha = 90^{\circ}$. $\beta = 102.298(4)^{\circ}$. b = 14.768(3) Å c = 16.339(4) Å $\gamma = 90^{\circ}$. 3550.9(13) Å3 4 1.659 mg·m-3 0.698 mm-1 1768 e 0.07 x 0.06 x 0.04 mm3 3.039 to 33.647°. $-23 \le h \le 23, -22 \le k \le 22, -25 \le l \le 25$ 117912 14026 [Rint = 0.0724] 11056 99.80% Gaussian 0.97433 and 0.95301 Full-matrix least-squares on F2 14026 / 0 / 496 1.02 R1 = 0.0303wR2 = 0.0651R1 = 0.0483wR2 = 0.07060 0.839 and -0.716 e·Å-3

6.2.18 Crystal Data and Structure Refinement of Compound 112f

| F3 (C F2 (C22 (C23 (C25 () | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | |
|---|--|---------------------------------|
| Empirical formula | C ₃₈ H ₂₄ F ₁₀ N P Pd | |
| Color | yellow | |
| Formula weight | 821.95 g·mol-1 | |
| Temperature | 100 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | MONOCLINIC | |
| Space group | p 21/c, (no. 14) | |
| Unit cell dimensions | a = 11.0106(11) Å | $\alpha = 90^{\circ}$. |
| | b = 14.0190(14) Å | $\beta = 96.5422(19)^{\circ}$. |
| | c = 21.167(2) Å | $\gamma = 90^{\circ}$. |
| Volume | 3246.0(6) Å3 | |
| Z | 4 | |
| Density (calculated) | 1.682 mg·m-3 | |
| Absorption coefficient | 0.709 mm-1 | |
| F(000) | 1640 e | |
| Crystal size | 0.22 x 0.21 x 0.19 mm3 | |
| θ range for data collection | 2.421 to 37.341°. | |
| Index ranges | $-18 \le h \le 18, -23 \le k \le 23, -35 \le l \le 35$ | |
| Reflections collected | 127102 | |
| Independent reflections | 16348 [Rint = 0.0252] | |
| Reflections with $I > 2\sigma(I)$ | 14984 | |
| Completeness to $\theta = 25.242^{\circ}$ | 99.90% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.90265 and 0.82904 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 16348 / 0 / 462 | |
| Goodness-of-fit on F2 | 1.058 | |
| Final R indices $[I \ge 2\sigma(I)]$ | R1 = 0.0214 | wR2 = 0.0575 |
| R indices (all data) | R1 = 0.0250 | wR2 = 0.0596 |
| Extinction coefficient | n/a | |
| Largest diff. peak and hole | 0.687 and -0.528 e·Å-3 | |

6.2.19 Crystal Data and Structure Refinement of Compound 112g



| Empirical formula |
|----------------------|
| Color |
| Formula weight |
| Temperature |
| Wavelength |
| Crystal system |
| Space group |
| Unit cell dimensions |

| Volume |
|---|
| Z |
| Density (calculated) |
| Absorption coefficient |
| F(000) |
| Crystal size |
| θ range for data collection |
| Index ranges |
| Reflections collected |
| Independent reflections |
| Reflections with $I \ge 2\sigma(I)$ |
| Completeness to $\theta = 25.242^{\circ}$ |
| Absorption correction |
| Max. and min. transmission |
| Refinement method |
| Data / restraints / parameters |
| Goodness-of-fit on F2 |
| Final R indices [I>2 σ (I)] |
| R indices (all data) |
| Extinction coefficient |
| Largest diff. peak and hole |
| |

| $C_{46}H_{43}B_2F_{18}N_7P_2Pd$ | |
|--|--------------------------------|
| colourless | |
| 1225.83 g·mol-1 | |
| 100 K | |
| 0.71073 Å | |
| MONOCLINIC | |
| p 21/c, (no. 14) | |
| a = 18.3894(13) Å | $\alpha = 90^{\circ}$. |
| b = 14.7845(14) Å | $\beta = 114.994(4)^{\circ}$. |
| c = 20.6566(7) Å | $\gamma = 90^{\circ}$. |
| 5090.2(7) Å3 | |
| 4 | |
| 1.600 mg⋅m-3 | |
| 0.535 mm-1 | |
| 2464 e | |
| 0.15 x 0.09 x 0.04 mm3 | |
| 2.609 to 35.008°. | |
| $-29 \le h \le 29, -23 \le k \le 23, -32 \le l \le 33$ | |
| 124759 | |
| 22373 [Rint = 0.0428] | |
| 18998 | |
| 99.80% | |
| Gaussian | |
| 0.98046 and 0.93073 | |
| Full-matrix least-squares on F2 | |
| 22373 / 0 / 692 | |
| 1.048 | |
| R1 = 0.0361 | wR2 = 0.0924 |
| R1 = 0.0465 | wR2 = 0.0988 |
| 0 | |
| 2.507 and -1.787 e⋅Å-3 | |

6.2.20 Crystal Data and Structure Refinement of Compound 112h



Empirical formula Color Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions

Volume Ζ Density (calculated) Absorption coefficient F(000) Crystal size θ range for data collection Index ranges Reflections collected Independent reflections Reflections with $I \ge 2\sigma(I)$ Completeness to $\theta = 25.242^{\circ}$ Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices $[I \ge 2\sigma(I)]$ R indices (all data) Extinction coefficient Largest diff. peak and hole

C54 H54 B2 F18 N4 O2 P2 Pd yellow 1322.97 g·mol-1 100 K 0.71073 Å TRICLINIC p -1, (no. 2) a = 12.5325(6) Å $\alpha = 93.239(6)^{\circ}$. b = 13.8883(13) Å $\beta = 103.518(7)^{\circ}$. $\gamma = 115.502(6)^{\circ}$. c = 18.2445(18) Å2741.7(4) Å3 2 1.603 mg·m-3 0.505 mm-1 1340 e 0.14 x 0.14 x 0.09 mm3 2.607 to 35.056°. $-20 \leq h \leq 20, \ -22 \leq k \leq 22, \ -29 \leq l \leq 29$ 78461 24146 [Rint = 0.0279] 21322 99.60% Gaussian 0.96402 and 0.92959 Full-matrix least-squares on F2 24146 / 0 / 767 1.047 wR2 = 0.0900R1 = 0.0352R1 = 0.0425wR2 = 0.09460 1.251 and -1.121 e·Å-3

6.2.21 Crystal Data and Structure Refinement of Compound 113



6.2.22 Crystal Data and Structure Refinement of Compound 114



| Empirical formula | $C_{37} H_{43} F_{12} N_5 Ni P_2 Sb_2$ | |
|---|--|-------------------------------|
| Color | yellow | |
| Formula weight | 1149.91 g·mol-1 | |
| Temperature | 100.15 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | MONOCLINIC | |
| Space group | p 21/n, (no. 14) | |
| Unit cell dimensions | a = 11.903(2) Å | $\alpha = 90^{\circ}$. |
| | b = 12.036(2) Å | $\beta = 97.511(13)^{\circ}.$ |
| | c = 33.183(4) Å | $\gamma = 90^{\circ}$. |
| Volume | 4713.2(14) Å3 | |
| Ζ | 4 | |
| Density (calculated) | 1.621 mg⋅m-3 | |
| Absorption coefficient | 1.680 mm-1 | |
| F(000) | 2272 e | |
| Crystal size | 0.26 x 0.22 x 0.08 mm3 | |
| θ range for data collection | 2.696 to 33.092°. | |
| Index ranges | $-18 \le h \le 18, -18 \le k \le 18, -50 \le l \le 50$ | |
| Reflections collected | 64200 | |
| Independent reflections | 16882 [Rint = 0.0373] | |
| Reflections with $I \ge 2\sigma(I)$ | 14536 | |
| Completeness to $\theta = 25.242^{\circ}$ | 97.50% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.87772 and 0.69551 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 16882 / 0 / 538 | |
| Goodness-of-fit on F2 | 1.123 | |
| Final R indices $[I>2\sigma(I)]$ | R1 = 0.0338 | wR2 = 0.0963 |
| R indices (all data) | R1 = 0.0427 | wR2 = 0.1028 |
| Extinction coefficient | n/a | |
| Largest diff. peak and hole | 0.846 and -2.010 e·Å-3 | |

6.2.23 Crystal Data and Structure Refinement of Compound 138a



C17 C1 C10 C15 C19 C9 Ð N1 C20 СЗ C1 C26 C32 C.2 C25 C5 C31 Č6 C28 \mathcal{O}_{C23} C30 × C29 Empirical formula C32 H53 F6 N P Sb Color yellow 718.47 g · mol-1 Formula weight Temperature 100.15 K Wavelength 0.71073 Å MONOCLINIC Crystal system Space group $P2_1/c$, (no. 14) Unit cell dimensions a = 16.9548(10) Å $\alpha = 90^{\circ}$. b = 12.0609(8) Å $\beta = 122.735(4)^{\circ}$. c = 19.0889(13) Å $\gamma = 90^{\circ}$. Volume 3283.5(4) Å3 Ζ 4 Density (calculated) $1.453 \text{ mg} \cdot \text{m-3}$ 0.945 mm-1 Absorption coefficient F(000) 1488 e 0.14 x 0.08 x 0.07 mm3 Crystal size θ range for data collection 2.722 to 33.180°. $-25 \le h \le 26, -18 \le k \le 18, -29 \le l \le 27$ Index ranges Reflections collected 64557 Independent reflections 12528 [Rint = 0.0314] Reflections with $I \ge 2\sigma(I)$ 10720 99.70% Completeness to $\theta = 25.242^{\circ}$ Absorption correction Gaussian Max. and min. transmission 0.95 and 0.88 Refinement method Full-matrix least-squares on F2 Data / restraints / parameters 12528 / 0 / 378 Goodness-of-fit on F2 1.054 Final R indices $[I \ge 2\sigma(I)]$ R1 = 0.0256wR2 = 0.0606R indices (all data) R1 = 0.0346wR2 = 0.06550.728 and -1.593 e · Å-3 Largest diff. peak and hole

6.2.24 Crystal Data and Structure Refinement of Compound 138b

6.2.25 Crystal Data and Structure Refinement of Compound 138c



| Empirical formula | C ₃₄ H ₃₉ F ₁₂ N P Sb | |
|---|--|-------------------------------|
| Color | yellow | |
| Formula weight | 842.38 g·mol-1 | |
| Temperature | 100 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | MONOCLINIC | |
| Space group | p 21, (no. 4) | |
| Unit cell dimensions | a = 10.6294(9) Å | $\alpha = 90^{\circ}$. |
| | b = 17.9592(17) Å | $\beta = 101.285(5)^{\circ}.$ |
| | c = 18.9360(18) Å | $\gamma = 90^{\circ}$. |
| Volume | 3544.9(6) Å3 | |
| Z | 4 | |
| Density (calculated) | 1.578 mg·m-3 | |
| Absorption coefficient | 0.912 mm-1 | |
| F(000) | 1696 e | |
| Crystal size | 0.30 x 0.13 x 0.12 mm3 | |
| θ range for data collection | 3.576 to 38.006°. | |
| Index ranges | $-18 \le h \le 18, -31 \le k \le 31, -32 \le l \le 32$ | |
| Reflections collected | 259850 | |
| Independent reflections | 38502 [Rint = 0.0336] | |
| Reflections with $I \ge 2\sigma(I)$ | 36933 | |
| Completeness to $\theta = 25.242^{\circ}$ | 99.20% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.90987 and 0.78315 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 38502 / 1 / 895 | |
| Goodness-of-fit on F2 | 1.044 | |
| Final R indices [I>2 σ I)] | R1 = 0.0272 | wR2 = 0.0705 |
| R indices (all data) | R1 = 0.0295 | wR2 = 0.0725 |
| Absolute structure parameter | -0.0103(16) | |
| Extinction coefficient | n/a | |
| Largest diff. peak and hole | 1.400 and -1.179 e∙Å-3 | |

6.2.26 Crystal Data and Structure Refinement of Compound 139a



6.2.27 Crystal Data and Structure Refinement of Compound 139b



6.2.28 Crystal Data and Structure Refinement of Compound 139c

Color

Ζ

F(000)



C24 C23 C5 C25 C28 C39 C38 C35 C26 C37 C3 C17 C40C62 C C63 C61 C16 C33 C10 C60 C9 C59 47 C54 C11_A P2 C4 C18 C C55 C53 C56 C12 C19 C48 \otimes C13 C20 C₃₂ H₄₁ N P Empirical formula Color colourless 470.63 g·mol-1 Formula weight Temperature 80(2) K 0.56305 Å Wavelength Crystal system monoclinic Space group $P 2_1/c$, (no. 14) $\alpha = 90^{\circ}$. Unit cell dimensions a = 17.015(3) Å $\beta = 101.80(3)^{\circ}$. b = 10.280(2) Å c = 31.520(6) Å $\gamma = 90^{\circ}$. Volume 5397(2) Å3 Ζ 8 Density (calculated) 1.158 mg·m-3 Absorption coefficient 0.072 mm-1 F(000) 2040 e 0.035 x 0.059 x 0.076 mm3 Crystal size θ range for data collection 0.969 to 22.047°. $-22 \le h \le 22, -13 \le k \le 13, -42 \le l \le 42$ Index ranges Reflections collected 175228 Independent reflections 13398 [Rint = 0.0811] Reflections with $I \ge 2\sigma(I)$ 11256 Completeness to $\theta = 19.745^{\circ}$ 100.00% Refinement method Full-matrix least-squares on F2 13398 / 0 / 613 Data / restraints / parameters Goodness-of-fit on F2 1.036 Final R indices $[I > 2\sigma I)$] R1 = 0.0443wR2 = 0.1140R indices (all data) R1 = 0.0545wR2 = 0.1210Extinction coefficient 0

0.404 and -0.556 e·Å-3

Largest diff. peak and hole

6.2.29 Crystal Data and Structure Refinement of Compound 140a

6.2.30 Crystal Data and Structure Refinement of Compound 140c



Empirical formula Color Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions

Volume Ζ Density (calculated) Absorption coefficient F(000) Crystal size θ range for data collection Index ranges Reflections collected Independent reflections Reflections with $I > 2\sigma(I)$ Completeness to $\theta = 25.242^{\circ}$ Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices $[I > 2\sigma(I)]$ R indices (all data) Extinction coefficient Largest diff. peak and hole Remarks

606.63 g·mol-1 100 K 0.71073 Å MONOCLINIC c 2/c, (no. 15) a = 61.265(8) Å $\alpha = 90^{\circ}$. b = 16.892(2) Å $\beta = 104.35^{\circ}$. c = 15.1854(19) Å $\gamma = 90^{\circ}$. 15225(3) Å3 16 1.059 mg·m-3 0.121 mm-1 5104 e 0.30 x 0.15 x 0.08 mm3 1.253 to 31.018°. $-88 \le h \le 88, -24 \le k \le 24, -21 \le l \le 21$ 174699 21294 [Rint = 0.1008] 12135 79.90% Gaussian 0.99085 and 0.97202 Full-matrix least-squares on F2 21294 / 0 / 764 0.996 R1 = 0.0749wR2 = 0.2094R1 = 0.1260wR2 = 0.2387n/a 1.023 and -0.719 e·Å-3 SQUEEZE was used !!

6.2.31 Crystal Data and Structure Refinement of Compound 141

| C23 C24 C24 C25 C31 C31 C32 C31 C32 C31 C32 C31 C32 C31 C32 C31 C32 C31 C32 C33 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | |
|--|--|---------------------------------|
| Empirical formula | C ₃₂ H ₄₁ Au Cl N P | |
| Color | red | |
| Formula weight | 703.04 g·mol-1 | |
| Temperature | 100 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | Triclinic | |
| Space group | p 1, (no. 1) | |
| Unit cell dimensions | a = 9.5266(4) Å | $\alpha = 96.442(4)^{\circ}$. |
| | b = 10.7603(6) Å | $\beta = 93.835(5)^{\circ}$. |
| | c = 15.1726(8) Å | $\gamma = 107.932(4)^{\circ}$. |
| Volume | 1461.94(13) Å3 | |
| Z | 2 | |
| Density (calculated) | 1.597 mg⋅m-3 | |
| Absorption coefficient | 5.199 mm-1 | |
| F(000) | 702 e | |
| Crystal size | 0.09 x 0.06 x 0.06 mm3 | |
| θ range for data collection | 3.146 to 33.135°. | |
| Index ranges | $-14 \le h \le 14, -16 \le k \le 16, -23 \le l \le 23$ | |
| Reflections collected | 41586 | |
| Independent reflections | 11061 [Rint = 0.0416] | |
| Reflections with $I > 2\sigma(I)$ | 10796 | |
| Completeness to $\theta = 25.242^{\circ}$ | 98.30% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.77363 and 0.65074 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 11061 / 0 / 333 | |
| Goodness-of-fit on F2 | 1.031 | |
| Final R indices [I>2 σ (I)] | R1 = 0.0186 | wR2 = 0.0490 |
| R indices (all data) | R1 = 0.0192 | wR2 = 0.0495 |
| Extinction coefficient | n/a | |
| Largest diff. peak and hole | 0.906 and -2.467 e·A-3 | |

6.2.32 Crystal Data and Structure Refinement of Compound 142



6.2.33 Crystal Data and Structure Refinement of Compound 143

Color

Volume

F(000)



6.2.34 Crystal Data and Structure Refinement of Compound 144

| C24 C25 C26 C26 C26 C26 C26 C26 C26 C26 C26 C26 | $\begin{array}{c cccccc} & & & & & & & & & & & & & & & & $ | |
|--|--|-------------------------|
| Empirical formula | C_{32} H ₄₁ Br ₃ N P | |
| Color | vellow | |
| Formula weight | 710.36 g·mol-1 | |
| Temperature | 100 K | |
| Wavelength | 0.71073 Å | |
| Crystal system | ORTHORHOMBIC | |
| Space group | p 21 21 21, (no. 19) | |
| Unit cell dimensions | a = 10.2579(8) Å | $\alpha = 90^{\circ}$. |
| | b = 12.5039(12) Å | $\beta = 90^{\circ}$. |
| | c = 23.888(2) Å | $\gamma = 90^{\circ}$. |
| Volume | 3063.9(5) Å3 | |
| Z | 4 | |
| Density (calculated) | 1.540 mg⋅m-3 | |
| Absorption coefficient | 4.024 mm-1 | |
| F(000) | 1440 e | |
| Crystal size | 0.20 x 0.13 x 0.10 mm3 | |
| θ range for data collection | 3.411 to 36.060°. | |
| Index ranges | $-16 \le h \le 16, -20 \le k \le 20, -39 \le l \le 39$ | |
| Reflections collected | 147315 | |
| Independent reflections | 14503 [Rint = 0.0247] | |
| Reflections with $I > 2\sigma(I)$ | 13716 | |
| Completeness to $\theta = 25.242^{\circ}$ | 98.50% | |
| Absorption correction | Gaussian | |
| Max. and min. transmission | 0.85103 and 0.69602 | |
| Refinement method | Full-matrix least-squares on F2 | |
| Data / restraints / parameters | 14503 / 0 / 343 | |
| Goodness-of-fit on F2 | 1.105 | |
| Final R indices $[I \ge 2\sigma(I)]$ | R1 = 0.0332 | wR2 = 0.0979 |
| R indices (all data) | R1 = 0.0372 | wR2 = 0.1025 |
| Absolute structure parameter | 0.028(6) | |
| Extinction coefficient | n/a | |
| Largest diff. peak and hole | 1.307 and -2.311 e·Å-3 | |
6.2.35 Crystal Data and Structure Refinement of Compound 145



Ζ

6.2.36 Crystal Data and Structure Refinement of Compound 146

Color

Ζ

F(000)



6.2.37 Crystal Data and Structure Refinement of Compound 147



Ζ

7 Bibliography

- [1] E. W. Abel, F. G. A. Stone, G. Wilkinson, *Comprehensive Organometallic Chemistry II, Vol. 7-9*, Pergamon, **1995**.
- [2] E. Jacobsen, A. Pflaltz, H. Yamamoto, *Comprehensive Asymmetric Catalysis, Vol. 1-3*, Springer, New York, **1999**.
- [3] J. F. Hartwig, Organotransition metal chemistry: from bonding to catalysis, Univ Science Books, **2010**.
- [4] D. J. Cole-Hamilton, *Science* **2003**, *299*, 1702-1706.
- [5] B. Averill, J. Moulijn, R. van Santen, P. van Leeuwen, *Catalysis: An Integrated Approach: An Integrated Approach, Vol. 123*, Elsevier, **1999**.
- [6] B. Cornils, W. A. Herrmann, *Applied homogeneous catalysis with organometallic compounds, Vol. 2, VCH Weinheim etc.*, **1996**.
- [7] B. Cornils, W. A. Herrmann, *Aqueous-phase organometallic catalysis: concepts and applications*, John Wiley & Sons, **2006**.
- [8] H. Olivier-Bourbigou, C. Vallee, Wiley-VCH: Weinheim, 2005.
- [9] B. Cornils, J. Mol. Catal. A: Chem. 1999, 143, 1-10.
- [10] D. M. Chisholm, J. Scott McIndoe, *Dalton Trans.* **2008**, 3933-3945.
- [11] J. Fenn, M. Mann, C. Meng, S. Wong, C. Whitehouse, *Science* **1989**, *246*, 64-71.
- [12] W. Henderson, J. S. McIndoe, *Mass Spectrometry of Inorganic and Organometallic Compounds: Tools-Techniques-Tips*, John Wiley & Sons, **2005**.
- [13] M. Eberlin, Eur. J. Mass Spectrom. 2007, 13, 19-28.
- [14] N. Taccardi, R. Paolillo, V. Gallo, P. Mastrorilli, C. F. Nobile, M. Räisänen, T. Repo, *Eur. J. Inorg. Chem.* 2007, 2007, 4645-4652.
- [15] A. B. Chaplin, P. J. Dyson, Organometallics 2007, 26, 2447-2455.
- [16] P.-A. Enquist, P. Nilsson, P. Sjöberg, M. Larhed, J. Org. Chem. 2006, 71, 8779-8786.
- [17] C. Vicent, M. Viciano, E. Mas-Marzá, M. Sanaú, E. Peris, *Organometallics* **2006**, *25*, 3713-3720.
- [18] L. S. Santos, J. O. Metzger, Angew. Chem. Int. Ed. 2006, 45, 977-981.
- [19] J. S. Uppal, D. E. Johnson, R. H. Staley, J. Am. Chem. Soc. 1981, 103, 508-511.
- [20] P. Chen, Angew. Chem. Int. Ed. 2003, 42, 2832-2847.
- [21] C. Hinderling, C. Adlhart, P. Chen, Angew. Chem. Int. Ed. 1998, 37, 2685-2689.
- [22] C. Adlhart, C. Hinderling, H. Baumann, P. Chen, J. Am. Chem. Soc. 2000, 122, 8204-8214.
- [23] K. Ohmatsu, M. Ito, T. Kunieda, T. Ooi, *Nat. Chem.* **2012**, *4*, 473-477.
- [24] M. Alcarazo, Chem. Eur. J. 2014, 20, 7868-7877.
- [25] F. W. Bennett, G. R. A. Brandt, H. J. Emeleus, R. N. Haszeldine, *Nature* **1950**, *166*, 225-225.
- [26] T. Drews, D. Rusch, S. Seidel, S. Willemsen, K. Seppelt, Chem. Eur. J. 2008, 14, 4280-4286.
- [27] Y. Canac, C. Maaliki, I. Abdellah, R. Chauvin, New J. Chem. 2012, 36, 17-27.
- [28] U. Zoller, *Tetrahedron* **1988**, *44*, 7413-7426.
- [29] N. Kuhn, J. Fahl, D. Bläser, R. Boese, Z. Anorg. Allg. Chem. 1999, 625, 729-734.
- [30] C. Maaliki, C. Lepetit, Y. Canac, C. Bijani, C. Duhayon, R. Chauvin, *Chem. Eur. J.* **2012**, *18*, 7705-7714.
- [31] M. Azouri, J. Andrieu, M. Picquet, P. Richard, B. Hanquet, I. Tkatchenko, *Eur. J. Inorg. Chem.* **2007**, 2007, 4877-4883.
- [32] J. J. Weigand, K.-O. Feldmann, F. D. Henne, J. Am. Chem. Soc. 2010, 132, 16321-16323.

- [33] Y. Wang, Y. Xie, M. Y. Abraham, R. J. Gilliard, P. Wei, H. F. Schaefer, P. v. R. Schleyer, G. H. Robinson, *Organometallics* **2010**, *29*, 4778-4780.
- [34] B. D. Ellis, C. A. Dyker, A. Decken, C. L. B. Macdonald, *Chem. Comm.* 2005, 1965-1967.
- [35] A. A. Tolmachev, A. A. Yurchenko, A. S. Merculov, M. G. Semenova, E. V. Zarudnitskii, V. V. Ivanov, A. M. Pinchuk, *Heteroat. Chem.* **1999**, *10*, 585-597.
- [36] N. Debono, Y. Canac, C. Duhayon, R. Chauvin, *Eur. J. Inorg. Chem.* **2008**, 2008, 2991-2999.
- [37] I. Abdellah, N. Debono, Y. Canac, L. Vendier, R. Chauvin, *Chem. Asian J.* **2010**, *5*, 1225-1231.
- [38] Y. Canac, N. Debono, L. Vendier, R. Chauvin, *Inorg. Chem.* 2009, 48, 5562-5568.
- [39] I. V.Komarov, M. Yu.Kornilov, A. A. Tolmachev, A. A. Yurchenko, E. B. Rusanov, A. N. Chernega, *Tetrahedron* **1995**, *51*, 11271-11280.
- [40] V. Lavallo, Y. Canac, B. Donnadieu, W. W. Schoeller, G. Bertrand, *Science* 2006, *312*, 722-724.
- [41] J. Petuškova, H. Bruns, M. Alcarazo, Angew. Chem. Int. Ed. 2011, 50, 3799-3802.
- [42] A. Kozma, T. Deden, J. Carreras, C. Wille, J. Petuškova, J. Rust, M. Alcarazo, *Chem. Eur. J.* **2014**, *20*, 2208-2214.
- [43] H. Tinnermann, C. Wille, M. Alcarazo, Angew. Chem. Int. Ed. 2014, 53, 8732-8736.
- [44] N. Burford, T. Stanley Cameron, K. N. Robertson, A. D. Phillips, H. A. Jenkins, *Chem. Comm.* **2000**, 2087-2088.
- [45] D. Gudat, Coord. Chem. Rev. 1997, 163, 71-106.
- [46] B. D. Ellis, P. J. Ragogna, C. L. B. Macdonald, *Inorg. Chem.* **2004**, *43*, 7857-7867.
- [47] N. Burford, P. J. Ragogna, R. McDonald, M. J. Ferguson, J. Am. Chem. Soc. 2003, 125, 14404-14410.
- [48] N. Burford, P. Losier, A. D. Phillips, P. J. Ragogna, T. S. Cameron, *Inorg. Chem.* 2003, 42, 1087-1091.
- [49] H. Jansen, F. B. Läng, J. C. Slootweg, A. W. Ehlers, M. Lutz, K. Lammertsma, H. Grützmacher, *Angew. Chem. Int. Ed.* **2010**, *49*, 5485-5488.
- [50] R. Weiss, S. Engel, *Synthesis* **1991**, 1077-1079.
- [51] G. Bouhadir, R. W. Reed, R. Réau, G. Bertrand, *Heteroat. Chem.* 1995, *6*, 371-375.
- [52] J. J. Weigand, K.-O. Feldmann, A. K. C. Echterhoff, A. W. Ehlers, K. Lammertsma, *Angew. Chem. Int. Ed.* **2010**, *49*, 6178-6181.
- [53] H. Bruns, M. Patil, J. Carreras, A. Vázquez, W. Thiel, R. Goddard, M. Alcarazo, *Angew. Chem. Int. Ed.* **2010**, *49*, 3680-3683.
- [54] H. Clavier, S. P. Nolan, *Chem. Comm.* **2010**, *46*, 841-861.
- [55] T. Dröge, F. Glorius, Angew. Chem. Int. Ed. 2010, 49, 6940-6952.
- [56] D. G. Gusev, Organometallics **2009**, 28, 6458-6461.
- [57] G. Kuchenbeiser, B. Donnadieu, G. Bertrand, J. Organomet. Chem. 2008, 693, 899-904.
- [58] W. W. Schoeller, G. D. Frey, G. Bertrand, *Chem. Eur. J.* **2008**, *14*, 4711-4718.
- [59] N. H. T. Huy, B. Donnadieu, G. Bertrand, F. Mathey, *Chem. Asian J.* 2009, *4*, 1225-1228.
- [60] J. Petuškova, M. Patil, S. Holle, C. W. Lehmann, W. Thiel, M. Alcarazo, J. Am. Chem. Soc. 2011, 133, 20758-20760.
- [61] F. D. Henne, A. T. Dickschat, F. Hennersdorf, K. O. Feldmann, J. J. Weigand, *Inorg. Chem.* **2015**, *54*, 6849-6861.
- [62] Y. H. So, *Macromolecules* **1992**, *25*, 516-520.
- [63] Y. Canac, C. Lepetit, M. Abdalilah, C. Duhayon, R. Chauvin, J. Am. Chem. Soc. 2008, 130, 8406-8413.
- [64] C. A. Tolman, *Chem. Rev.* **1977**, *77*, 313-348.

- [65] C. A. Tolman, J. Am. Chem. Soc. 1970, 92, 2953-2956.
- [66] O. Kühl, Coord. Chem. Rev. 2005, 249, 693-704.
- [67] O. Schuster, L. Yang, H. G. Raubenheimer, M. Albrecht, *Chem. Rev.* 2009, 109, 3445-3478.
- [68] M. Alcarazo, T. Stork, A. Anoop, W. Thiel, A. Fürstner, *Angew. Chem. Int. Ed.* **2010**, 49, 2542-2546.
- [69] S. Wolf, H. Plenio, J. Organomet. Chem. 2009, 694, 1487-1492.
- [70] A. B. P. Lever, *Inorg. Chem.* **1990**, *29*, 1271-1285.
- [71] A. B. P. Lever, *Inorg. Chem.* **1991**, *30*, 1980-1985.
- [72] S. Leuthäußer, D. Schwarz, H. Plenio, Chem. Eur. J. 2007, 13, 7195-7203.
- [73] C. Palau, Y. Berchadsky, F. Chalier, J.-P. Finet, G. Gronchi, P. Tordo, J. Phys. Chem. 1995, 99, 158-163.
- [74] J. P. Bullock, A. M. Bond, R. T. Boeré, T. M. Gietz, T. L. Roemmele, S. D. Seagrave, J. D. Masuda, M. Parvez, J. Am. Chem. Soc. 2013, 135, 11205-11215.
- [75] D. G. Gusev, Organometallics **2009**, 28, 763-770.
- [76] J. Sirieix, M. Oßberger, B. Betzemeier, P. Knochel, Synlett 2000, 2000, 1613-1615.
- [77] S. Saleh, E. Fayad, M. Azouri, J.-C. Hierso, J. Andrieu, M. Picquet, Adv. Synth. Catal. 2009, 351, 1621-1628.
- [78] C. C. Brasse, U. Englert, A. Salzer, H. Waffenschmidt, P. Wasserscheid, *Organometallics* **2000**, *19*, 3818-3823.
- [79] D. J. Brauer, K. W. Kottsieper, C. Liek, O. Stelzer, H. Waffenschmidt, P. Wasserscheid, *J. Organomet. Chem.* **2001**, *630*, 177-184.
- [80] I. Alonso, B. Trillo, F. López, S. Montserrat, G. Ujaque, L. Castedo, A. Lledós, J. L. Mascareñas, J. Am. Chem. Soc. 2009, 131, 13020-13030.
- [81] P. Mauleón, R. M. Zeldin, A. Z. González, F. D. Toste, J. Am. Chem. Soc. 2009, 131, 6348-6349.
- [82] J. Carreras, M. Patil, W. Thiel, M. Alcarazo, J. Am. Chem. Soc. 2012, 134, 16753-16758.
- [83] J. Carreras, G. Gopakumar, L. Gu, A. Gimeno, P. Linowski, J. Petuškova, W. Thiel, M. Alcarazo, J. Am. Chem. Soc. 2013, 135, 18815-18823.
- [84] J. W. Dube, C. L. B. Macdonald, P. J. Ragogna, Angew. Chem. Int. Ed. 2012, 51, 13026-13030.
- [85] R. J. Abernethy, A. F. Hill, M. K. Smith, A. C. Willis, *Organometallics* **2009**, *28*, 6152-6159.
- [86] R. E. Cobbledick, F. W. B. Einstein, *Acta Crystallogr., Sect. B: Struct. Sci.* **1975**, *31*, 2731-2733.
- [87] Z. B. Maksic, B. Kovacevic, J. Chem. Soc., Perkin Trans. 2 1999, 2623-2629.
- [88] B. Machura, R. Penczek, R. Kruszynski, J. Kłak, J. Mroziński, J. Kusz, *Polyhedron* 2007, 26, 4833-4840.
- [89] J. Zhou, Y. Tang, Chem. Comm. 2004, 432-433.
- [90] F. Malbosc, V. Chauby, C. Serra-Le Berre, M. Etienne, J.-C. Daran, P. Kalck, *Eur. J. Inorg. Chem.* 2001, 2001, 2689-2697.
- [91] E. Lee, A. S. Kamlet, D. C. Powers, C. N. Neumann, G. B. Boursalian, T. Furuya, D. C. Choi, J. M. Hooker, T. Ritter, *Science* 2011, *334*, 639-642.
- [92] P. Neves, S. Gago, S. S. Balula, A. D. Lopes, A. A. Valente, L. Cunha-Silva, F. A. A. Paz, M. Pillinger, J. Rocha, C. M. Silva, I. S. Gonçalves, *Inorg. Chem.* 2011, 50, 3490-3500.
- [93] S. Gaillard, J.-L. Renaud, *Dalton Trans.* **2013**, *42*, 7255-7270.
- [94] D. J. M. Snelders, G. van Koten, R. J. M. Klein Gebbink, Chem. Eur. J. 2011, 17, 42-57.

- [95] S. Bontemps, G. Bouhadir, K. Miqueu, D. Bourissou, J. Am. Chem. Soc. 2006, 128, 12056-12057.
- [96] F. Inagaki, C. Matsumoto, Y. Okada, N. Maruyama, C. Mukai, *Angew. Chem. Int. Ed.* 2015, 54, 818-822.
- [97] Y. Tulchinsky, M. A. Iron, M. Botoshansky, M. Gandelman, *Nat. Chem.* 2011, 3, 525-531.
- [98] X. Luo, H. Zhang, H. Duan, Q. Liu, L. Zhu, T. Zhang, A. Lei, Org. Lett. 2007, 9, 4571-4574.
- [99] S. Basra, J. G. de Vries, D. J. Hyett, G. Harrison, K. M. Heslop, A. G. Orpen, P. G. Pringle, K. von der Luehe, *Dalton Trans.* 2004, 1901-1905.
- [100] K. M. Gillespie, C. J. Sanders, P. O'Shaughnessy, I. Westmoreland, C. P. Thickitt, P. Scott, J. Org. Chem. 2002, 67, 3450-3458.
- [101] A. F. Holleman, E. Wiberg, *Lehrbuch der anorganischen Chemie*, Walter de Gruyter, **1995**.
- [102] W. Levason, G. Reid, M. Webster, Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 2006, 62, 438-440.
- [103] G. Mancino, A. J. Ferguson, A. Beeby, N. J. Long, T. S. Jones, J. Am. Chem. Soc. 2005, 127, 524-525.
- [104] R. Jackstell, H. Klein, M. Beller, K.-D. Wiese, D. Röttger, *Eur. J. Org. Chem.* 2001, 2001, 3871-3877.
- [105] S. L. Mukerjee, S. P. Nolan, C. D. Hoff, R. Lopez de la Vega, *Inorg. Chem.* **1988**, *27*, 81-85.
- [106] C. Taouss, P. G. Jones, Z. Naturforsch., B: Chem. Sci. 2013, 68, 860-870.
- [107] M. C. Nielsen, K. J. Bonney, F. Schoenebeck, Angew. Chem. Int. Ed. 2014, 53, 5903-5906.
- [108] T. Korenaga, T. Kosaki, R. Fukumura, T. Ema, T. Sakai, Org. Lett. 2005, 7, 4915-4917.
- [109] T.-a. Koizumi, A. Yamazaki, T. Yamamoto, *Dalton Trans.* 2008, 3949-3952.
- [110] M.-N. Birkholz, Z. Freixa, P. W. N. M. van Leeuwen, *Chem. Soc. Rev.* **2009**, *38*, 1099-1118.
- [111] J. E. Marcone, K. G. Moloy, J. Am. Chem. Soc. 1998, 120, 8527-8528.
- [112] J. F. Hartwig, Science 2002, 297, 1653-1654.
- [113] X. Yao, C.-J. Li, J. Org. Chem. 2005, 70, 5752-5755.
- [114] Z. Wang, B. J. Reinus, G. Dong, J. Am. Chem. Soc. 2012, 134, 13954-13957.
- [115] F. Mo, G. Dong, *Science* **2014**, *345*, 68-72.
- [116] B. M. Trost, C. Jäkel, B. Plietker, J. Am. Chem. Soc. 2003, 125, 4438-4439.
- [117] B. M. Trost, J. Xie, J. D. Sieber, J. Am. Chem. Soc. 2011, 133, 20611-20622.
- [118] M. R. Uehling, A. M. Suess, G. Lalic, J. Am. Chem. Soc. 2015, 137, 1424-1427.
- [119] A. M. Suess, M. R. Uehling, W. Kaminsky, G. Lalic, J. Am. Chem. Soc. 2015, 137, 7747-7753.
- [120] M. J. Goldfogel, S. J. Meek, Chem. Sci. 2016.
- [121] A. Fürstner, P. W. Davies, Angew. Chem. Int. Ed. 2007, 46, 3410-3449.
- [122] H.-B. Sun, B. Li, R. Hua, Y. Yin, Eur. J. Org. Chem. 2006, 2006, 4231-4236.
- [123] M. Soleilhavoup, G. Bertrand, Acc Chem Res 2015, 48, 256-266.
- [124] A. Igau, H. Grutzmacher, A. Baceiredo, G. Bertrand, J. Am. Chem. Soc. 1988, 110, 6463-6466.
- [125] M. N. Hopkinson, C. Richter, M. Schedler, F. Glorius, *Nature* 2014, 510, 485-496.
- [126] A. J. Arduengo, R. L. Harlow, M. Kline, J. Am. Chem. Soc. 1991, 113, 361-363.
- [127] J. Vignolle, X. Cattoën, D. Bourissou, Chem. Rev. 2009, 109, 3333-3384.
- [128] A. J. Arduengo, G. Bertrand, Chem. Rev. 2009, 109, 3209-3210.

- [129] W. A. Herrmann, M. Elison, J. Fischer, C. Köcher, G. R. J. Artus, *Chem. Eur. J.* **1996**, 2, 772-780.
- [130] V. Lavallo, Y. Canac, C. Präsang, B. Donnadieu, G. Bertrand, Angew. Chem. Int. Ed. 2005, 44, 5705-5709.
- [131] O. Back, B. Donnadieu, P. Parameswaran, G. Frenking, G. Bertrand, *Nat. Chem.* **2010**, 2, 369-373.
- [132] R. Kretschmer, D. A. Ruiz, C. E. Moore, A. L. Rheingold, G. Bertrand, *Angew. Chem. Int. Ed.* **2014**, *53*, 8176-8179.
- [133] R. Kinjo, B. Donnadieu, M. A. Celik, G. Frenking, G. Bertrand, *Science* **2011**, *333*, 610-613.
- [134] D. A. Ruiz, G. Ung, M. Melaimi, G. Bertrand, Angew. Chem. Int. Ed. 2013, 52, 7590-7592.
- [135] P. Jerabek, H. W. Roesky, G. Bertrand, G. Frenking, J. Am. Chem. Soc. 2014, 136, 17123-17135.
- [136] D. S. Weinberger, M. Melaimi, C. E. Moore, A. L. Rheingold, G. Frenking, P. Jerabek, G. Bertrand, *Angew. Chem. Int. Ed.* **2013**, *52*, 8964-8967.
- [137] N. Arnold, H. Braunschweig, P. B. Brenner, M. A. Celik, R. D. Dewhurst, M. Haehnel, T. Kramer, I. Krummenacher, T. B. Marder, *Chem. Eur. J.* 2015, 21, 12357-12362.
- [138] S. Roy, K. C. Mondal, J. Meyer, B. Niepötter, C. Köhler, R. Herbst-Irmer, D. Stalke, B. Dittrich, D. M. Andrada, G. Frenking, H. W. Roesky, *Chem. Eur. J.* 2015, 21, 9312-9318.
- [139] D. S. Weinberger, N. Amin Sk, K. C. Mondal, M. Melaimi, G. Bertrand, A. C. Stückl, H. W. Roesky, B. Dittrich, S. Demeshko, B. Schwederski, W. Kaim, P. Jerabek, G. Frenking, J. Am. Chem. Soc. 2014, 136, 6235-6238.
- [140] G. Ung, J. Rittle, M. Soleilhavoup, G. Bertrand, J. C. Peters, Angew. Chem. Int. Ed. 2014, 53, 8427-8431.
- [141] K. C. Mondal, S. Roy, S. De, P. Parameswaran, B. Dittrich, F. Ehret, W. Kaim, H. W. Roesky, *Chem. Eur. J.* 2014, 20, 11646-11649.
- [142] K. C. Mondal, P. P. Samuel, Y. Li, H. W. Roesky, S. Roy, L. Ackermann, N. S. Sidhu, G. M. Sheldrick, E. Carl, S. Demeshko, S. De, P. Parameswaran, L. Ungur, L. F. Chibotaru, D. M. Andrada, *Eur. J. Inorg. Chem.* 2014, 2014, 818-823.
- [143] P. P. Samuel, K. C. Mondal, H. W. Roesky, M. Hermann, G. Frenking, S. Demeshko,
 F. Meyer, A. C. Stückl, J. H. Christian, N. S. Dalal, L. Ungur, L. F. Chibotaru, K.
 Pröpper, A. Meents, B. Dittrich, *Angew. Chem. Int. Ed.* 2013, 52, 11817-11821.
- [144] A. P. Singh, P. P. Samuel, H. W. Roesky, M. C. Schwarzer, G. Frenking, N. S. Sidhu, B. Dittrich, J. Am. Chem. Soc. 2013, 135, 7324-7329.
- [145] Y. Li, K. C. Mondal, H. W. Roesky, H. Zhu, P. Stollberg, R. Herbst-Irmer, D. Stalke, D. M. Andrada, J. Am. Chem. Soc. 2013, 135, 12422-12428.
- [146] R. Kinjo, B. Donnadieu, G. Bertrand, Angew. Chem. Int. Ed. 2010, 49, 5930-5933.
- [147] O. Back, M. A. Celik, G. Frenking, M. Melaimi, B. Donnadieu, G. Bertrand, J. Am. Chem. Soc. 2010, 132, 10262-10263.
- [148] P. Bissinger, H. Braunschweig, A. Damme, I. Krummenacher, A. K. Phukan, K. Radacki, S. Sugawara, *Angew. Chem. Int. Ed.* **2014**, *53*, 7360-7363.
- [149] K. C. Mondal, P. P. Samuel, H. W. Roesky, B. Niepötter, R. Herbst-Irmer, D. Stalke, F. Ehret, W. Kaim, B. Maity, D. Koley, *Chem. Eur. J.* 2014, 20, 9240-9245.
- [150] K. C. Mondal, P. P. Samuel, M. Tretiakov, A. P. Singh, H. W. Roesky, A. C. Stückl, B. Niepötter, E. Carl, H. Wolf, R. Herbst-Irmer, D. Stalke, *Inorg. Chem.* 2013, 52, 4736-4743.
- [151] K. C. Mondal, H. W. Roesky, M. C. Schwarzer, G. Frenking, B. Niepötter, H. Wolf, R. Herbst-Irmer, D. Stalke, *Angew. Chem. Int. Ed.* 2013, 52, 2963-2967.

- [152] C. D. Martin, M. Soleilhavoup, G. Bertrand, *Chem. Sci.* 2013, 4, 3020-3030.
- [153] J. K. Mahoney, D. Martin, F. Thomas, C. E. Moore, A. L. Rheingold, G. Bertrand, J. *Am. Chem. Soc.* **2015**, *137*, 7519-7525.
- [154] J. K. Mahoney, D. Martin, C. E. Moore, A. L. Rheingold, G. Bertrand, J. Am. Chem. Soc. 2013, 135, 18766-18769.
- [155] S. Styra, M. Melaimi, C. E. Moore, A. L. Rheingold, T. Augenstein, F. Breher, G. Bertrand, *Chem. Eur. J.* 2015, 21, 8441-8446.
- [156] S. Roy, A. C. Stuckl, S. Demeshko, B. Dittrich, J. Meyer, B. Maity, D. Koley, B. Schwederski, W. Kaim, H. W. Roesky, J. Am. Chem. Soc. 2015, 137, 4670-4673.
- [157] J. C. J. Bart, J. Chem. Soc. B 1969, 350-365.
- [158] S. Styra, M. Melaimi, C. E. Moore, A. L. Rheingold, T. Augenstein, F. Breher, G. Bertrand, Chem. Euro. J. 2015, 21, 8441-8446.
- [159] L. Ackermann, A. R. Kapdi, C. Schulzke, Org. Lett. 2010, 12, 2298-2301.
- [160] D.-F. Hu, C.-M. Weng, F.-E. Hong, Organometallics 2011, 30, 1139-1147.
- [161] Y.-C. Chang, W.-C. Chang, C.-Y. Hu, F.-E. Hong, *Organometallics* **2014**, *33*, 3523-3534.
- [162] Y. Ji, R. E. Plata, C. S. Regens, M. Hay, M. Schmidt, T. Razler, Y. Qiu, P. Geng, Y. Hsiao, T. Rosner, M. D. Eastgate, D. G. Blackmond, *J. Am. Chem. Soc.* 2015, 137, 13272-13281.
- [163] M. Filatov, D. Cremer, J. Chem. Phys. 2005, 123, 124101.
- [164] J. A. Pople, P. M. W. Gill, N. C. Handy, Int. J. Quantum Chem. 1995, 56, 303-305.
- [165] B. J. Stokes, L. Liao, A. M. de Andrade, Q. Wang, M. S. Sigman, Org. Lett. 2014, 16, 4666-4669.
- [166] J. M. Landesberg, M. A. Slam, M. Mandel, J. Org. Chem. 1981, 46, 5025-5027.

Summary

1) Bis- and Trispyrazoylborate/methane-Stabilized P(III)-Centered Cations

Making use of an –onium substituent transfer strategy, we have been able to isolate and structurally characterize several P-centered polycations stabilized by bis- and tris-(pyrazoyl)borate or methane ligands. In all of these compounds, the phosphorus center adopts a pyramidal environment, which is indicative of the presence of a lone pair mainly located on this atom. However, the high positive charge at phosphorus lowers the energy of this orbital to a level that makes it unavailable for donation. The same positive charge also stabilizes quite efficiently the σ *(P-N) orbitals, thus conferring Lewis acid character to the phosphorus atom. This Lewis acidity is evident from the short contacts observed between the triflate anions and the phosphorus centers.



2) Dicationic Chelating Phosphines: Synthesis, Structure and Reactivity

We outlined the preparation of new bidentate dicationic phosphines and their coordination chemistry towards different metals. Moreover, we showcased for the first time the utility of cationic ligands to promote difficult reductive elimination processes under mild condition, such as the formation of polyfluorinated biaryls from Pd(II) centers. Finally, the unique properties of these ligands in catalysis has been proven in the hydorarylation of phenyl diene with indoles and electron rich arenes.



3) Isolation and Coordination Chemistry of CAACs Substituted a-Radical Phosphines

We have successfully isolated and characterized a series of CAAC (Cyclic (Alkyl)(Amino)Carbene) derived cationic phophines. Their cyclovoltammetry showed a quasi-reversible redox potential, which indicated that stable radicals were formed after one electron reduction. As a result, a series of α -radical phosphines have been synthesized and fully characterized. More intriguingly, these radical phosphines could coordinate to Au(I) and form a range of stable gold complexes that are unprecedented. In addition, we were also able to synthesize the radical phosphorus oxide. All of the synthesized radicals have been characterized by EPR and most have been crystallized. These novel compounds could be named as α -radical phosphine ligands, which might be useful in catalysis.



Zusammenfassung

1) Bi- und Tri-Pyrazolyl(borat/methan) stabilisierte P(III)-zentrierte Kationen

Durch eine Onium-Substituenten-Transfer-Strategie ist es uns gelungen, mehrere Phosphorzentrierte Polykationen, die durch Bi- und Tri-Pyrazolyl(borat/methan)-Liganden stabilisiert sind, zu isolieren und strukturell zu charakterisieren. Bei all diesen Verbindungen befindet sich das Phosphor-Zentrum in einer trigonal-pyramidalen Umgebung, was auf ein hauptsächlich am Phosphor lokalisiertes, freies Elektronenpaar hinweist. Die hohe positive Ladung am Phosphor senkt die Energie dieses Orbitals so weit ab, dass es als Donor nicht mehr zur Verfügung steht. Des Weiteren stabilisiert diese positive Ladung das $\sigma^*(P-N)$ -Orbital und sorgt so für einen Lewis-aciden Charakter am Phosphor-Atom. Die Lewis-Acidität spiegelt sich in der geringen Bindungslänge zwischen dem Triflat-Anion und dem Phosphor-Zentrum wieder.



2) Dikationische chelatisierende Phosphine: Synthese, Struktur und Reaktivität

Im Rahmen dieser Arbeit haben wir die Darstellung und Koordinationschemie bidentater dikationischer Phosphine gegenüber verschiedenen Metallen beschrieben. Ebenso haben wir erstmalig die Anwendung kationischer Liganden auf schwierige reduktive Eliminierungen unter milden Bedingungen aufgezeigt, wie z.B. die Bildung polyfluorierter Biaryle von Pd(II)-Zentren. Darüber hinaus konnten die besonderen Eigenschaften dieser Liganden in Hydroarylierungen von Phenyl-Dienen mit Indolen und elektronenreichen Aromaten aufgezeigt werden.



3) Isolierung und Koordinationschemie von CAACs-substituierten α -radikalen Phosphinen

Wir haben erfolgreich eine Reihe von "CAAC" (Zyklische(Alkyl)(Amino)Carbene) abgeleiteten kationischen Phosphinen isoliert und charakterisiert. Durch Cyclovoltammetrie konnte ein quasi-reversibles Redoxpotential aufgezeigt werden, was ein Indiz für die Bildung stabiler Radikale durch Ein-Elektron-Reduktion ist. Wir haben eine Reihe α -radikaler Phosphine synthetisiert und diese voll charakterisiert. Diese Radikale wurden an Au(I) koordiniert und lieferten eine Reihe stabiler Gold-Komplexe, welche bis dato unbekannt waren. Wir konnten ferner ein Phosphoroxid-Radikal darstellen. Die Radikale wurden durch EPR-Spektroskopie charakterisiert und die meisten wurden darüber hinaus durch Kristallstrukturanalysen bestätigt. Die neuen Verbindungen können als α -radikale Phosphin-Liganden bezeichnet werden mit potentiellen Anwendungsmöglichkeiten in der Katalyse.

